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Abstract 
This thesis investigates the epidemiology of tuberculosis (TB) disease in populations. It applies 
molecular epidemiological methods to elucidate the relative effects of HIV on TB disease 
following recent first infection, reactivation and recent reinfection with Mycobacterium 
tuberculosis (Mtb). Finally it aims to explore the impact of Antiretroviral Therapy (ART) on the 
incidence of TB in a population in rural Sub Saharan Africa.  
The data in chapters 2 and 3 is taken from a systematic literature review I performed of 
population based studies that reported TB molecular epidemiological data. In the subsequent 
chapters I analyse existing and newly collected data from the Karonga Prevention Study, set in 
Northern Malawi, to address the research questions.  
The results strongly suggest that HIV-infection increases an individual’s risk of TB disease due 
to recent Mtb (re)infection more than through reactivation in populations with generalised 
HIV epidemics. The last chapter suggests that patients on ART experience a high risk of TB 
compared to HIV positive/ART naive patients, especially in the first months after initiating 
ART. Also, it appears that after the introduction of ART in 2005 TB incidence in Karonga 
District plateaued after declining in the previous 10 years.  
These findings strongly suggest that TB programmes in areas with generalised HIV epidemics 
should focus more of their efforts on reducing Mtb transmission. Improved collaboration 
between TB and ART programmes may help to reduce TB rates in the highly vulnerable ART 
receiving population and subsequently in the general population.  
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1 Introduction 
1.1 Chapter Outline  
In this chapter I will introduce the epidemiology of Mycobacterium tuberculosis and 
tuberculosis disease. The molecular epidemiology of TB is introduced, as well as its 
applications so far. In section 1.6 I will outline the main questions this thesis aims to answer 
and where I do so. Finally I will give an overview of the chapters and a brief summary of their 
content.  
1.2 The burden of Tuberculosis 
1.2.1 Overview 
Tuberculosis disease (TB) was declared a “global emergency” by the WHO in 1993. [1] 
Nevertheless, fuelled by the HIV epidemic TB disease remains one of the major health threats, 
still causing about 9 million cases and 2 million deaths a year worldwide. [2] A large 
proportion of these cases occurs in areas with generalised HIV epidemics (defined as a HIV 
epidemic established in the general population and sustainable without the contribution of 
high risk groups and where HIV prevalence is consistently measured as > 1% in pregnant 
women [3]), which includes many of the countries of East and Central Sub Saharan Africa.  
1.3 The epidemiology of Tuberculosis  
1.3.1 Definition of TB disease 
The epidemiology of tuberculosis disease (TB) is complex. The symptoms of TB disease are 
caused by the immune system’s reaction to an active infection with a member of the 
Mycobacterium genus, predominantly Mycobacterium tuberculosis (Mtb). TB can involve 
other members of the Mycobacterium species such as Mycobacterium bovis and 
Mycobacterium avium. However, Mtb underlies the majority of TB episodes. For the purpose 
of this thesis TB is defined as a disease episode caused by an active infection with a strain of 
Mtb.  
1.3.1.1 Measurement of Mtb infection 
Infection with Mtb is difficult to measure. The most commonly used test to determine Mtb 
infection has been the same since the beginning of the 19
th
 century; The Tuberculin Skin Test 
(TST), also referred to as the Mantoux test. This test determines the body’s immune response 
after an intradermal injection of ~2ml non species specific purified protein derivative from 
mycobacteria into the volar surface of the forearm. [4] After 48 to 72 hours after the 
induration (palpable raised and hardened area) at the location of the injection is measured. If 
the individual has experienced an Mtb infection in the past an induration is expected to be 
seen. The required induration for a ‘positive’ TST has been under intense discussion. I use 
results from TST in Chapter 6 and will discuss the limitations in more detail there. 
The TST can be false positive due to cross contamination with other mycobacteria, from a BCG 
vaccination or due to boosting following multiple tests. The TST can be false negative in 
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immunocompromised individuals, such as HIV positive patients with advanced 
immunosuppression. Advantages include that the TST is cheap, and its methods and 
interpretation are reasonably well standardised.  
In recent years new blood based tests for measuring Mtb infection have been developed and 
evaluated. Despite a huge body of research [5], their use and interpretation is still not clear. 
[6] This thesis does not use any results from these new tests and I will therefore not discuss 
them further.   
1.3.1.2 Presentations of TB disease 
I will not go into detail on the diagnosis of TB disease. In short, diagnosis is usually through 
sputum examination, confirmed by a culture growth positive for Mtb. For the epidemiology 
the following concepts are important: 
1.3.1.2.1 Pulmonary versus Extra Pulmonary TB 
A TB episode can have foci in multiple places, although the main focus is often the lung which 
is referred to as pulmonary TB (PTB). If there is no pulmonary involvement, and TB is present 
in other organs the TB is referred to as Extra Pulmonary TB (EPTB). Epidemiologically three 
points are important to mention:  
1. Patients can have both PTB and EPTB in the same episode [7, 8] 
2. Pulmonary (or laryngeal) involvement in the TB is required for Mtb transmission, as 
transmission occurs when sputum with live Mtb bacilli is coughed up from the lung 
and spread. Patients without pulmonary involvement will, in principle, not be the 
source of Mtb transmission. [8] 
3. Patients with an Mtb and HIV co-infection are more likely to have extra pulmonary 
foci when they develop TB disease. [7] 
1.3.1.2.2 Smear positive versus Smear negative TB disease 
A TB episode can be smear positive (SS+), which refers to Mtb bacilli seen under a microscope 
after staining fixed smear of any sputum samples. If no smear can be done, or no Mtb bacilli 
are seen in any of the smears, the TB episode is referred to as smear negative (SS-). For the 
epidemiology the following 2 points are important to note: 
1. SS- patients are less infectious than SS+, although transmission is still possible [9, 10] 
2. Patients with an Mtb and HIV co-infection are more likely to be SS- when they develop 
TB disease. [11-14] 
1.3.1.2.3 Culture Positive versus Culture Negative TB disease 
The gold standard of the diagnosis of TB disease is a positive culture of Mtb. If a patient is SS- 
and culture negative (C-), the diagnosis of TB disease is not confirmed and treatment initiation 
is only based on clinical symptoms and X-ray if available. For the epidemiology the following 
points are important: 
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1. Patients with PTB that are SS- but culture positive (C+) are the subgroup that are likely 
to still transmit Mtb, albeit at a lower intensity [9, 10] 
2. Patients with an Mtb and HIV co-infection are more likely to be culture negative (C-) 
[8] 
1.3.2 Pathways from Mtb infection to a first episode of TB disease 
The first step in the pathway to TB disease is an effective contact with an infectious TB case, 
defined as a contact between an infectious person and someone who has not been infected 
that leads to the uninfected person to become infected with Mtb. After an Mtb infection has 
been established, 3 pathways are distinguished in the epidemiology of TB that can lead from 
Mtb infection to a first episode of TB (see figure 1—1).  
1.3.2.1 Rapid progression to TB disease 
Following a first Mtb infection an individual can progress ‘rapidly’ to TB disease. By 
convention, this period for rapid progression is defined as within the first 5 years after the 
Mtb infection event. [15, 16]. This 5 year cut off is based on the relatively higher risk of 
developing TB in the first years after Mtb infection (see figure 1—2). [15, 17] It is arbitrary to 
an extent, and can be varied. I will discuss this issue in more detail in section 1.5:  The 
molecular epidemiology of TB In this thesis TB following a rapid progression from a first Mtb 
infection is referred to as TB following recent infection or primary TB. Please note that in 
clinical discussions primary TB can refer to the first pulmonary foci of Mtb infection before 
haematogenous spread occurs. However, this definition is not used in this thesis.  
1.3.2.2 Reinfection and exogenous disease 
After a first infection with Mtb an individual can be re-infected with Mtb before their first TB 
episode. After a reinfection event the risk of developing TB follows a similar pattern to that 
seen after a first Mtb infection. [15, 17] If the person develops TB within a set period after 
reinfection, again conventionally defined as 5 years, this TB episode is referred to as TB 
following recent re-infection TB or exogenous TB.  
Note that it is difficult to distinguish between these two types of TB that follow a recent Mtb 
infection event. Although the importance of re-infection disease  is unclear, its relevance as 
part of TB pathogenesis in areas with moderate to high rates of Mtb transmission has been 
demonstrated in modelling studies [15, 17] and elegantly illustrated through population data 
by Styblo et al.[8] In Chapter 5 I will explore this issue in more detail.   
1.3.2.3 Reactivation disease 
If an Mtb infection does not progress to TB disease within a set period, usually defined as 5 
years, it is assumed to have become established in the body as a latent infection. In this 
process Mtb bacteria are encapsulated in granulatomous foci in the lungs or other parts of the 
body. This latent Mtb infection can reactivate in later life to cause an episode TB disease, 
which is referred to as reactivation or endogenous TB.  
Although the risk of reactivation TB from a latent infection is low compared to TB following a 
recent infection, it is assumed to last life–long and increase with age. [15] It therefore plays an 
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important part of TB epidemiology, especially in populations with low levels of ongoing Mtb 
transmission such as the non-migrant populations in developed countries.   
Please note that under the current TB paradigm an Mtb infection will last lifelong. However, 
results from recent studies on long term Mtb infection suggest that this process is less clear 
and that some individuals appear to clear their Mtb infection without ever developing TB or 
taking TB treatment. Crampin et al. in preparation 
1.3.3 Recurrent TB  
After completing TB treatment for a first TB episode an individual can experience a 
recurrence. This subsequent TB episode can either be a relapse or re-infection. A relapse is 
defined as a new episode with the same Mtb strain, which was not cleared by the treatment 
for the preceding TB episode. A recurrence due to re-infection is defined as a new TB episode 
caused by a different Mtb strain than the Mtb strain involved in the previous TB episode.  
Although I will refer to studies on recurrent TB, the main focus of this thesis in on first TB 
episodes.  
Figure 1—1: Pathways from first Mtb infection to first episode TB 
 
Figure courtesy of Judith Glynn and Paul Fine  
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Figure 1—2: Percentage of cases occurring by year since first Mtb infection  
 
Data in figure reproduced from Medical Research Council vaccine trial [18] 
1.4 TB and HIV 
The link between HIV and tuberculosis (TB) has been clear since the beginning of the HIV-
epidemic [19]. In countries with high prevalences of HIV TB incidence rates increased 
dramatically, as shown in figure 1—3. [20] Tuberculosis is the main cause of death in HIV-
positive individuals from low resource settings [21]. The effect of HIV on TB rates is often 
separated in a direct effect on the risk of TB in infected with HIV and an indirect effect for the 
risk of TB in the general population. [22, 23] 
Figure 1—3: Annual incidence of SS+ TB by country (1991 – 2007) 
 
Data from Global TB database http://www.who.int/tb/country/global_tb_database/en/index.html 
(accessed at 13-Feb-2010). Showing data from selected countries.   
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1.4.1 Direct effect of HIV infection on TB 
If an Mtb infected person remains HIV-negative their lifetime risk of TB is estimated at 10%. 
[17] If they become co-infected with HIV their risk of active TB disease increases to 10% 
annually [22].  
In the beginning of the HIV epidemic it was assumed that the risk of TB was high immediately 
after HIV infection, then decreased to close to null and then start rising. [24-27] Recent 
studies have shown that the relative risk of TB actually starts to increase immediately after 
HIV infection and continues to do so for at least 10 years afterwards [28].  
Although it is clear that HIV infection dramatically increases the risk of active TB and affects all 
three pathways to from Mtb infection to TB disease [22] , the relative effects on the risk for 
primary, exogenous and endogenous TB may vary [29]. This issue of the relative effect of HIV 
infection on the different pathways from Mtb infection to TB disease is one of the main 
focuses of this thesis and will be discussed in more detail in section 1.5.6 and chapters 3, 4 
and 5.  
1.4.2 Indirect effect of HIV on TB incidence   
It is assumed that the high number of additional TB cases in the HIV positive population have 
a knock on effect in the general population, which is referred to as the indirect effect of HIV. 
[30] 
Odhiambo et al. showed that in Kenyan districts where HIV prevalence in TB cases was high 
(~50%) the annual risk of Mtb infection (ARI) had increased as well [31].  
In addition a long term cohort study among South African miners showed that overall TB 
incidence rates increased in HIV negatives as well as HIV positives, suggesting that active 
transmission from the additional TB cases in HIV positives was also affecting TB incidence in 
the general population [23]. However, a similar gold mine study found no such increase [32] 
and to date the relative contribution of the indirect effect of HIV on the TB incidence remains 
under discussion [30, 33].  
1.4.3 HIV, TB and the effect of ART 
The roll out of antiretroviral therapy (ART) will change the interaction between HIV and TB 
disease dynamics and affect TB incidence. The extent and direction of this effect will depend 
on various, interrelated factors, including the immune status of patients starting ART, their 
risk of TB and survival. [21, 34] Several studies have looked at the relative incidence in cohorts 
of HIV positive or ART receiving patients [35-46], but none looked at the effect on the overall 
TB incidence in a a complete population, which is what I will do in Chapter 7. I will discuss the 
existing literature on ART and TB in more detail there. 
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1.5 The molecular epidemiology of TB 
1.5.1 Measuring TB following recent transmission 
Historically one of the complications in the study of TB epidemiology has been the difficulty of 
distinguishing between TB disease following recent (re-)infection or reactivation. [17]  For the 
last 15 years molecular epidemiology of TB explored this distinction through the application of 
DNA fingerprinting of Mtb strains involved in TB episodes. [47]  
1.5.2 General theory of TB molecular epidemiology 
Molecular epidemiology works from the assumption that active TB cases are likely to be 
epidemiologically related if their Mtb strains have identical, or at least similar DNA 
fingerprints. These cases with similar or identical Mtb strains are referred to as clustered. DNA 
fingerprinting techniques thus distinguish between TB cases whose episodes involves a unique 
Mtb strain and TB cases whose episodes involve clustered (i.e. non-unique) Mtb strains.  
If the strain causing the TB episode is unique, it is assumed that the patient’s TB episode is 
more likely to have followed the reactivation of a latent Mtb infection. If the strain is clustered 
it is assumed that the individual was involved in recent transmission. In each group of 
clustered cases with identical strains (so called cluster)  at least one TB case is due to 
reactivation of a latent infection. This is referred to as the source case. All other cases are 
assumed to be due to a recent first infection or reinfection with the Mtb strain transmitted by 
the source case (or by other cases in the cluster). [48] These cases are referred to as 
secondary cases. This definition of secondary cases includes all subsequent cases in the 
cluster, regardless whether the source of their Mtb infection was the original source case or 
another secondary case.  
There are several DNA fingerprinting techniques available; IS6110 Restriction Fragment 
Length Polymorphism (RFLP), Spoligotyping, Polymorphic GC Rich Sequencing (PGRS), 
Mycobacterial Interspersed Repetitive Units-Variable Number of Tandem Repeats (MIRU-
VNTR), and more recently whole genome sequencing. In this thesis I will mostly use data 
acquired with IS6110 RFLP and will discuss this technique in more detail later in this chapter.  
1.5.3 The definition of a clustered case 
The main application of clustering is to identify cases involved in ongoing Mtb transmission. 
Straightforward as this may sound, the application of and interpretation molecular 
epidemiology has varied between studies and settings. In this section I discuss some of the 
areas of variation and the impact on the interpretation of the results.   
1.5.3.1 Identical versus similar 
Firstly, studies can vary the level of required similarity between strains. Some studies allowed 
a small difference between DNA fingerprint patterns. However, usually only strains with 
identical DNA patterns are classified as clustered. If similar as well as identical strains are 
considered to be clustered the proportion of clustered cases will increase. This issue is 
discussed in more detail in Chapter 2.  
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1.5.3.2 Time between source and secondary case 
The definition of what constitutes ‘recent’ in the expression recent (re)infection differs 
between studies. Each researcher needs to decide on the cut-off for the maximum amount of 
time between diagnosis of 2 cases in which the secondary case is still considered to have been 
recently infected by the source case and then rapidly progressed to TB disease from that Mtb 
infection. If the two cases are less than 2 or more than 10 years apart there is usually no 
discussion; in the first cluster the secondary case is assumed to be due to recent infection; in 
the second cluster both cases are assumed to be due to reactivation where the first case may 
have been the source of the Mtb infection, but the infection in the second case first went 
through a latent phase before reactivating. Usually the cut off is set on 4 to 5 years, following 
the development of the risk of TB after Mtb infection (see figure 1—2) although most studies 
do not follow cases sufficiently long to fully capture this effect. 
1.5.3.3 Excluding the source case in a cluster 
The first case, usually based on time of diagnosis, is usually assumed to be the case that was 
the source of the cluster and that the TB followed a reactivation  [10, 49] However, it is 
important to note that TB has a highly variable period between Mtb infection and TB disease 
which has an estimated minimum of 2-3 months [50] to a maximum of the individual’s lifetime 
[17]. Also, some TB cases experience low intensity symptoms for a long period (up to 18 
months) without being diagnosed [12], which makes it difficult to be sure when Mtb 
transmission occurred.  
Still some studies have opted to exclude the first case in a cluster with the aim of acquiring a 
better estimate of the TB cases due to, rather than involved in, recent Mtb transmission. [10, 
49]  
This approach is commonly referred to as the n-1 method. [48] In this method one calculates 
the number of cases in a cluster, minus the number of clusters, as a proportion of all cases. In 
theory, this gives an estimate of the proportion of TB due to recent transmission.  
1.5.3.4 Retrospective clustering  
Another approach is measuring retrospective clustering, which aims to use clustering as a 
measure of cases due to, rather than involved in, recent transmission [51]. Here a case is 
defined as clustered if in a set number of years before (the researchers explored cut offs 
between 1-7 years) another TB case had been found with an identical Mtb strain. This 
approach deals with the issue of the cut off as well as the source case.  
1.5.3.5 Definitions of clustering in this thesis 
Throughout the chapters in this thesis I will use different definitions of what constitutes a 
clustered case depending on the data available and the analysis goal.   
1.5.4 IS6110 RFLP 
Until recent years the main DNA fingerprinting technique used worldwide was Restriction 
Length Fragment Polymorphism typing using the 6110 insertion sequence (IS6110 RFLP). The 
majority of existing molecular epidemiological data is based on this technique, and it forms 
the mainstay of this thesis.  
  
IS6110 RFLP was standardised in 1993 
transmission in outbreak and population settings as I will discuss section 1.5.5.  
Please note that this thesis foc
fingerprinting results, not on the technique itself. This is why I will keep the description of the 
technique brief. In short, IS
IS6110 RFLP uses the variability between Mtb strains in both the number of copies and the 
chromosomal positions of these fragments by cleaving the DNA at the location of each IS
insertion fragment (see figure 1
Each fragment is labelled and then put through a Southern gel Blot. Different sized fragments 
will travel through the blot at different speeds. After photographing a barcode pattern is 
revealed which is referred to as the ‘DNA fingerprint’ for that s
illustration).  
The DNA fingerprints are compared to each other using software and visual inspection and 
grouped clusters of identical DNA patterns. 
An important determinant of the usefulness of a marker is the expected rate of e
half-life of a pattern. This needs to be slow enough to allow identification of epidemiologically 
related cases, but fast enough to see differences over time. The half life for an IS
pattern during active disease is roughly estimated a
for various applications, which are discussed in section 1.5.5. However,
IS61110 RFLP pattern that remained unchanged during a latent Mtb infection for 30 years. 
[54] 
Figure 1—4 Graphic representation of the circular Mtb genome
Blsck sections depict IS6110 
result in Mtb DNA fragments of different length. (Figure courtesy of Judith Glynn) 
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Figure 1—5 Mtb DNA fingerprint patterns from IS6110 RFLP  
Note: each band represents a IS6110 fragment of a specific length. (Figure courtesy of Judith Glynn).  
 
1.5.4.1 Limitations of molecular epidemiology/RFLP 
Unfortunately the molecular epidemiology of TB has some issues that can limit the 
interpretability of its results. In this section I discuss some of the issues related to the 
technique/basic theory and how they affect the interpretation of DNA fingerprints. Factors 
relating to study design, population and setting are discussed in detail in Chapter 2.  
Molecular epidemiology relies on the assumption that a TB episode is caused by 1 strain of 
Mtb. However, recent studies from South Africa extracted multiple strains from the sputum 
sample of individual patients. [55] In a high incidence setting they detected multiple strains in 
19% of their samples, although other studies found percentages between 0.4 and 6% [56, 57]. 
The frequency and clinical significance of mixed Mtb infections underlying the same TB 
episodes is still under investigation. [58]  
The extent to which mixed infections affect the interpretation of molecular epidemiological 
results will depend on the proportion of TB episodes in which mixed Mtb infections are 
shown. This in turn depends on the technique and definition used to detect ‘different’ Mtb 
strains in one sample. In Karonga District, where the majority of the data for this thesis comes 
from, the estimated rate of mixed infections is <4% (preliminary and unpublished data). Also, 
as the next section will show, molecular epidemiology as a method has been validated in 
different settings and applied successfully for different purposes.  
Another issue is that clustering analyses are limited to culture positive TB cases. As the 
proportion of culture positive TB cases differs by HIV status, analyses that compare HIV 
positive and HIV negative cases could give biased results if the proportion of cases following 
recent infection is different for culture negative (e.g. most EPTB cases) and culture positive TB 
cases. There are few reports that clustering is lower in EPTB (which is hard to detect), and a 
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comparison of 4 year retrospective clustering (which excludes presumptive source cases) 
between EPTB and PTB cases in the KPS database showed that the proportion clustered was 
50% in EPTB and 61% in PTB cases. Unpublished data So although there could potentially be 
some bias, the evidence base is small.  
One issue with clustering is stable strains, for which the RFLP pattern appears to remain 
unchanged over a long period, e.g. 10 years or more. Theoretically, if strains predominate in 
an area over a long period the interpretation of clustering as a marker for recent transmission 
becomes problematic as the infection event could have occurred more than 5 years before 
the disease episode started.  
Also, there is a possibility that 2 different strains evolved to an identical pattern 
simultaneously.  
The assumption that only identical strains are part of the same active transmission chain does 
not always hold; a small deletion or recombination in the mycobacterium’s DNA shortly after 
Mtb transmission can cause DNA fingerprints or RFLP patterns to differ, causing the secondary 
case to be attributed to reactivation, whereas in reality they are due to recent transmission.  
RFLP is quite labour intensive. Up to 2mg of live TB culture is required for DNA extraction, 
which means a healthy growth is required for each case which takes time to obtain.   
Also, despite the computer supported process of comparing strains, IS6110 RFLP, is vulnerable 
to technical problems in the preparation which can lead to unclear fingerprints as well as 
subjective interpretation of the results, both of which can lead to misclassification [47].  
In addition, IS6110 RFLP is insufficiently discriminatory when the number of IS6110 fragments 
is low, usually defined as below 6. [59] This makes the technique difficult to interpret in areas 
where a substantial part of the circulating Mtb strains have less than 6 insertions as in South 
East Asia. [47] 
1.5.5 Applications of Molecular Epidemiology 
Despite these potential limitations, DNA fingerprinting data from IS6110 RFLP have been 
extensively validated as a tool to identify TB cases due to recent Mtb infection in various 
settings. However, caution is required in their interpretation. [59]  
1.5.5.1 Outbreaks  
IS6110 RFLP was first validated as a tool in conjunction with epidemiological investigations to 
map TB outbreaks in industrialised settings. [60] IS986 RFLP (an alternative marker to 6110) 
was used to show that all 11 of the culture positive TB cases involved in the outbreak had a 
similar Mtb strain to the source case, whereas 2 other cases had a distinctively different RFLP 
pattern. [60] 
In outbreak settings DNA fingerprinting can show which of the suspected cases was actually 
part of the outbreak, which cases were missed in the epidemiological investigations and which 
suspected TB cases involved in the outbreak were likely to have developed reactivation TB 
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and not involved in the transmission chain. Molecular epidemiology can thus help to inform 
interventions aimed to prevent future outbreaks. [60-64] 
1.5.5.2 Laboratory quality control 
Multiple studies aimed to explore potential cross contaminations in a TB laboratory used 
IS6110 RFLP to compare the Mtb strains of both samples in a pair of potential cross 
contamination. [65-68] Molecular epidemiology was thus able to provide useful information 
on whether cross contamination had occurred and if so, which of the two samples was the 
likely source of contamination.  
1.5.5.3 Spread of Drug resistance 
Molecular epidemiology has been used to study the spread of drug resistance and the relative 
contribution of the transmission of drug resistant Mtb strains or the development of drug 
resistance during TB treatment. [61, 64] 
1.5.5.4 Population studies 
The main area where TB molecular epidemiology has been applied is in population studies. A 
population can be defined narrowly (e.g. a prison population or hospital workers) or wider as 
the whole population in hospital catchment area, city or province.  
By typing all or a sample of TB cases in such a defined a population it is possible to get an 
estimate of the proportion of TB cases either involved in (the crude proportion clustered 
cases) or due to recent Mtb transmission (e.g. through retrospective clustering).  
When measured repeatedly or over a longer period, trends in the proportion clustered can 
give an indication of the progress on TB control in the population. [49, 69]  A reduction in the 
proportion of TB cases that is clustered in an area over time is considered to be a sign of 
improved TB control [70].  
It is important to note however that the observed proportion clustered in a population 
depends on various factors relating to study design, study population and study setting. In 
Chapter 2 I describe these factors and how they affect the observed proportion clustered in 
more detail. In short, an ideal study on TB clustering includes all TB cases from a complete, 
stable and well defined population. For example all TB cases in a district with low levels of 
migration over a long period of time, preferably 5 years or more. [59]   
1.5.6 Application of TB molecular epidemiology in TB and HIV  
Over the years molecular epidemiology has been applied to study the interaction between HIV 
and TB disease.  
1.5.6.1 Relative infectiousness of HIV positive TB cases 
Molecular epidemiology of TB has been applied to study the relative infectiousness of HIV 
positive TB cases within households. DNA fingerprints for TB cases that had identified each 
other as a contact were compared to see whether the first case could have been the source of 
the Mtb strain causing the TB episode in the second case.  
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This study found that if the suspected source case was HIV positive the strains were less likely 
to match (OR (95%CI) = 0.32 (0.14 – 0.74)). [71]  This suggests that HIV positive TB cases are 
less likely to be the source of infection.  
1.5.6.2 HIV and recurrent TB in populations 
Two studies of recurrent episodes of TB compared the DNA fingerprints of the strains involved 
in both episodes and were able to report the rate of recurrent TB due to relapse or recent 
reinfection, stratified by HIV status. [72, 73]  Their analyses showed that the rate of 
recurrences due to recent re-infection was much higher in HIV positive TB cases. In South 
Africa the hazard ratio (95% CI) was 18.7 (2.4 – 14.3) [73], in Malawi this was 13.5 (1.8-103.7) 
[72]. There was no relevant difference by HIV status in the rate of recurrences due to relapses.  
1.5.6.3 HIV and the risk of TB following recent infection versus reactivation 
In Chapter 3 I report the results of a systematic review on this issue. Please refer to that 
chapter for a detailed description of the available work on this issue.   
1.6 Main questions and thesis structure 
1.6.1 Main questions 
In this thesis I will address and attempt to answer the following questions 
1. Why does the population proportion clustered vary so strongly between studies and 
settings? (Chapter 2)  
2. What is the relative effect of HIV on TB following recent Mtb (re-)infection and TB 
following reactivation of a latent Mtb infection? (Chapter 2, 3, 4 and 5) 
3. What is the effect of the roll out of ART on the incidence of TB in a rural African 
population? (Chapter 6 and 7)  
1.6.2 Structure of the thesis 
Chapter by chapter I will discuss the following: 
1.6.2.1 Chapter 2 
In Chapter 2 I will explore the variation in the observed proportion clustered between studies 
of general populations using data from a systematic literature review on all population–based 
studies on TB clustering that used IS6110 based RFLP as the main DNA fingerprinting 
technique. I will use the resulting dataset to examine the extent to which this variation in 
observed clustering can be explained by study design, study setting (the local epidemiology of 
TB) and study population. In the process I develop a new tool for the interpretation of a locally 
observed proportion clustered in the context of a study’s design and setting.  
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1.6.2.2 Chapter 3 
In this chapter I describe a systematic review and pooled data analysis of studies with 
information on HIV and TB cluster status of TB cases from populations where HIV is 
generalized and TB prevalence is high to examine the association between HIV and TB 
clustering. The overall aim of the chapter is to infer a valid estimate of the relative effect of 
HIV on TB due to recent (re-)infection and reactivation.  
1.6.2.3 Chapter 4 
In this chapter I will introduce the general methods and database of the Karonga Prevention 
Study (KPS) a large, longitudinal research project in Northern Malawi. I will also show the 
results of an analysis aimed to investigate the stability over time of the associations found in 
Chapter 3.  
1.6.2.4 Chapter 5 
In this chapter I combine KPS data from population TST surveys done before 1990 and DNA 
fingerprint data from Individuals experiencing a first TB episode between 1996 and 2008 in 
Karonga District to explore the association between recent re-infection with Mtb before an 
individual’s first TB episodes and the effect of HIV infection.  
1.6.2.5 Chapter 6 
In Chapter 7 I will describe analyses of the incidence of TB in Karonga District over time and by 
HIV and ART status. This chapter describes the data collection and processing required to 
obtain valid estimates for the denominators used for those incidence analyses; the sizes of the 
general population by year, the proportion of that population that was HIV positive and the 
number of people receiving ART in the district.  
1.6.2.6 Chapter 7  
This chapter aims to estimate TB incidence over time in the general population as well as by 
HIV and ART status in Karonga District. Also I explore how ART, which was introduced in mid 
2005, has affected these trends.  
1.6.2.7 Chapter 8 
In chapter 8 I will summarise the results of this thesis, discuss the answers to the questions 
and how these answer can affect public health and future policy decisions. Finally I will outline 
remaining research questions and future work that follows from this thesis.  
1.6.3 Ethical approval 
The majority of the analyses done here were secondary analyses of previously collected and 
anonymised data. All original studies were approved by the Malawi National Ethics Committee 
and the ethics committee of the UK home institution (LSHTM). For the individual ethics 
submission approval numbers, please see the publications of the work. Where I initiated a 
new study I will describe the ethical approval procedures.  
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1.6.4 Statistical analysis software 
All statistical analyses were done using the Stata statistical software package (version 9 or 10) 
unless otherwise specified.  
1.6.5 Publications from work in this thesis 
Since the start of my PhD I developed several pieces of work presented in this thesis into 
papers. As of July 2010, work described in chapters 2, 3, 4 and 5 have been published, are in 
print or are accepted for publication. A paper based on Chapter 7 is currently under review 
with a journal, and I am preparing the ART register work described in Chapter 6 for 
publication.  
1.6.6 Personal contribution to data collection 
The data used in Chapter 2 and 3 were collected from literature reviews that I executed. 
Chapter 4 described the data collection methods from the Karonga Prevention Study, where 
the data from the remaining chapters comes from. Most of the data was collected before I 
started my PhD, but I spent 1 year (February 2009 – February 2010) on site in Northern 
Malawi supervising the ongoing data collection (see Chapter 4). While there I also set up new 
studies to collected specific data I required for my thesis (see Chapter 6).  
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2 A systematic review and meta-analysis of molecular 
epidemiological studies of tuberculosis: development of a new 
tool to aid interpretation 
2.1 Summary 
In this chapter I explore the variation in the observed proportion clustered between studies of 
general populations through a systematic literature review of all population–based studies on 
TB clustering that used IS6110 based RFLP as the main DNA fingerprinting technique. I will use 
the resulting dataset to examine the extent to which this variation in observed clustering can 
be explained by factors describing study design, study setting (the local epidemiology of TB) 
and study population. Through the analyses I develop a new tool to aid the interpretation of 
the locally observed proportion clustered considering the study’s design and setting.  
The work described in this chapter has been adapted into a paper which has since been 
published. [74] 
2.2 Introduction 
2.2.1 Background 
It has been observed that proportion clustered varies strongly between populations [51, 75, 
76].  However, as mentioned in Chapter 1, the proportion clustered that is observed in a 
population depends on a variety of factors relating to study design as well as the study 
population and study setting. [59, 77, 78]. 
This complicates the comparison of results between studies. It is difficult to know to what 
extent this variation between studies represents true variation in the proportion of TB that is 
involved in ongoing Mtb transmission, and how much on other factors.  
For example, a low proportion of clustered cases in a study population could be interpreted as 
that showing there is little TB due to recent transmission and therefore good TB control. 
However, the proportion could merely be an artefact of study design and be concealing a 
higher true proportion clustered in the population.  
2.2.2 Factors that affect the observed proportion clustered  
2.2.2.1 Study design 
The observed proportion clustered depends on the design of the study that measures it. 
Modelling and molecular epidemiological studies have shown that who is included in the 
study can have a major influence on measured clustering. Clustering is underestimated as the 
proportion of all TB cases in the region that are included (the sampling fraction) decreases 
[78].  
Conventionally the period between a new Mtb infection and what is considered to be TB 
disease following recent infection TB disease is 5 years. [15, 17]  A study measuring the 
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proportion clustered in a population therefore needs to have a study duration sufficiently long 
to be able to record whether a unique case in year 1 may still cluster with a case in year 5. [51, 
59] A number of long term population based studies looked at how the proportion clustered 
changed if they artificially reduced the follow up time. They showed that the observed 
proportion clustered increases with study duration up to a plateau after about 4 years [51, 79, 
80].  
A clearly defined study area is also important, as high levels of migration in and out of a poorly 
defined area will artificially decrease the proportion of cases found to be clustered, as cases 
due to recent infection are misclassified as reactivation. This problem is reduced when an area 
approximates to a complete and relatively isolated population such as a country or district 
[59, 78]. 
In general, any feature which means that the study population is not a complete sample of a 
closed population will tend to underestimate the true proportion clustered.  
Over–estimation of the proportion clustered is less likely, although theoretically possible with 
biased sampling and contact tracing. In areas where there is insufficient variation in strains, or 
predominance of strains with few bands, identical strains cannot be assumed always to reflect 
recent transmission. There is also variation between studies in the laboratory techniques 
used, and in the rigour of the definition of clustered strains [59, 81].  
In practice no study can be designed that satisfies all criteria perfectly; some bias will always 
remain.  
2.2.2.2 Study setting 
The proportion of TB due to recent transmission in a population depends on the annual risk of 
infection (ARI), both currently and in the past. A higher ARI represent higher levels of ongoing 
transmission which should result in a higher proportion of clustered cases. Modelling studies 
have shown that if the ARI changed over time the age patterns in the proportion clustered get 
more pronounced. [82] The decrease in ARI seen in most industrialised countries [83, 84] has 
been associated with a pronounced pattern of a relatively high proportion of clustered cases 
in the younger population and low proportion of clustered cases in the old in the non-migrant 
populations in those areas. [49]   
2.2.2.3 Study population 
Population based studies have confirmed that with age the risk of reactivation TB increases 
and in older age groups the proportion of all TB cases that is clustered is lower. This effect was 
both seen in low and high resource settings [69, 85] 
Also, as discussed in Chapter 1, HIV prevalence in the TB case population could also be 
important as the relative effect on the risk of disease following recent or past infection could 
be different. 
For studies in industrialised settings the proportion of TB cases that are foreign born is also 
relevant. [59]. In these regions immigrants usually account for a substantial part of the TB case 
population. They are likely to have been infected with Mtb in their country of origin where the 
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annual risk of infection is relatively high [70, 79, 86], and therefore often have unique (non-
clustered) strains, adding to the diversity of Mtb strains in the population [48, 87]. However, 
through socio–demographic factors they could also be at a higher risk of being in a cluster, 
thus increasing the proportion clustered.  
TB in industrialised countries is often focussed in high risk groups such as people who are 
homeless, abuse alcohol or use Intravenous drugs. Ongoing Mtb transmission in those pockets 
of society may be higher than in the general population, resulting in higher rates of clustering.  
2.2.3 Other reviews on this subject 
During the final phases of the work described in this chapter 2 other systematic literature 
reviews on the subject of IS6110 RFLP were published. [88, 89] This piece of work was 
prepared separately.  
My approach distinguishes itself from these other publications by examining the variability of 
clustering on the population level. Rather than collating results from varying study designs 
and populations on the risk of clustering for individual TB cases, this chapter sets out to take a 
more public health approach by investigating the proportion clustered in populations while 
explicitly taking into account the differences in study design and setting. Furthermore, the 
methods used for the literature search and statistical analysis of one of these publications 
gave serious reasons for concern, which I formulated in a letter to the editor. [90]  
2.3 Methods  
2.3.1 Inclusion and Exclusion criteria systematic literature review 
Studies on TB clustering that used IS6110 RFLP as the main DNA fingerprinting technique were 
eligible for inclusion in the review if they were population–based and reported clustering 
results (number of strains in RFLP analysis and proportion clustered) for more than 100 
individuals. Studies were excluded if the sample population was not representative of the 
general population as this could bias the proportion clustered. For example, I excluded studies 
on prison population, drug resistant patients only and outbreak studies.  
In addition, the study area had to be suitable for making a valid estimate of local TB clustering. 
For example, inclusion of patients from a single hospital would be acceptable if all TB patients 
in the area are likely to go to that hospital, but not otherwise. In practice study areas had to 
minimally consist of a geographically defined urban or rural district. Overall, these criteria 
were necessary to reduce bias (which cannot be corrected for) in the dataset, allowing a valid 
examination of and correction for factors that influence the estimated proportion clustered. 
There was no language restriction, and papers were translated by a fluent speaker as 
required. 
2.3.2 Paper collection  
Pubmed and Embase databases were searched between 1990 and November 2006. After 
maximizing the sensitivity of the search by using a private collection of relevant TB clustering 
papers, the following Pubmed search query was used: ‘IS6110 OR RFLP OR fingerprint* OR 
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cluster* OR genotyp* OR "Epidemiology, Molecular"(MeSH) OR "molecular typing" OR 
transmission OR "molecular epidemiological" OR "molecular epidemiology") AND (tuberculosis 
OR tb) AND ("1990" : "3000"(PDAT))’. A similar search query was used for Embase. The TB 
publications archive from the Centers for Disease Control and Prevention was accessed but 
yielded no additional papers [91]. After excluding duplicates all titles were scanned twice for 
possible relevance. The remaining abstracts were read and eligible full length papers were 
retrieved if possible.  
2.3.3 Data extraction 
From each paper I collected information on study methods (secondary DNA typing methods, 
the cut–off points (if present) for Mtb strains with few IS6110 bands, matching of DNA 
fingerprints), the number of patients eligible and included in the final DNA fingerprint analysis, 
TB clustering results, characteristics of the study population (age, proportion males, HIV 
positive and foreign born) and TB disease (proportion of smear positive, extra pulmonary, or 
drug resistant TB cases). In addition, I recorded TB incidence in the region. Where more than 
one paper provided data on the same population and study period only the one with the 
longest study duration was included. Queries regarding the extracted data were discussed 
with Professor Judith Glynn.  
2.3.3.1 Measures of TB disease due to recent Mtb transmission 
The main study outcome was the proportion of clustered TB cases, i.e. number of cases in 
clusters / total number of cases. The reported proportion clustered was used, although the 
strictness of the definition differed between papers; most requiring identical fingerprints, but 
some allowing one band difference. IS6110 RFLP is not sufficiently discriminatory in strains 
with low band numbers (usually 5 or less) [59], and if sufficient information was provided we 
either excluded these strains or recorded the overall proportion clustered when a secondary 
DNA typing technique (Spoligotyping, Polymorphic GC Sequencing (PGRS), Direct Repeats) was 
used for these low band number strains. The proportion of TB due to recent transmission was 
estimated as (number of clustered cases – number of clusters)/number of cases, the “n-1” 
method [48]. This assumes that each cluster consists of one source case, due to reactivation 
disease, the rest being due to recent infection.  
2.3.3.2 Study Design 
Study duration was recorded in months. Cross sectional surveys were assigned a duration of 0 
months. If studies only allowed cases to cluster in a certain period after the source case, this 
“clustering interval” was used as study duration. I recorded the fraction of all culture positive 
(C+) TB cases (of all types) in the catchment area that had RFLP results available. I recorded 
whether the RFLP analysis included Mtb strains with low band numbers, and if so, whether a 
secondary DNA typing technique (e.g. spoligotyping or polymorphic GC sequencing) was 
applied for these [92, 93].  
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2.3.3.3 Study setting  
When possible the TB incidence in the study region as reported in the paper was used. 
Otherwise the sampling fraction, reported TB incidence, study duration and study population 
size were combined to estimate the regional TB rate. If that was not possible, the scientific 
literature was searched for region specific estimates or we used the WHO website for a 
country wide estimate [20]. Studies were classified into low, middle and high burden TB areas 
(TB incidence <10, 11–50 and 50+ TB cases /100,000 /year respectively).  
2.3.3.4 Study population  
Studies from industrialized areas (e.g. Western Europe, North America) were grouped 
together. For these areas I recorded the proportion of TB cases that were foreign born. Where 
available I also collected data on the proportion of cases with (a history of) homelessness or 
drug and alcohol abuse.  
Age was recorded as the average for the TB case population; either as the reported mean or 
median age or, if only age strata were reported, through estimation of the median age within 
the age stratum that held the median observation. Gender was recorded as the proportion of 
males in the study population. As historical data on the annual risk of infection were not 
available for the majority of studies, the mean age of the TB case population can be used a 
proxy, with a declining annual risk of infection shown by a high mean age of TB disease [82].  
If at least 50% of all TB cases were systematically tested for HIV, we recorded the proportion 
HIV positive of those with test results. If the paper itself did not report the variable, an 
estimate was extracted from papers that reported on the same population.  
2.3.4 Statistical analyses 
Non–parametric tests (Wilkoxon rank sum) were used to compare studies from industrialized 
countries with those from other countries.  
To assess the extent to which the variation in clustering seen can be explained by study 
design, study setting (the local epidemiology of TB) and study population I applied meta–
regression (metareg command; Stata v10) [94, 95]. This technique allows multivariate 
regression analysis to ascertain how well individual or a combination of variables can explain 
the between study variation in the proportion clustered (the ‘tau^2’) [96, 97].  
Meta–regression assumes a linear association between the outcome (proportion clustered) 
and the independent variable as well as an approximately normal distribution of the residuals. 
The latter was checked through visual inspection of the residuals (scatterplots and 
histograms) and statistical tests (sktest in Stata v10). The choice between entering a variable 
as categorical or linear was dependent on its distribution, known epidemiological associations 
and the impact on the between study variation. A variable describing the standard error of the 
outcome (proportion clustered) is required for each study. I calculated this by taking the 
square root of ‘p*(1-p)/N’, where ‘p’ stands for the proportion clustered in a study, and N the 
total number of study participants.  
The effect of the study design and recorded variables was first examined through univariate 
meta–regression. To allow for potential negative and positive confounding due to high 
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heterogeneity of variable values between studies, all variables were considered for the 
multivariate models. Final inclusion of a variable in a multivariate model was based on 
whether adding the variable had a significant impact (>2.5% reduction) on the between study 
variation.  
Four models were created. The main model was limited to variables describing study design 
and epidemiological setting (the local TB incidence), to ascertain to what extent these could 
reduce the variation in the proportion clustered.  
The second model included variables describing the study population as well. A third model 
was limited to studies from industrialized countries, and included the proportion of TB cases 
that were foreign born. These models were designed to test to what extent the observed 
variation could be explained by known factors, and how much residual, unexplained variation 
would remain. A fourth model excluded local TB incidence from the main model.  
All models were repeated with the proportion of cases due to recent transmission (n-1 
method) as the outcome measure to test the robustness of the findings.   
2.3.5 Tool to interpret local proportions clustered  
The coefficients from the main model were applied to each study to acquire a predicted value 
for the proportion clustered based solely on the study’s design and local TB incidence. These 
estimates were compared to the observed values ((observed – expected) / expected *100%) 
to provide a measure of how much the observed proportion clustered differed from its 
expected value. This correction for study design and setting provides a new perspective on the 
proportion clustered, and allows for better comparison between studies. Confidence intervals 
for the relative differences were estimated using the standard error of the predicted values 
(stdp option in Stata v10).  
2.4 Results  
2.4.1 Systematic literature review 
The primary literature search yielded 11654 records, and after selection (figure 2—1) 46 
papers were included for analysis.  
2.4.2 Descriptive analyses 
The majority of studies (36) were performed in industrialized country settings (North America, 
Western Europe, Japan or Hong Kong); the others were done in sub–Saharan Africa (n=3), 
South America (n=4) and in South East Asia, Eastern Europe, and the Middle East (one each).  
Figure 2—2a shows a Forest plot for the proportion clustered in all 46 included studies 
arranged by study location. It shows a large variation in the proportion clustered between 
studies (Q–test for heterogeneity chi square=6622 (df=46), p <0.0001), from 6% in Northern 
Bangladesh to 86% in Greenland. Included studies and their recorded variables are listed in 
table 2.4 at the end of this chapter.  
Table 2.1 summarizes the main characteristics of all studies by the region in which they were 
conducted. It shows that studies were diverse in their design (e.g. study duration between 0 
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months (cross sectional study) and >10 years) as well as the setting (recorded local TB 
incidence between 1.7 and 304 cases/100,000/year). TB incidence differed strongly between 
industrialized settings and other settings (p <0.001), whereas the proportion of HIV positive 
TB cases did not (p=0.88). Insufficient data were available on homelessness and drug or 
alcohol abuse so these variables were not included in the analyses.  
Figure 2—1 Flow diagram of systematic literature review process 
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Figure 2—2 Observed (left) and predicted (right) proportions clustered of 46 included studies. 
 
The predicted values for each study were acquired using the coefficients from the meta-regression model 1 (see table 2.2, column 2) that included study duration, 
sampling fraction, handling of Mtb strains with low band numbers and local TB rate. Table 2.4 (see end of chapter) holds the values for each study, see Table 2.3 for 
further illustration of the calculations. Box size and error bars indicate number of patients included in the study.  
* ‘Other regions’ refers to sub Saharan Africa, South East Asia, South America, Eastern Europe and Middle East. 
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Table 2.1: Summary of included studies by study region 
 Study region 
Variablesa 
Industrialized countries Other countriesb 
N=36 N=10 
Study design   
Study Duration (months)  48 (3 to 120) 13 (0 to 87) 
Number of patients  520 (114 to 4266) 372 (105 to 1029) 
Sampling fractionc  
0.90 (0.30 to 1.00) n=36 0.82 (0.002 to 1.00) 
n=10 
Low band numbers included n/N (% 
studies)  
13/36 (36) 6/10 (60) 
Secondary DNA typing method used for 
low band numbers n/N (% studies) 
13/36 (36) 3/10 (27) 
   
Study setting    
TB rate in the region (n/100,000/year) 9 (2 to 185) 90 (8 to 761) 
   
Study population   
Average age (years)  45 (30 to 69) n=30 45 (33 to 55) n=9 
Sex (% male) 65 (44 to 74) n=28 59 (47 to 76) n=8 
% Foreign born 44 (3 to 83) n=28 Not recorded 
% HIV positive 16 (1 to 57) n=21 16 (1 to 65) n=4 
% Resistant to ≥ 1 drug  10 (0 to 31) n=17 10 (6 to 23) n=5 
   
TB Transmission    
% clustered  35 (8 to 86) 29 (6 to 72) 
% recent transmission 25 (4 to 78) n=34 20 (3 to 59) 
‘N’ = total number of studies in TB burden category; ‘n’ = number of studies used in cell; ‘%’ = 
Proportion of all study participants. 
a Median and range given unless otherwise indicated.  
b Studies performed in sub Saharan Africa (n=3) South America (n=4), South East Asia (n=1), Eastern 
Europe (1), and the Middle East (n=1). 
c Sampling fraction is fraction of all culture positive TB patients in the study area with RFLP results 
available. 
 
2.4.3 Meta–regression analyses 
Figure 2—3 shows that the proportion clustered increased with increasing study duration, 
sampling fraction and TB incidence, decreased with increasing age and proportion foreign 
born (in industrialized countries) and changed little with increasing study size. In the 
univariate meta–regression analyses these associations were confirmed (Table 2.2). Some 
variables reduced the tau^2 by more than 10% (duration of study, handling of low band Mtb 
strains, age and country of birth of TB case population), whereas others had less or no effect.  
Study duration was entered as a categorical variable so its association with clustering could 
take any shape, including the one shown within populations where clustering increases with 
study duration, but reaches a plateau after 4 years [51, 78-80].  
Chapter 2 – TB clustering in populations 
 
36 
 
In the multivariate meta–regression model (table 2.2, model 1) 28% of between study 
variation was explained by study duration, sampling fraction, handling of strains with low 
band numbers and local TB incidence. Most coefficients of the included variables were 
statistically significant at the 0.05 level, and the residuals were approximately normally 
distributed (p value sktest=0.46). In this model, the proportion clustered increased with study 
duration and sampling fraction. The model also showed that including strains with a low 
number of IS6110 bands increased the proportion clustered, unless secondary typing methods 
were applied. Additionally, study settings with high TB incidence reported higher proportions 
clustered.  
Incorporating variables describing the study population further reduced the tau^2, explaining 
up to 60% of the between study variance (table 2.2, model 3). When studies for all countries 
were considered (table 2.2, model 2), the average age of the TB case population showed a 
strong negative association with the proportion clustered. In studies from industrialized 
settings, the proportion clustered decreased as the proportion foreign born increased (p value 
coefficient <0.001). This negative association was found in 18 out of the 21 studies from 
industrialized settings that reported the proportion of foreign born TB cases by cluster status, 
whereas only one study, from Italy, found a positive association [98].   
Excluding local TB incidence from the main model (model 4) reduced the explained variation 
from 28 to 10% as well as the precision of the coefficients. However, the direction and size of 
the coefficients remained similar. 
None of the other variables I recorded had a relevant effect on the tau^2. Similar results were 
found using the proportion of cases due to recent Mtb transmission (estimated using the n-1 
method) as the study outcome, rather than the total proportion clustered (results not shown). 
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Table 2.2: Meta–regression models: % explained between study variation and coefficients for change in the 
proportion clustered for variables describing study design, setting and population  
 
Univariate modelsa 
Model 1: 
Study design 
and setting  
Model 2:  
Overall   
 
Model 3:  
Industrialized 
countriesb 
 
 
 
 (n=46) 
28% of variation 
explained 
(n=39) 
36% of variation 
explained 
(n=25) 
60% of variation 
explained 
     
Study design  
 
Study duration (months) 
 
11.7 
 
18.3 
 
5.6 
 
24.9 
0–12 ref ref  ref  ref  
13–48  -7.3 (-23 to 9) -3.2 ( -20 to 13) -2.6 (-17 to 12) 21.1 (4 to 38) 
>48  11.5 (-5 to 28) 18.3 (2 to 35) 11.1 (-4 to 26) 28.1 (10 – 46) 
Sampling fraction (proportion of 
culture positive cases with 
RFLP) 
 
2.2 
 
8.9 
 
8.7 
 
5.6 
0–0.50 ref ref  ref  ref  
0.50–0.75 22.2 (-4 to 48) 27.7 (0 to 55) 30.1 (5 to 55) 29.4 (-2 to 61) 
0.75–1 18.9 (-11 to 49) 29.6 (6 to 53) 22.7 (0 to 45) 24.1 (-3 to 51) 
 
Low band strains  
 
10.8 
 
3.9 
 
– 
 
16.1 
Excluded ref ref   ref  
Included with secondary typing 9.1 (-5 to 23) 0.6 (-12 to 13)  3.3 (-9 to 16) 
 Included, no secondary typing  21.8 (5 to 38)  18.8 (-1 to 39)  21.7 (5 to 38) 
 
Number of patients included 
 
0 
 
– 
 
– 
 
– 
100–200 ref 
201–500 -0.1 (-17 to 17) 
>500 8.0 (-7 to 24) 
 
Matching of fingerprints 
 
0 
 
– 
 
– 
 
– 
Identical ref 
1 band difference 1.6 (-21 to 18) 
     
Study setting     
 
TB incidence in study area 
 
0.8 
 
17.9 
 
3.8 
 
3.1 
Low (<=10/100,000/year) ref ref  ref  ref  
Medium (11–50/100,000/year) 3.7 (-11 to 19) 17.9 (2 to 34) 9.8 (-4 to 23) 8.3 (-6 to 22)  
 High (> 50/100,000/year) 12.2 (4 to 28) 25.4 (9 to 41) 13.6 (-2.5 to 30) 16.4 (-14 to 47) 
     
Study population      
Average age 
 
27.6 NA 7.9 9.3 
-1.28 (-1.9 to -0.6) -0.83 (-1.6 to 0.04) -0.9 (-1.9 to -0.02) 
 
% foreign born 
 
 
17.7 
 
NA 
 
NA 
 
63.7 
-0.54 (-0.8 to -0.3) -0.36 (-0.6 to -0.1) 
 
Sex (% male) 
 
0 
 
NA 
 
– 
 
– 
 -18.9 (-102 to 65) 
 
% HIV positive 
 
9.5 
 
NA 
 
– 
 
– 
  0–10 ref 
  10–25 14.8 (-1 to 31) 
  >25 12.7 (-3 to 28) 
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% Resistant to ≥ 1 drug  0 NA – – 
0–10 ref 
10–20 -10.0 (-34 to 14) 
> 20 -5.9 (-35 to 23) 
Constant  
(baseline value + (95% CI)) 
 -12 (-40 to 17) 42 (-9 to 92) 46 (-16 to 109) 
The bold numbers show the proportion of the heterogeneity explained by each variable, calculated as 
the absolute reduction in explained variation when the variable is removed from the meta–regression 
model. Only variables that increased the overall explained variation by at least 2.5% were included in 
the multivariate models, otherwise a “–“ is shown .The coefficients (95% CI) in the multivariate analysis 
show the difference in proportion clustered between categories (e.g. low versus medium TB burden) or 
per unit increase (e.g. 1 year of average age) in the variable. The interpretation of the coefficients is 
further illustrated in Table 2.3  
Note: the individual % explained variation per variable do not sum up to the overall % explained 
variation in the model. This is because of high levels of correlation between some explanatory 
variables.  
NA – not applicable. 
a Proportion of explained variation in the univariate analysis.  
b Includes studies from Western Europe, North America, Hong Kong and Japan.  
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Figure 2—3: The association between the proportion clustered and recorded variables  
 
Scatter plots show univariate associations between the proportion clustered and selected recorded variables. Vertical lines show the categories used in the meta-
regression. Open diamonds signal outlier values for the recorded variable.  
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2.4.4 Observed versus expected proportion clustered 
For each study the expected proportion clustered could be estimated from the coefficients of 
the main model. The results are shown in figure 2—2b and the relative difference between 
the expected and observed values is shown in figure 2—4. Table 2.3 illustrates these 
calculations. Figure 2—4 illustrates that high observed proportions clustered often lie close to 
their expected values (e.g. studies from Elche (Spain), Cape Town (South Africa) and Karonga 
(Malawi) [51, 99, 100]). However, for some studies the levels of reported clustering were 
twice as high as expected based on study design and setting alone. This applied to regions 
with apparent moderate as well as higher levels of clustering, for example Arkansas (~40% 
clustered) and Gran Canaria ( 72% clustered) [101-103]. On the other hand, studies from 
Vancouver, Japan and Bangladesh reported proportions clustered half as high as that 
expected [87, 104, 105].  
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Figure 2—4: Relative difference (in %) between observed and expected proportion clustered. 
 
*Other regions’ refers to sub Saharan Africa, South East Asia, South America, Eastern Europe, Middle East. Error lines indicate 95% confidence intervals of predicted 
values, calculated using standard error of predictions. 
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Table 2.3 Calculation of relative difference in proportion clustered  
  Study location  
Variable Coefficienta Hokkaido [106] Cape Town [100] Arkensas [101] 
Constantb -12  X X X 
Study duration (months)     
0–12 0    
13–48  -3.2  X  X 
>48  18.3   X  
Sampling fraction 
proportion of culture positive cases 
included 
    
0–0.50 0     
0.50–0.75 27.7     
0.75–1 29.6  X X X 
Low band strains     
Excluded 0  X  X 
Included with secondary typing 0.6   X  
Included, no secondary typing  25.4    
TB burden in study area     
Low (<=10/100,000/year) 0    X 
Medium (11–50/100,000/year) 17.9  X   
High (> 50/100,000/year) 25.4   X  
     
Expected proportion clustered 32.3 61.9 14.4 
Observed proportion clusteredc 8 72 42 
Relative differenced -75.2% +16.3% +191.6% 
a Coefficients gives the change in the expected proportion clustered for each category. 
b The baseline value of the proportion clustered. 
c As reported by the study. See table 2.4 for details. 
d Relative difference is calculated as (observed - expected / expected) * 100%. 
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2.5 Discussion 
2.5.1 Systematic review and meta-regression  
In this chapter I show that although the proportion clustered varies widely between 
population based studies, 28% of this variation can be explained by just four variables 
describing study design and setting. Models including the average age and immigrant status of 
the TB case population explained up to 60% of the between study variation in industrialized 
countries.  
The residual variation can be due to imprecision of included variables, unmeasured factors, 
and interactions of the included variables (for which there were insufficient studies to test). 
With the current level and detail of reporting of clustered studies it seems likely that any 
explanatory model will have a lot of unknowns.  
Although most coefficients of the main model were statistically significant at the 0.05 level, 
the confidence intervals were wide. This is in part due to the low number of included studies 
(46–25 depending on the model) and possibly the high heterogeneity in variable values.  
The latter is also suggested in model 4. The removal of one explanatory variable (local TB 
incidence) has a big impact on the unexplained variation between studies as well the precision 
of the coefficients, without affecting their overall patterns.  
This high heterogeneity is one of the main reasons for the exclusion of studies that applied 
DNA fingerprinting techniques other than IS6110 RFLP as their main method of strain typing. 
The number of studies per technique is relatively low, and insufficient to correct for the added 
variation due to, for example, an unknown level of difference in molecular clocks of the 
markers used in each technique.  
Most associations found in this review are statistically strong and in line with observations 
made in individual epidemiological and modelling studies, thus giving the meta–regression 
models additional validity. The importance of study duration in clustering studies has been 
well documented through modelling [78] and epidemiological studies [51, 79, 80]. The results 
show that this is also important when comparing between studies. The effect of the sampling 
fraction has been predicted through modelling [78, 107] and is intuitive, especially when the 
average cluster size is small: the ‘missing’ part of the population will lead to more clustered 
cases being classified as unique, thus underestimating the proportion clustered. The expected 
increases in clustering with local TB incidence and with younger age were also seen [70, 79, 
86].   
The strong negative association of foreign born TB cases and the proportion clustered, and the 
fact that 18 out of 21 studies from industrialized countries reported the same statistically 
significant association on the individual level, both imply that on average foreign born cases 
have a lower risk of being part of an identified cluster in a study setting.  
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2.5.2 Observed versus expected clustering  
The comparison between observed and expected clustering highlights outliers. More 
clustering than expected could arise in situations where there is a low number of circulating 
Mtb strains and little population movement, so that identical strains could reflect 
transmission many years previously; this could account for the findings from Arkansas [101]. 
TB outbreaks will increase clustering, which was the case in Gran Canaria where two Mtb 
strains were involved in 30% of all clustered TB cases [103]. 
Lower than expected clustering (based on model 1) could reflect an old population with much 
disease due to reactivation, as in Japan where the average age was 69 years [106]. If we apply 
model 2, which includes age, to this study the expected clustering is estimated at 18%, which 
lies much closer to the observed value. The results from the Bangladesh study appear to be 
due to under sampling; only 111 out of 1264 (9%) notified cases from the region and study 
period were confirmed by culture and thus potentially included in the clustering analysis 
[105]. This effect is not included in our model; the sampling fraction was calculated as the 
fraction of confirmed culture positive cases due to limitations in the reporting of studies. 
 The comparison of observed and expected clustering also shows the degree to which high 
observed clustering can be explained: in Malawi, Cape Town and Greenland the high levels of 
clustering were largely due to the studies’ long duration, high sampling fraction and the high 
local TB rates [51, 100, 108-110]. 
It would have been preferable to be able to include more studies from high burden countries, 
but no further studies were available. However, the effect of study design factors is likely to 
be constant in different regions (as is the case with study duration [51, 79, 80]). A total of 10 
included studies were from areas with a high annual TB incidence (>50/100,000O), which 
should make these results applicable to high burden settings.  
2.6 Conclusion 
This chapter focussed on the variability of observed proportions clustered in all populations 
and the extent to which it can be explained by known factors. The methods and associations 
presented in this chapter can be applied by researchers to acquire a new perspective on the 
proportion clustered, after adjusting for study design and setting. This will allow a more valid 
comparison between studies, highlight outliers, and help researchers to assess their local 
levels of ongoing Mtb transmission.  
This chapter aimed to take a broad view on the molecular epidemiology of TB in populations 
and therefore included studies from all regions. In the next chapter the focus will turn to areas 
with generalised HIV epidemics [3] and to start examining the association between TB 
clustering and HIV infection. 
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Table 2.4 Summary of studies included in meta–regression analysis 
Study Location  
 
 Study Design Study Setting & Population 
TB trans-
mission 
 Study population and DNA fingerprinting methodsa 
 Inclu
sion
 by IS
6110
 band
 num
be
r 
 S
econdary D
N
A
 typing
 m
e
thod
 (cut–o
ff) b 
 P
a
tients in
 D
N
A
 fingerprint analysis
 
 D
ura
tion
 (m
on
ths) 
 S
am
pling
 fraction
c 
 Local T
B
 incidence
   
 (n
\year\100,000) 
 A
verage
 age
 (years) 
 H
IV
 positives (%
) 
 S
ex  (%
 m
ale) 
 F
oreign
 born (%
) 
 C
lustered (%
) 
 R
e
cen
t transm
ission
 (%
) 
WESTERN EUROPE              
Brescia (Italy) [98] All c+ cases from Brescia province, '91–'97  All Spol  (<3) 195 84 0.30 15 47 14 67 30 27 16 
Denmark & Greenland [111] Nearly all c+ patients in Denmark & Greenland, '92–'01, 4% of 
all strains were second or third isolate from same patient 
All . 3936 120 0.97 4 40 . . 58 56 . 
Department Nord (France) [112] Most (~90%) c+ TB cases in Department Nord, '95d  All . 154 12 0.66 9 54 7 73 26 18 9 
Elche (Spain) [99] Sample of all c+ diagnosed patients in Elche Health district, 
'93–'99. No information reported about sampling method 
>4 . 141 84 0.59 99 37 29 70 . 55 38 
Gran Canaria (Spain) [103] All c+ TB patients in Gran Canaria between '93–'96 >4 . 566 48 0.79 29 39 16 69 7 72 58 
Greenland (Denmark) [108] All identified TB patients from Greenland, ‘90–‘97 
15 c+ cases from study region were not notified, and not 
included in DNA fingerprint analysis 
>7e . 310 96 0.93 130 30 . 53 . 85 78 
Greenland (Denmark) [109] All notified patients from Greenland, ‘98–‘02 
No data on missed cases, ~60% of notified cases were c+ 
>7e . 198 60 0.94 185 . . . . 86  
Hamburg (Germany) [113] All reported c+ TB cases in Hamburg, '97–'02 
 
>4 . 848 72 0.88 16 44 57  43 34 25 
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London (United Kingdom) [114] All c+ TB patients in greater London area, July '95–December 
'96 
>4 . 2042 30 0.76 33 37  59 80 23 14 
Milan (Italy) [115] All diagnosed TB cases from Milan metropolitan area 
residents, ‘95–‘97 
All Spol (<5) 581 24 1.00 13 38 22 63 30 41 28 
Netherlands [79] All reported cases in The Netherlands between '93–'97 All PGRS (<5) 4266 60 0.75 9 34 4 61 44 46 35 
Norway [116] All diagnosed TB patients in Norway between ‘1999–‘2001 >4 . 485 36 0.92 7 43 0 0 71 10 6 
Norway [85] All diagnosed TB patients in Norway, ‘94–‘98 >4 . 619 60 0.89 5 45 . 54 50 15 11 
Tuscany (Italy) [117] All c+ TB cases in Tuscany, '02d All . 248 12 1.00 7 50 11 . 37 33 19 
Zaragoza (Spain) [118] All c+ TB patients  in Zaragoza in '93 'Nearly all samples' went 
to 2 participating labs 
>4 . 226 12 0.84 32 44 44 69 4 39 27 
Zurich (Switzerland) [119] Patients from the Zurich Canton, '91–'93 All PGRS (<5) 361 36 . 12 . 10 63 51 17 11 
NORTH AMERICA              
Alabama (USA) [120] All diagnosed TB cases from state of Alabama, '94–'00 >5 . 1136 76 0.80 8 56 6 69 . 28 25 
Alberta (Canada) [121] All c+ TB cases from Alberta province, '94–'98 All Spol (<6) 573 60 1.00 6 45 . 48 42 20 14 
Arkansas (USA) [101] All c+ cases in Arkensas, '92–'93d >5 . 192 24 0.71 7 62 . 67 3 42 30 
Arkansas (USA) [102] All c+ TB cases in Arkensas, '96–'99 >6 . 419 48 0.98 7 56 . 61 9 39 28 
Baltimore (USA) [76] All c+ cases TB reported in Baltimore City , '94–'96 All PGRS (<7) 182 30 1.00 15 54 28 69 3 46 32 
Denver (USA) [81] All c+ TB cases from Denver metropolitan area, '88–'94. >5 . 131 66 0.63 3 . 15 72 48 28 19 
Houston (USA) [122] All reported TB cases in Houston, '95–'98 All Spol (<5) 1139 36 0.91 20 . 19 70 70 60 53 
Manitoba (Canada) [123] All diagnosed TB cases in Manitoba province, '92–'99d All . 629 96 1.00 9 45 . 57 30 68 60 
Manitoba (Canada)[124] All diagnosed TB cases Manitoba province, '03 All . 126 12 1.00 9 . . . . 65 56 
Maryland (USA) [125] All c+ TB cases in Maryland, '96–'00d All Spol (<7) 1172 60 0.98 5 45 12 44 46 37 28 
Massachusetts (USA) [126] All reported TB cases in Massachusetts July '96–December 
'00d 
All Spol (<7) 983 54 0.95 4 50 27 57 70 28 19 
Montreal (Canada) [127] All reported TB patients in Montreal, '96–'98 >5 . 347 36 0.95 10 40 34 55 80 8 4 
New York (USA) [128] All c+ TB cases in New York in April '91 >4 . 344 0f 0.83 47 39 29 74 22 37 28 
San Francisco (USA) [129] All reported TB cases in San Francisco area, ‘91–‘99 All PGRS (<6) 1800 108 0.84 35 45 20 69 65 38 28 
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Tarrant County (USA) [130] All c+ TB patients resident in Tarrant County ‘93–‘00 All Spol (<7) 488 96 0.59 6 45 . 67 34 60 50 
Vancouver (Canada) [104] All c+ cases in Vancouver area, ‘92–‘94 All . 114 18 0.67 6 52 . . . 12 8 
Vancouver (Canada) [87] All new c+ TB cases in Greater Vancouver area, '95–'99 
5 cases were excluded for having experienced a previous TB 
episode 
All Spol (<6) 791 51 0.98 6 51 5 54 83 17 12 
Wisconsin (USA) [131] All c+ TB cases in Wisconsin, ‘00–‘03 >6 . 200 46 0.99 2 . . . . 16 10 
JAPAN AND HONG KONG              
Hokkaido (Japan) [106] All diagnosed patients in Hokkaido prefecture, '01 >5 . 207 36 0.83 20 69 . . . 8 4 
Hong Kong [132] All c+ TB cases with residence on Hong Kong island, May 
'99– April '02 
All PGRS (<6) 1533 36 0.66 108 58 1 68 63 30 20 
OTHER REGIONS              
Cape Town (South Africa) [100] All patients diagnosed with TB that reported in and are 
residents of 2 high incidence urban communities of Cape 
Town. ‘93–‘98 
All Spol (<5) 797 72 0.78 761 33 . 57 . 72 58 
Hlabisa (South Africa) [133] All consecutive SS+ cases in Hlabisa, a rural district in South 
Africa, May '93 – 'March 94 
All PGRS (<5) 246 11 1.00 305 36 30 62 . 45 29 
Karonga (Malawi) [51] All c+ TB cases in Karonga district, '95–'03 >4 . 948 87 0.82 81 33 65 47 . 72 59 
Malaysia [134] Nationwide random sample of c+TB cases in Malaysia, ‘93–
‘94 
>4 . 331 24 0.03 58 45 . . . 11 6 
Republic of Korea [135] Multistage stratified cluster sample of Korean population >4 . 136 0f 0.002 98 55 . 69 . 11 7 
Sunamganj district (Bangladesh) 
[105] 
All SS+ TB cases come from 4 sub districts in Sunamganj 
district (Northern Bangladesh), November '03 – December–04 
>4 . 106 13 0.95 111 . . . . 6 3 
Tirruvalur District (India) [136] All DOTS notified TB cases in Tirruvallur district, ‘99–‘00 >5 . 151 19 0.78 111 45 . 76 . 19 10 
Veracruz (Mexico) [137] All c+ patients in Veracruz state, March ‘95–April ‘03 All Spol (<6) 623 12g 1.00 28 44 2 52 . 25 18 
Slovenia [110] Nearly all (99.7%) of C+ patients in Slovenia, '01 >4 . 304 12 0.99 19 55 1 61 24 38 26 
East Azerbadjan (Iran) [138] All c+ TB cases in East Azerbadjan September '02 – March 
'03 
All . 105 7 0.82 8 47 . 57 . 33 23 
‘c+’ = culture positive; ‘.’ = data not available or found; ‘%’ = percentage of all study participants; ‘Spol’ = Spoligotyping; ‘PGRS’ = polymorphic GC–
repetitive sequence typing; ‘no.’ = number; ‘~’ = approximately. 
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a Sample collection as reported by the authors. 
b Secondary DNA fingerprinting method used for clustering analysis, if number of IS6110 RFLP bands is below cut off (shown in parentheses). 
c Sampling fraction was based on proportion of all c+ cases that had RFLP results available.  
d One band difference in IS6110 RFLP pattern was allowed between clustered strains. 
e All typed Mtb strains had >7 IS6110 bands in their RFLP pattern. 
f cross sectional survey, duration set to 0 months. 
g time difference between first and secondary patients in cluster limited to 12 months. 
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3 A systematic review and pooled data analysis of population—
based studies on HIV infection and TB clustering 
3.1 Summary 
In this chapter I describe a systematic review and pooled data analysis of studies with 
information on HIV and TB cluster status of TB cases from populations where HIV is 
generalized and TB prevalence is high to examine the association between HIV and TB 
clustering. The overall aim of the chapter is to infer a valid estimate of the relative effect of 
HIV on TB due to recent (re-)infection and reactivation.  
The work described in this chapter has been presented as a poster at the ‘Research in 
Progress’ of the Royal Society of Tropical Medicine and Hygiene in 2008, where it won a prize. 
[139] A paper is currently under review with a peer reviewed journal. [140] 
3.2 Introduction 
3.2.1 Literature on TB in HIV positive cases 
Early studies of TB in HIV positive individuals demonstrated high rates of, presumably, 
reactivation tuberculosis in HIV–infected patients with latent M. tuberculosis (Mtb) infection 
[141] However, as discussed in Chapter 1 there is evidence from individuals with recurrent 
episodes of TB, and from age patterns, to suggest that HIV-infection might have a greater 
effect on (re)infection disease than on reactivation.  
3.2.1.1 Studies on recurrent TB  
In two studies that measured incidence of relapse (recurrence due to same Mtb strain) and 
reinfection disease (recurrence due to new Mtb infection) after a first episode of TB in 
patients with known HIV status, HIV-infection was shown to greatly increase the risk of 
reinfection disease, but not of relapse [72, 73].  
3.2.1.2 Relative risk of TB by HIV and age 
After HIV-infection the risk of TB increases over time due to progressive immunosuppression 
[28]. On average, older individuals will have been HIV-infected for longer so one would expect 
the effect of HIV on TB risk to increase with age. However, in practice the opposite is found, 
with lower relative risks in older age groups [142-146]. As younger individuals are more likely 
to be experiencing their first Mtb infection, and may also be more exposed to Mtb 
(re)infection, this contradictory age pattern could be explained by HIV mainly increasing the 
risk of TB disease following first or recent infection.  
3.2.2 Relative infectiousness of HIV positive TB cases and clustering  
HIV-positive TB cases are, on average, less infectious than HIV-negative cases: their TB episode 
is more often extra pulmonary or smear negative; and even among smear positive cases they 
are less likely to be the source of transmission, perhaps because they become ill and seek 
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treatment, or die, earlier [11, 12, 22, 29, 71, 147-150]. This in turn means that HIV-positive TB 
cases are less likely than HIV-negative cases to be a source case within a cluster.  
The next step in the argument is that in each cluster it is assumed there is at least one source 
case that followed reactivation of a latent Mtb infection and that the other cases presumably 
followed recent transmission.  
Therefore, even if an equal proportion of HIV-positive and HIV-negative cases are 
clustered, since HIV positive cases are less likely to be source cases, a higher proportion of 
these cases are likely to be due to recent transmission compared to HIV-negative cases.  
So when taking the relative infectiousness, i.e. relative likelihood of being a source case within 
a cluster of HIV-positive TB cases, into account an equal or higher proportion clustered in the 
HIV-positive population would  suggest that HIV mainly increases the risk of TB disease due to 
recent Mtb infection. 
3.2.3 Study requirements 
Considering these arguments molecular epidemiological studies can provide an estimate of 
the relative effect of HIV on the risk of TB following recent (re-)infection or reactivation. Such 
studies would require information on HIV and TB cluster status of TB cases from populations 
where HIV is generalized and TB prevalence is high, so that both HIV-positives and negatives 
are likely to experience similar exposure to Mtb. Unfortunately, few suitable studies have 
been done to date.  
In this chapter I describe the process of finding those eligible studies, where available 
collecting the individual patient data from these studies and using appropriate statistical 
analyses to examine the association between HIV and TB clustering and its consistency across 
studies. The overall aim of the chapter is to infer a valid estimate of the relative effect of HIV 
on TB due to recent infection and reactivation.  
3.3 Methods   
3.3.1 Systematic review 
The same literature search as described in chapter 2 was used to find all population-based 
studies of TB clustering that used IS6110 Restriction Fragment Length Polymorphism (RFLP) as 
their main DNA fingerprinting technique.  However, for the purpose of this chapter studies 
had to describe TB clustering by HIV status for a population in which HIV has become 
generalized (taken as a prevalence consistently over 1% in regular surveillance [3]). As in 
chapter 2 studies were excluded if the sample was small (<100) or would present a too 
skewed picture of the population.  
Studies only including patients with drug resistance or from a single outbreak were excluded. 
However, as the goal was to estimate relative clustering between HIV-positive and and HIV-
negative TB cases, rather than the absolute proportion clustered in the general population, 
study populations did not have to be representative of the general population to the same 
extent as studies included in the analyses of Chapter 2. For example, a study of a gold miner 
population would not be representative of the proportion clustered in the general population 
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due to the high risk of TB disease. But as long as HIV was generalised so that the assumption 
that HIV positive and HIV negative cases mix homogeneously is sufficiently reasonable, the 
study can give a valid indication of the relative clustering between HIV positive and HIV 
negative TB cases.  
See sections 3.4.1 and 3.4.2 for a detailed description of the paper selection process.  
Authors of eligible papers were contacted and asked to participate in a collaborative analysis. 
For each study the individual patient data was requested describing age, sex, HIV status, 
number of bands in the RFLP fingerprint and whether the TB case was part of a cluster or not.  
3.3.2 Variable definition 
Within each study, all TB cases whose strain matched that from another TB case within a 5 
year period were considered clustered [59]. TB cases were categorized according to their age 
in years as young adults (15–25), middle aged (26–50) or older (50+ years of age) or in 5 strata 
(15–25 years, 26–35, 36–45 46–55 and 55+) for a more detailed age-specific analysis. Children 
<15 years of age were excluded from the analyses as data on this population are often 
incomplete due to difficulties in the diagnosis.[151] Also, childhood TB cases are much less 
infectious than adult TB cases and thus have little part in a population’s Mtb transmission 
[151]. 
As IS6110 RFLP is insufficiently discriminatory if the number of bands is low (e.g. <5) [59] 
included studies performed secondary DNA typing (e.g. Spoligotyping or Polymorphic GC 
sequencing [92, 93]) on strains with <5 bands for further differentiation, or excluded these 
strains from the clustering analysis.   
3.3.3 Statistical analyses 
Fixed-effects meta–analysis (‘metan’ command, Stata v10) was applied to investigate study 
specific associations between HIV and cluster status. A fixed effect meta–analysis assumes a 
priori that there is one ‘true’ or fixed association present in each study. This is opposed to a 
random effects analysis where the association of interest is expected to vary between studies. 
More technically speaking, a fixed effect analysis assumes that any variation in the association 
between studies is due to sampling variation and that there is one true effect, whereas a 
random effects analysis assumes the effect for each study varies and is drawn from a normal 
distribution of which the mean represents the true effect. In practice a random effects 
analysis is often more conservative because of the uncertainty that follows from the 
heterogeneity in the OR that needs to be adjusted for. [152]  
Forest plots were created for the overall association and for each age category. Heterogeneity 
between studies was assessed visually and using I-squared following guidelines from the 
Cochrane collaboration [153, 154]. No summary odds ratio (OR) was calculated if more than 
moderate heterogeneity was present. [155]  
For the individual patient data analysis I used random-effects logistic regression (xtlogit 
command, Stata v10). This is similar to standard logistic regression but allows for within study 
correlation and between study variation. [156] The association between a patient’s cluster 
status and HIV-infection, age or sex was first tested in univariate analysis. Multivariate models 
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included all variables, unless the Likelihood Ratio (LR) test showed interaction. In that case 
separate multivariate models were run. Estimates for the proportion clustered by HIV status 
in each age group, adjusted for study and sex, were estimated from the pooled data by 
converting the xtlogit coefficients into percentages.  
3.3.4 Sensitivity analyses 
Analyses were repeated after excluding all strains with <5 IS6110 bands in their DNA 
fingerprint. The robustness of the outcomes was further tested by excluding data from each 
study in turn.  
As discussed in detail in chapter 2, several factors (e.g. study duration or population sampling) 
will affect the reported proportion clustered [59, 74]. To assess the impact of study duration 
on the results, I re-analysed the data after changing the definition of clustering as ‘clustering 
with a previous isolate within a 12 month period’ to compensate for differences between 
studies.  
In small clusters the proportion of clustered cases attributable to ongoing transmission is 
relatively small compared to larger clusters [59]. I therefore checked whether the effect of HIV 
on the risk of clustered TB changed if only larger clusters (4 or more cases) were included in 
the 3 studies that had cluster size data available: Karonga, Namibia and Hlablisa. 
3.4 Results  
3.4.1 Data collection 
The literature search yielded 11654 results, from which seven studies fitted the inclusion 
criteria [51, 133, 157-161]. For one study the original data could not be traced [158] and it was 
therefore only included in the overall meta–analysis. Analyses for the still ongoing Karonga 
Prevention Study from Karonga District, Malawi were updated to include data up to 2006, 
which constitutes four additional years of data (see Chapter 4 for more details) [51, 162]. 
Individual patient records were available for 2787 TB cases, 95% (2787/2921) of the total 
eligible population (table 3.1). HIV results were available for 77% (2141/2787) of these TB 
cases, of which 25 were excluded either because they were under 15 years old (n=22) or had 
no information on age (n=3). For one study the number of IS6110 bands was no longer 
available for any of the strains [133]. In total 2116 cases were included in the individual 
patient data analysis. 
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Table 3.1 Summary of population based studies that reported on HIV and TB cluster status 
    
HIV-
positive   
HIV-
negative  Study designa 
Study Patient selection  N 
% 
clustered 
(n/N) 
Age 
median 
(range) 
Sex 
%male  
(n/N) 
% 
clustered 
(n/N) 
Age 
median 
(range) 
Sex 
%male  
(n/N) 
Strains with 
<5 IS6110 
bands 
Cluster 
definition 
Karonga (Malawi) 
[51] 
All c+ TB cases in Karonga district, '95–'06. 
 
1581 79 
(560/706) 
34       
(3 – 72) 
42 
(295/706) 
72 
(278/387) 
37           
(0 – 83) 
52 
(201/387) 
Excluded Identical 
Gold Mines (South 
Africa) [159] 
All c+ TB cases of pulmonary TB in 4 South 
African communities of male gold miners, '95. 
371 64 
(113/177) 
37      
(24 –62) 
100 
(177/177) 
70 
(135/193) 
39          
(24 – 64) 
100 
(193/193) 
Excluded Identical 
Windhoek (Namibia) 
[160] 
All new patients in hospital serving all TB 
patients in greater urban area, April ‘95 – 
March ‘96. Patients with TB treatment in 
previous 6 months were excluded.  
263 45     
(33/73) 
34     
(20 –64) 
68 (50/73) 45  
(63/139) 
32         
(16 – 72) 
75 
(104/139) 
Spoligo Identical 
Hlablisa (South 
Africa) [133] 
All consecutive SS+ cases in Hlabisa, a rural 
district in South Africa, May '93 – March ’94. 
246 49    
(32/65) 
29     
(17–74) 
45 (29/65) 44  
(68/153) 
35          
(11 – 80) 
70 
(107/153) 
PGRS  Identical 
Addis Ababa 
(Ethiopia) [157] 
Sample of patients with pulmonary TB in 
Addis Ababa referral hospital (September ’96 
– August ’97). Patients <15 year old and those 
with TB diagnosis in the last 3 months were 
excluded. 
121 51    
(37/72) 
30.5  
(17 –50) 
61 (44/72) 33    
(16/49) 
25          
(15 – 62) 
70  
(34/49) 
Spoligo Identical 
Botswana [161] Random sample of cases from nationwide 
surveillance programme (includes 1/10 of all 
new and 1/5 of all re–treatment cases) in 
Botswana, January ’95 – October ’96. 
205 44    
(28/63) 
31     
(21 –74) 
57 (36/63) 38    
(25/65) 
36         
(14 – 70) 
75  
(49/65) 
Included 1 band 
difference 
or 
identicalb 
Dar es Salaam 
(Tanzania) [158]  
‘Randomly selected' sample from TB patients 
admitted to Muhimbili Medical Centre, a 
university medical centre in Dar es Salaam, 
end ‘92 – mid ’93. 
134 37    
(25/68) 
35c    
(18 –61) 
N.A. 30    
(20/66) 
33‡       
(14 – 76) 
N.A. Included Identical 
Total 
 
2921 68 
(828/1224) 
34       
(3 – 74) 
55 
(631/1156) 
58 
(605/1051) 
36           
(0 – 83 ) 
70 
(688/985) 
  
‘PGRS’ = typed with Polymorphic GC Sequencing, ‘Spoligo’ = Spoligotyped, ‘Mtb’ = Mycobacterium tuberculosis, % = proportion of total, ‘n’ = number of cases in 
group with characteristic, ‘N’ = total number of cases in group, ‘N.A.’ = not available, ‘c+’ = culture positive, ‘SS+’ = sputum smear positive.  
a Variables describe how strains with <5 IS6110 bands were handled and the required similarity of clustered DNA fingerprints.  
b One band difference allowed in Mtb strains with > 5 IS6110 bands, other strains had to be identical.  
c mean age instead of median age.  
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3.4.2 Meta–analyses 
Five out of 7 included studies found a trend towards a higher proportion clustered in HIV-
positives than in HIV-negatives, one found no association and one (the South African Gold 
Mine study) suggested a trend in the opposite direction (figure 3—1). This is reflected in the 
combined odds ratio (OR) for HIV and TB clustering (OR = 1.24, 95% CI = 1.03–1.50).  
 Figure 3—1 Forest plot for HIV and TB cluster status 
 
‘MW’ = Malawi, ‘SA’ = South Africa 
Note: Heterogeneity between study outcomes was moderate (I^2 = 39%, p–value = 0.13)  
 
The association differed by age. In the young adult population (15–25 years, figure3— 2a) 3 
out of 5 studies show a positive association, and only 1 study shows a negative effect 
(Botswana). This results in an overall positive association (summary OR (95%CI) = 1.62 (1.0–
2.6)). In the middle age group (26–50 years, figure 3—2b) HIV has no effect in any of the 
studies (summary OR (95% CI) = 1.00 (0.8–1.3)) whereas in the older population (>50 years, 
figure 3—2c) all but 1 of the 4 studies found HIV to be a risk factor for clustering (summary OR 
(95%CI) = 2.38 (1.3–4.4). In the Botswana study the one older HIV-positive case was clustered, 
compared to 4 out of 15 (27%) of the HIV-negative TB cases.  
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Figure 3—2a–c. Forest plots for the association between HIV status and TB clustering, stratified for young adults 
(15–25 years), middle aged (26–50 years) and older (>50) TB cases 
 
‘MW’ = Malawi, ‘SA’ = South Africa 
2a: Insufficient data from the gold mines (n=8) to calculate an odds ratio in this age group. In this study 
3 out of 5 (60%) HIV-positive cases were part of a cluster, compared to 3 out of 3 of the HIV-negative TB 
cases. Heterogeneity between study outcomes was low to moderate (I^2 = 22%, p value = 0.3)  
2b: No Heterogeneity between study outcomes (I^2 = 0%, p-value = 0.8) 
2c: Both the Botswana (n=16) and Ethiopia (n=3) study had insufficient patients in this age category to 
calculate an odds ratio. In the Botswana study the 1 HIV-positive case was part of a cluster, compared 
to 4 out of 15 (27%) of the HIV-negative TB cases. Heterogeneity between study outcomes was low (I^2 
= 0%, p–value = 0.4).  
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3.4.3 Individual Patient Data analyses 
The univariate random-effects logistic regression (table 3.2) confirmed the results of the 
meta–analysis. Age and HIV-infection showed a strong interaction (p value LR test = 0.01, DF = 
2) so separate multivariate models were run for each age group (table 3.2 column 3–5). These 
show that clustering is as or more likely in each age group; HIV is a clear  risk factor for TB 
clustering in the older population (OR (95% CI) = 2.57 (1.4–4.7), is positively associated with 
clustering in the young adult population, albeit less strongly (OR (95%CI) = 1.50 (0.9–2.3)) and 
in the middle aged population clustering is equally likely in HIV-positive and HIV-negative TB 
cases (OR (95%CI) = 1.01 (0.8–1.3)).  
Within each age group sex had little effect. Additional adjustment for age as a linear variable 
within each age stratum hardly changed the results in the different age groups (OR (95%CI) = 
1.50 (0.9–2.3), 1.00 (0.8–1.3) and 2.57 (1.4–5.7) for the young adult, middle and older age 
groups respectively).   
To investigate the effect of HIV on clustering by age in more detail, the proportions clustered 
by HIV status were estimated in 5 age categories using coefficients from random-effects 
logistic regression (figure 3—3a ). This shows that in the HIV-negative population the 
proportion clustered decreases in the older age groups, whereas it increases in the HIV-
positive population. The resulting ORs for the 5 age groups are shown in figure 3—3b.  
3.4.4 Sensitivity analyses 
The exclusion of any individual study did not change the associations found. Figure 3—4a and 
b show the trends in clustering after either one of the two largest studies (Karonga and Gold 
Mines) were excluded.  Although the difference in the older age groups was less pronounced 
without the Karonga data (figure 3—4a), clustering remained as or more likely for HIV-positive 
TB cases in each age group.  
Excluding the 341 cases whose Mtb strain had <5 IS6110 bands or no such information did not 
affect the outcome. After compensating for study duration (only cases with an identical strain 
within a 1 year period are considered clustered) the same pattern of equal or higher clustering 
for HIV- positives persisted, with the OR (95%CI) = 2.10 (1.2–3.7) in the older age category.  
When small clusters of 2–3 cases were excluded from a dataset of the 3 studies with data on 
cluster size the age-specific effect became more pronounced; the OR in the >50 year old age 
group for these three studies increased from 2.79 (95%CI = 1.4–5.6) to 3.79 (95%CI = 1.7–8.6), 
whereas the OR’s in the other age groups remained similar.  
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Table 3.2 Odds Ratio’s for being part of cluster  
Variable 
Univariate OR (95% 
CI)  
Multivariate ORa 
(95% CI)  
 Overall 
Young (15–25) 
n = 339 
Middle (26–50) 
n = 1506 
Old (>50) 
n = 271 
HIV status     
  Negative ref ref ref ref 
  Positive 1.26 (1.0 – 1.5) 1.50 (0.9 – 2.3) 1.00 (0.8 – 1.3) 2.57 (1.4 – 5.7) 
     
Sex     
  Female ref ref ref ref 
  Male 1.34 (1.1 – 1.6) 1.16  (0.7 – 2.0) 1.19 (0.9 – 1.5) 1.11 (0.6 – 2.1) 
     
Age      
  Young ref    
  Middle aged 0.85 (0.7 – 1.1)    
  Older 0.68 (0.5 – 0.9)    
Note: Random effects logistic regression was used to adjust for study effect 
a Multivariate models included sex and HIV status 
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Figure 3—3a-b. Study corrected estimates of proportion clustered and OR’s in 5 age categories  
 
 
‘n = …’ = number of TB cases in each age category 
3a. Lines show estimates for the proportion clustered based on coefficients from random-effects 
logistic regression (converted from log–odds), the error bars represent 2 times the standard error for 
the proportion clustered: 2 * sqrt(p * (1 - p) / n).  
3b. All studies contributed cases to each age category. Estimates are corrected for study effect 
(acquired using xtlogit command, stata v10) and sex.  
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Figure 3—4a-b: Study corrected estimates of proportion clustered in 5 age categories after excluding data from 
Karonga (a) and Gold Mines (b) 
 
 
4a and 4b. Lines show estimates for the proportion clustered are based on coefficients from random-
effects logistic regression (converted from log–odds to proportion) and are corrected for sex. Error bars 
represent 2 times the standard error for the proportion clustered: 2 * sqrt(p * (1 - p) / n). 
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3.5 Discussion  
3.5.1 Overview 
The analyses in this chapter pooled individual patient data for over 2000 TB cases from 6 
different populations. The results show that although the association between HIV infection 
and TB clustering varies across age categories, HIV-positive individuals are consistently as or 
more likely to be part of a TB cluster as the HIV-negative population. Since HIV-positive TB 
cases are less likely to be a source of infection than are HIV-negative cases [11, 12, 22, 29, 71, 
147-150] this suggests that HIV-infection increases an individual’s risk of TB disease due to 
recent Mtb (re)infection more than through reactivation.  
3.5.2 Age specific pattern of HIV infection and TB clustering 
The age specific pattern seen here may be the combined effect of two mechanisms. First, in 
the HIV-negative population, TB clustering decreases with age (see figure 3—3a), which 
reflects the increasing proportion of the population who have latent tuberculosis in older age 
groups. This pattern has been shown in multiple studies [51, 69]. Second, in the HIV-positive 
population it is likely that, on average, older individuals will have been HIV-infected for longer 
and more immunosuppressed than younger individuals. If HIV-infection has a greater effect 
on disease following recent infection, this may become more marked with increasing 
immunosuppression and would thus result in the pattern seen here: increased, rather than 
decreased, clustering with age in the HIV positive (see figure 3—3a). When combined these 
two mechanisms would result in the rough J-shape seen in the OR’s; little difference in 
clustering in the young adult and middle aged population and a sharp increase in older 
individuals (figure 3—3b).  
Additional explanations for these patterns could include HIV and age-specific mixing patterns, 
leading to increased transmission of Mtb strains and clustering within these groups, or other 
environmental and behavioural factors. For example, HIV-positive and older individuals are 
likely to spend more time in a hospital setting than their HIV-negative and/or younger 
counterparts, which could also increase their risk of clustered TB through nosocomial 
infections.  
These results suggest that the emphasis on the influence of HIV on TB following reactivation in 
early studies may have been misleading [141]. The relative homogeneity of the observed 
trends across studies in different settings but all with generalized HIV epidemics gives further 
support to the interpretation conclusions, as does the robustness of the results to the 
exclusion of the Karonga data, which contributed 51% (1076/2116) of the cases for the 
individual patient data analysis.  
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3.5.3 Potential sources of bias 
3.5.3.1 Study specific 
Some risk of bias remains. The Gold Mine populations experience an extremely high risk of TB 
disease, partly due to silica dust exposure [163], although this effect is independent of HIV. All 
the miners were male, but no association with sex was found in the other studies. The 
Ethiopian population came from a TB referral hospital. It is possible that this attracts patients 
with complicated TB disease, which is associated with HIV-infection, from a larger population 
than non–complicated TB cases, which would reduce clustering in the HIV-positive population. 
However, excluding the data from this study did not change the observed associations.  
Anti-retroviral therapy (ART) was rolled out for clinically eligible HIV-positive patients in the 
Malawi study area from June 2005 onwards [164]. Through subsequent restoration of the 
immune system it is possible that these patients have a lower risk of TB than HIV-positives not 
on ART, thus reducing the effect of HIV. However, there was only a 6 month overlap between 
the study period and the availability of ART in the study area. This makes it unlikely that ART 
affected these results. 
3.5.3.2 Study design issues 
Misclassification of clustering is possible, although underestimation is most likely. [59] As 
discussed in chapter 2, duration, sampling and other factors related to study design and 
setting can differ between studies and act as an important source of variability of the 
proportion clustered [59, 74]. Any misclassification is however likely to be non-differential 
between HIV-infected and non-infected cases and will tend to bring odds ratios closer to one.  
However, when misclassification was reduced by removing small clusters, the observed trends 
became more pronounced. Conversely, when more bias was introduced by limiting cluster 
duration to 1 year, the associations persisted, albeit less pronounced. Both observations 
would suggest that our results approach the true association, and probably underestimate it.  
3.5.3.3 Biased for culture positive samples  
Any clustering analysis is limited to culture positive TB cases. The proportion of culture 
positive TB cases differs by HIV status which could bias the results. This however requires that 
culture negative patients are more likely to follow reactivation, i.e. not be part of cluster, 
compared to culture positive patients. Although the absence of Mtb DNA excludes molecular 
epidemiological results to support or refute that hypothesis, EPTB is more often culture 
negative, and more common in HIV positive patients. Within the dataset from the Karonga 
Prevention Study (see Chapter 4 for a detailed description) I compared 4-year retrospective 
clustering, which reduces the number of source cases in the analysis, between TB cases with 
PTB only and EPTB only. The proportion retrospectively clustered was 61% for the PTB cases 
and 50% in the EPTB cases. So although there could potentially be some bias, the evidence 
base is small.  
3.5.3.4 Assessment of source cases 
These analyses extend the well established observation that HIV positive TB cases are on 
average less likely to be a source of Mtb infection [11, 12, 22, 29, 71, 147-150] to their relative 
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likelihood for being the source case in a cluster compared to HIV negative TB cases. I did not 
attempt to determine which cases within clusters were likely to be the source case. Most 
studies were of short duration, so the source cases may not have been included, and the long 
and variable latent period of TB [17] makes misclassification of source and secondary cases 
likely, especially in settings with moderate to high rates of ongoing Mtb transmission in the 
general population.   
3.5.4 Implications for public health and patient care 
These new insights into the interaction between HIV and TB have implications for policy 
decisions. Efforts to control TB in settings with generalized HIV epidemics should always be 
multi-facetted [165], but these results help focus the debate on how control measures should 
be implemented and prioritised. The higher the proportion of disease attributable to recent 
transmission, the more important intensified case finding and isoniazid-based prophylaxis of 
recently (rather than latently) Mtb infected individuals are for TB control.  
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4 The Karonga Prevention Study 
4.1 Summary 
After looking at the molecular epidemiology of TB across different populations the remaining 
chapters of this thesis will use data from the Karonga Prevention Study (KPS). In this chapter I 
will introduce KPS, its general methods and its data. I will also show the results of an analysis 
of the KPS data that builds on the results shown in chapter 3. [162] 
The majority of the studies described in this chapter were designed, set up and some of them 
completed before the work on this PhD started in August 2006. My active involvement with 
the data collection and processing started in February 2009 when I arrived for a year of field 
work at KPS headquarters in Malawi (see figure 4—1). During my year on site I helped 
supervise the TB studies described here.  
4.2 Introduction  
During its 30 years of study activity in Karonga District KPS has performed a wide range of 
studies, not all of which are relevant for this thesis. I will only describe the methods for the 
relevant studies most of which were started or even completed before the work on this PhD 
started in 2006. Where I was actively involved in the data collection of ongoing studies I will 
outline my contribution. 
I also led the data collection in three areas during my time in Malawi; an updated estimate of 
the population size and distribution in Karonga District, an updated HIV prevalence estimate 
and a study, which I designed and got funding for, of ART clinic records to quantify the uptake 
of ART in the district. These pieces of information are described in more detail in Chapter 6. 
4.2.1 Setting 
The Karonga Prevention Study is set in Karonga District in Northern Malawi (see figure 4—1). 
Total area is ~2000 square kilometres. The majority of the population lives along the coastal 
area, including Karonga Town in the north of the district. KPS headquarters is located in 
Chilumba, a small harbour town in the south of the District.  
4.2.2 Population 
The population consists mostly of subsistence farmers, fishermen and small traders. Apart 
from the main town Karonga (see map) there are few urban areas. Between 1979 and 2009, 
the population size increased from 112,000 to over 250,000 [166, 167].  
Karonga District is relative isolated from the rest of the country and has a low level of 
population movement. [168] This has facilitated long term follow-up of study participants, 
ideal for diseases such as leprosy and tuberculosis which can have a long period of latency, 
incubation or disease. [17] 
Figure 4—1 Map of Karonga District 
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4.2.3 KPS Studies – General  
KPS started with large studies on leprosy, with an interest in TB. Currently there are about 15 
ongoing studies, ranging from basic sciences such as immunology and to anthropological 
studies on the uptake of ART.    
During two total population surveys carried out between 1979-1984 and 1986-1989 KPS 
developed a system for identifying individuals who were seen more than once within one 
study but also across different studies. This system has been used since and the KPS database 
now holds data on interviews, clinical examinations and biological samples from over 800,000 
contacts with ~300,000 individuals. [168] This system allows researchers to link information 
from the same individual collected across multiple studies and decades.  
4.2.4 TB case finding   
KPS has strong ties with the TB control programme in Karonga District. From 1985 onwards 
KPS recorded demographic and clinical information on all diagnosed TB cases in Karonga 
district, including HIV test results since 1988 [169] Due to the involvement of KPS, Karonga 
district has had a form of ‘enhanced passive case finding’ since 1990. [170]  
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The active involvement of KPS in the District’s TB programme has expanded over time.  
Working in collaboration with the District TB Officer, KPS staff now man all major health 
facilities where they screen self presenting TB suspects with TB symptoms, including cough 
and examination of enlarged lymph nodes [171]. Since 1991 participants in all community 
based KPS studies are asked about chronic cough [171]. Since 2007 KPS has added an annual 
follow up round in which trained interviewers visit patients who were recorded to have 
started TB treatment in Karonga District after 1985 and who are still alive and living in the 
district.  
4.2.5 TB diagnostics 
From 1985 onwards the KPS laboratory has processed biological samples for TB suspects in 
Karonga District. Culture isolates from TB cases are sent to the UK for Mycobacterium species 
confirmation, drug susceptibilities and molecular typing.  
Sputum smears procedures have been relatively consistent over time. Overall three sputum 
samples are obtained from TB suspects and individuals starting TB treatment at Karonga 
District Hospital. For smear positive TB cases review samples are obtained after 2 months and 
around the end of treatment [5]. Currently, all sputa are examined under a fluorescent 
microscopy after auramine staining, after which positive samples are confirmed using 
standard Ziehl Nielsen staining. [172]  
Currently all sputa are put on Löwenstein-Jensen medium, regardless of the microscopy result 
for culture confirmation. Cultures are stored in 37 °C for 10 weeks to allow for slow growing 
Mtb specimens. Cultures are checked biweekly for growth typical of Mtb.   
Since late 1995 at least one sample per patient with a culture growth indicative of Mtb has 
been sent to the UK for mycobacterium species identification and drug sensitivity testing. 
Samples are the transported to LSHTM for DNA fingerprinting and strain identification. See 
section 4.4 for a description of DNA fingerprinting methods and Mtb strain specification.    
4.2.6 TB treatment 
The TB treatment regimen has followed Malawi government guidelines. Treatment starts with 
a hospital phase followed by an outpatient phase. During both phases the patients are 
monitored by KPS staff members.  
From 1997 to 2000, individuals with smear-positive TB received 2 months of streptomycin, 
isoniazid, rifampicin, and pyrazinamide, followed by 6 months of isoniazid and ethambutol. 
Individuals with smear negative TB received 1 month of streptomycin, isoniazid, and 
ethambutol, followed by 11 months of isoniazid and ethambutol. The initial phase was in the 
hospital. Before 1997, thiacetazone was used instead of ethambutol. Currently, both smear-
positive and smear-negative patients receive rifampicin, Isoniazid, pyrazinamide and 
ethambutol during the first 2 months of initial treatment, followed by 6 months continuation 
phase of rifampicin and Isoniazid. [66, 169] 
4.2.7 Interview and HIV test 
TB cases are interviewed by a KPS staff member about their disease history, occupation, 
education, marital status and contacts with known TB cases in the past. Since 1988 all patients 
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starting TB treatment are asked to undergo a HIV test. [173] After informed consent venous 
blood is taken for HIV testing in the KPS laboratory.  
4.3 ART in Karonga District 
The national scale up of ART in Malawi started in June 2004 [174] with the first ART clinic in 
Malawi. The first ART clinic in Karonga District opened in June 2005. [164] Since then over 
4500 patients have started on ART in the district (see Chapter 6). In Chapter 6 I will discuss a 
study I set up and executed with the aim of getting an overview of the uptake of ART in 
Karonga District over time.  
4.4 Mtb DNA fingerprinting and strain identification  
4.4.1 Strain identification 
Cultures identified as containing Mtb species are selected for DNA fingerprinting using 
standardised techniques. [52] All DNA fingerprints are scanned and stored electronically for 
computer assisted visual comparison using the either GelCompar or Bionumerics software 
(both from Applied Maths).  
Strains were considered clustered if they had identical patterns on the RFLP. For the majority 
of analyses strains with less than 5 bands were not included in the analyses of the molecular 
epidemiological data.  
4.4.2 Strength of KPS molecular typing  
The techniques used for DNA fingerprinting of KPS samples have been standardised since 
1996. As of December 2009 the database holds 570 different IS6110 RFLP patterns from 1943 
Mtb fingerprinted strains from TB episodes. This database holds a DNA fingerprint for 87% 
(1723/1991) of culture positive TB cases at KPS between January 1997 and December 2008.  
This longevity and relative high coverage of culture positive TB cases from an area with high 
HIV prevalence make the KPS database unique in the world. Combined with high quality 
laboratory confirmation and epidemiological description of the (TB case) population stored in 
the linked KPS database, the Karonga data allow researchers to address questions that no 
other study can, as I will illustrate in the following chapters.  
4.4.3 Missing values 
Despite the rigorous and standardised data collection procedures there have been periods 
where certain parts of the data collection have been less complete, leading to missing data. 
Missing data is present in all studies, and need not reduce the validity of the results.  
In Chapter 7 and Chapter 8 I will address the issue of missing data in more detail and explore 
the effect of imputing missing values for HIV infection at time of TB episode, cluster status and 
ART status.  
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4.5 HIV and the risk of TB due to recent transmission over 12 years 
in Karonga District, Malawi 
4.5.1 Objective 
The results from Chapter 3 suggest that HIV mainly increases the risk of TB following recent 
Mtb infection. In theory this association could be a chance finding, have changed over time or 
be affected by unmeasured changes in the HIV population (e.g. increase in average time since 
infection due to a maturing HIV epidemic). In this section I will analyse the KPS data in more 
detail to investigate the robustness over time of the finding and the stability of the association 
between HIV and TB clustering found in chapter 3.  
The analyses described here were published in the Transactions of the Royal Society of 
Hygiene and Tropical Medicine. [162] 
4.5.2 Methods 
I first excluded potential cross contaminations using previously described methods. [66] In this 
method all TB cases that had only 1 positive sample (either smear or culture) positive were 
highlighted as Isolated Positive Culture and suspect of cross contamination. The DNA 
fingerprints of the strains were compared with those from any other positive samples 
collected or processed (for smear or culture) on the same day. If the strains of an isolated 
positive culture was identical to that of another sample processed on the same day the 
likelihood of cross contamination was deemed high, and the case was excluded from further 
analysis.  
For this analysis TB cases were considered clustered if another patient had an identical Mtb 
strain in the previous 4 years. As discussed in Chapter 1 this retrospective clustering with a 
fixed time window was used to improve the likelihood that a clustered case was actually due 
to recent Mtb transmission and allows comparison between time periods which is unbiased 
by the total duration of the study. [51] The 4 year cut-off was based on a previous KPS study 
which showed that maximum clustering was reached  within 4 years.[51] Cases in the first 4 
years were used to determine cluster status of subsequent cases, but were then excluded 
from the analysis. Cases with less than 5 bands in the RFLP were excluded from the analysis. 
For the main statistical analysis two periods were compared; data that were previously 
reported (October 1999 – March 2003) [51] and new data (April 2003 – October 2007). Cases 
were stratified into three age groups (15–25, 26–50 and >50 years respectively).  
Multivariate logistic regression (Stata v10) was used to calculate age and period stratified 
odds ratios for the association of HIV with TB clustering, adjusted for sex. Interactions were 
assessed through likelihood ratio tests.  
To test the robustness of the results I explored the impact of restricting clustering to time-
windows of either 1 or 2 years [51], or expanding clustering to any case with an identical Mtb 
strain in the study period, both retrospectively and prospectively. I also used the latter 
definition of clustering to repeat the analyses including the first 4 years of data, where I 
compared either 2 6-year periods or 3 4-year periods.  
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4.5.3 Results 
DNA fingerprints were available for 1630/1968 (83%) of all culture positive cases between late 
1995 and October 2007. The median age was 35 years (range 17 – 85 years) and 767/1630 
(47.1%) were male. Excluding the cases in the first 4 years, 705/1031 (68%) of cases were 
clustered with a case in the previous 4 years, and 493/746 (66.1%) were HIV-positive.  
As in chapter 3, an interaction was shown between age and HIV in the overall model (p value 
LR test =0.05) and both study periods (p value LR tests =0.1). The models (figure 4—2) show 
that in both time periods and overall the ORs in the young and middle age categories were not 
statistically different from 1. However, in the older age group HIV infection was associated 
with increased clustering. This pattern was consistent in all sensitivity analyses.  
Overall, in the two periods together, the proportion retrospectively clustered among the HIV-
negative was 36/49 (73%), 77/122 (63%) and 41/82 (50%) in age groups 15-25, 26-50 and > 50 
respectively. The equivalent numbers for the HIV-positive were 36/45 (80%), 297/411 (72%) 
and 31/37 (84%). 
4.5.4 Discussion 
This analysis shows that the association between HIV and TB clustering seen in Chapter 3 is 
consistent across time periods. What is not yet clear is whether the increase in TB following 
recent infection applies to patients with and without an established Mtb infection before they 
become HIV positive.  
Figure 4—2: Odds Ratios for TB clustering according to HIV status, by study period  
 
All odds ratios are stratified for age and adjusted for sex. Overall odds ratios are adjusted for study 
period. Error bars show 95% confidence intervals for the odds ratio 
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5 The risk of tuberculosis due to recent re-infection in 
individuals with latent infection and the influence of HIV 
infection 
5.1 Summary 
HIV-associated TB can follow reactivation of a latent Mtb infection or recent infection or 
recent re-infection with Mtb. However little individual patient data is available to show the 
occurrence of recent re-infection on top of an established Mtb infection as the route to a first 
episode of TB, or how HIV affects this pathway. 
In this chapter I combine data from population TST surveys done before 1990 and DNA 
fingerprint data from Individuals experiencing a first TB episode between 1996 and 2008 in 
Karonga District to explore this issue. The results show that HIV-infection strongly increases 
the risk of TB following recent re-infection in patients with a latent Mtb infection.  
The results described in this chapter have been converted into a paper, which is currently in 
press with the International Journal of Tuberculosis and Lung Disease. [175] 
5.2 Introduction 
5.2.1 TB following recent reinfection and HIV 
As discussed in the previous chapters, the pathogenesis of TB is complex, and further 
complicated by HIV co-infection. To recapitulate, a first episode of active TB disease can follow 
a primary infection with Mycobacterium tuberculosis (Mtb), reactivation of an established 
(“latent”) Mtb infection, or a subsequent re-infection. [15, 17, 176]  
It is known that HIV infection dramatically increases the risk of active TB and that all three 
pathways to disease are affected. [22] The literature and results from chapters 3 and 4 
suggest that HIV-positive individuals are predominantly at risk of TB disease from recently 
acquired infection. [72, 73, 139, 142-146, 162] Whether this principle applies to the same 
extent for TB following a recent first Mtb infection and TB following recent re-infection is 
unknown.  
The importance of re-infection disease in TB epidemiology is unclear. Its relevance in areas 
with moderate to high rates of Mtb transmission has been demonstrated in modelling [15, 17] 
and elegantly illustrated through population data by Styblo et al [8].  
Styblo discussed the case of Eskimo population in north America and Greenland, During the 
1950s, these populations experienced an extremely high annual risk of Infection of 25%, which 
meant everybody was infected in childhood. However, when the ARI fell during the 1960s and 
1970s, TB incidence fell simultaneously in all age groups, including those that were already 
infected with Mtb at least once during their childhood in the 1950s. This showed that recent 
reinfection with Mtb contributed to the high rates of TB seen in the Eskimo populations 
during the 1950s 
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However, to date there are no direct data showing multiple Mtb infections preceding a first TB 
episode in individuals. It is also unclear whether a prior Mtb infection confers any protection 
from further Mtb infections or subsequent disease. [8, 177, 178]  
5.2.2 Identifying TB following recent reinfection with Mtb 
TB research has relied on two main tools to gain insights into Mtb transmission and 
subsequent TB disease; tuberculin skin tests (TST) to measure Mtb infection [4] and DNA 
fingerprinting of Mtb strains involved in active TB to distinguish between TB disease due to 
recent (re-)infection and reactivation. [47]  
5.2.2.1 Tuberculin Skin Testing  
TST assesses an individual’s delayed type hypersensitivity to TB antigens. Although the merits 
and interpretation of this tool are much debated, a large (i.e. ≥15mm) induration after a 
standardised Mantoux test is considered strongly indicative of a previous Mtb infection. [4, 
179, 180] However, a large TST provides little information on time since infection or the 
number of (re-)infections.  
5.2.2.2 DNA fingerprinting 
As discussed in previous chapters, DNA fingerprinting has allowed researchers to distinguish 
between patients whose TB is likely to have followed a recent infection (or recent reinfection) 
with a circulating strain of Mtb and those whose TB episode is assumed to have followed 
reactivation of a prior, latent Mtb infection. For the purposes of this chapter I apply the 
conventional TB definitions and consider an Mtb infection acquired less than five years before 
TB disease as being “recent”. 
5.2.2.3 Combined interpretation of TST and DNA fingerprinting 
When the results from DNA fingerprinting and TST are combined for an individual 
experiencing their first TB episode one can distinguish between the three possible preceding 
scenarios; a reactivation of a prior, latent Mtb infection as indicated by a unique strain and 
prior high TST, a progression from recent re-infection as indicated by a clustered strain with 
prior high TST or a progression from recent primary infection as indicated by a clustered strain 
with prior low TST.  
On average, the DNA fingerprint of the Mtb strain in patients experiencing reactivation 
disease is less likely to match another in the population compared to those from patients 
experiencing TB following a recent infection. This should be reflected in a lower proportion of 
clustered strains in those with a previous Mtb infection compared to those without a previous 
Mtb infection. By comparing this ratio of clustering in those with and without a prior Mtb 
infection between HIV-positive and HIV-negative patients, any influence of HIV can be 
inferred. For example, a weaker association between prior TST result and the proportion of 
clustered TB in the HIV-positive compared to the HIV-negative population would suggest that 
HIV particularly increases re-infection disease. 
5.2.3 Objective of the chapter 
In this chapter I combine TST and DNA fingerprint date from 2 large TST population surveys 
done by KPS between 1980 and 1989 with the DNA fingerprint database which holds 
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information on TB cases from 1996 onwards. This unique dataset allowed me to study the 
association of prior Mtb infection status on whether a first TB episode followed recent 
infection, reinfection or reactivation and examine how HIV affects it.  
5.3 Study population and Methods  
5.3.1 Study population 
Between 1980 and 1989 KPS carried out two large TST population surveys that applied 
standardised Mantoux testing. Two IU of RT23 (Statens Serum Institut, Copenhagen, 
Denmark) were injected on the volar surface of the forearm, and indurations were read 2-3 
days later. [181] As described before, KPS has performed DNA fingerprinting on culture 
positive TB cases arising in Karonga district since late 1995 using IS6110 RFLP. [52, 162]. The 
last reported TB incidence for Karonga district was ~100 new smear positive cases per 100,000 
annually [171].  
Patients were included if they had had a DNA fingerprint recorded for their first TB episode 
and a TST result recorded between 1980 and 1989. Using a case-control approach, I aimed to 
compare the TST result in cases with TB due to recent infection, and controls with TB due to 
past infection. IS6110 RFLP clustering was used to infer likely recent and past infection. 
5.3.2 Case definition 
Cases were patients with a strain of TB identical to a strain found in another patient in the 
same population in the previous 5 years. [16] To reduce misclassification, I excluded from 
analysis the first patient in each cluster of identical strains and all other patients in each 
cluster diagnosed within the first six months. As IS6110 RFLP is not sufficiently discriminatory 
if the number of bands is low [59] strains with <5 bands were excluded from the analysis. 
Controls were TB patients with unique strains. 
5.3.3 Explanatory variables 
The risk factor of interest was Mtb infection status before 1990. Restricting the TST results to 
this period reduced the risk of patients having received Isoniazid Preventive Therapy, which 
was introduced opportunistically in several later KPS studies for HIV-positive individuals with 
TST > 5mm. In this analysis Mtb infection is defined as a large TST, i.e. an induration of 
≥15mm. Patients with an induration <5mm were considered not to be Mtb infected. Those 
with an intermediate result (≥5mm and <15mm) were excluded from the main analysis.  
Age at first TB episode was grouped in three categories: < 25, 25-49, and 50 or more years old. 
To correct for the time between an individual’s recorded TST and start of first TB episode, this 
period was divided into three categories of <=10, 11-20 and more than 20 years.   
HIV infection status was recorded at time of TST based on anonymised retrospective testing of 
filter papers [182], and at time of TB episode through testing of serum. [144]   
BCG scar status at time of TST was recorded during the TST surveys. [181] 
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5.3.4 Statistical analysis 
I used logistic regression to assess the association between TST history and TB cluster (case-
control) status. Age at first TB episode, gap between TST and first TB episode, sex, HIV 
infection and BCG scar status were investigated as potential confounders. The presence of 
interaction (e.g. by HIV infection at time of TB episode) was assessed using likelihood ratio 
(LR) tests. Differences between groups in non-normally distributed continuous variables were 
analysed using the Wilcoxon rank-sum test. I also compared clustered TB cases with a 
confirmed prior Mtb infection with all other clustered TB cases from a first TB episode in the 
KPS database.  
5.3.5 Sensitivity analyses 
We examined the impact of applying more or less strict criteria to define Mtb infection status 
based on the TST. Additionally, analyses were repeated including the first cases of each cluster 
as either unique or as clustered cases. We also explored the effect of excluding all cases 
diagnosed within the first two years after the index case in each cluster (rather than the first 6 
months).  
5.4 Results 
5.4.1 Patient selection 
The selection of cases for analysis is illustrated in figure 5—1. Between October 1995 and 
September 2008 88% (1707/1946) of all culture positive cases underwent DNA fingerprinting, 
which resulted in 556 different patterns. After selecting first episodes and cases with a TST 
recorded between 1980 and 1989, 532 cases were included (see figure 5—2 for the 
distribution of the induration sizes). Following the strict definitions for clustering and TST 
result (to ensure distinct groups) left 262 for the main analysis.  
Out of these cases, 212 had a TST induration of <5mm and 50 had an induration of ≥15mm, so 
in total 19% (50/262) of included cases were classified as having an established Mtb infection 
prior to 1990.  
  
Chapter 5 – Mtb infection history and TB clustering 
 
73 
 
Figure 5—1 Selection of cases and controls for analysis  
 
 
  
1946 Culture positive TB cases 
239 No DNA Fingerprint 
1524 first TB episodes with DNA 
fingerprint available 
183 Recurrent episodes 
992 no recorded TST between 
1980-1989  
262 Cases included 
532 cases with TST result and DNA 
fingerprint  
179 TST induration >=5mm or 
<15mm  
63 Cases first 6 months of 
cluster or diagnosed >5 years 
after last case of cluster 
28 Strains <5 bands 
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Figure 5—2 Histogram of all non-0mm indurations 
 
Note: The 248 zero indurations were included in the statistical analyses. Darker bars on left and right 
side show TST results that were interpreted as ‘no prior Mtb infection’ and ‘prior Mtb infection’ 
respectively.  
 
HIV test results at the time of TST were negative for all 154 individuals for whom results were 
available. At the time of the TB episode HIV status was known for 74% (198/262) of individuals 
of whom 60% were HIV-positive (119/198). Since the overall HIV prevalence in Karonga 
district was below 1.5% [182] before 1990 and given the long time between the TST and first 
TB episode (between 8 and 29 years) it is likely that all HIV seroconversions occurred between 
the TST and the TB episode. 
5.4.2 Prior Mtb infection and cluster status 
In the overall analysis, the proportion of cases that occurred as part of a cluster was 
significantly lower among those with a prior Mtb infection (64% (32/50)) compared to  those 
without a prior infection (81% (171/212), OR (95% CI) = 0.43 (0.22–0.83)). After adjustment 
for key confounding variables the association was weaker (table 5.1, top row). 
HIV infection strongly modified the association between a prior Mtb infection and TB 
clustering (p value LR test for interaction = 0.004 (DF=1)). In individuals who remained HIV-
negative the difference between those with and without a prior Mtb infection was 
pronounced (adjusted OR (95% CI) = 0.15 (0.04–0.59), whereas among those who acquired 
HIV between their TST and first TB episode the association disappeared (adjusted OR (95%CI) 
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= 1.85 (0.41–8.29)). For those with unknown HIV status at time of TB episode the OR lay 
between the OR’s of the two other categories, suggesting that there was little bias due to 
missing HIV status.  
Table 5.1 Association between prior Mtb infection status and TB clustering 
   Crude  Adjusteda  
 Prior TST+ Prior TST-  OR  (95% CI) OR  (95% CI) 
 Clustered 
% (n/N) b 
Clustered 
% (n/N)b 
    
All 64 (32/50) 81 (171/212) 0.43 0.22 – 0.83 0.51 0.23 – 1.10 
HIV-positive 88 (22/25) 84 (79/94) 1.39 0.37 – 5.24 1.85 0.41 – 8.29 
HIV-negative 29 (5/17) 77 (48/62) 0.12 0.04 – 0.40 0.15 0.04 – 0.59 
Unknown HIV 
status 
63 (5/8) 79 (44/56) 0.45 0.09 – 2.17 0.24 0.02 – 3.04 
Note: HIV was an effect modifier (p value LR test = 0.004 (DF=1)) 
a adjusted for sex, BCG status at time of TST, time between TST and first TB episode and age at first TB 
episode  
b ‘N’ is the number of TB cases for that category, ‘n’ is the number clustered  
 
Among those with no evidence of prior Mtb infection the odds for clustering were similar in 
the HIV positive and HIV negative (adjusted OR (95%CI) = 1.57 (0.64–3.88), whereas among 
those with prior Mtb clustering was much more common in the HIV positive (adjusted OR 
(95%CI) = 74.51 (3.75–1480.95).  
5.4.3 TB following recent reinfection 
Almost a third of HIV-negative TB cases (5/17) with a prior Mtb infection were part of a cluster 
despite having an established Mtb infection 11 or more years before their first TB episode. 
This suggests they experienced a recent re-infection before progressing to active TB disease. 
In the HIV-positive group, this applied to 88% (22/25) of those with a prior Mtb infection.  
Table 5.2 compares the clustered TB cases with a confirmed prior Mtb infection with all 
remaining clustered TB cases from a first TB episode in the study population. It shows that the 
number of years a particular strain was found was similar for both groups, regardless of HIV 
status (all p values for Wilcoxon rank-sum test > 0.12). The 203 clustered cases represented a 
total of 60 different Mtb strains. There was no evidence that HIV-positive cases with a prior 
infection were preferentially found in large clusters.  
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Table 5.2. Comparison of cluster characteristics for all clustered TB cases compared to those with confirmed 
prior Mtb infection  
 N Time between first and last 
case of cluster (years) 
Median (IQR) 
p 
valueb 
Size of Cluster  
Median (IQR) 
p 
valueb 
All clustered casesa 888 10 (7 – 12) 0.98 16 (7 – 27) 0.70 
Prior Mtb infection 32 10 (7 – 12)  14 (9 – 27)  
      
All HIV-negative clustered casesa  224 10 (7 – 12) 0.32 15 (6 – 26) 0.35 
Prior Mtb infection  5 11 (10 – 12)  17 (13 – 23)  
      
All HIV-positive clustered casesa  433 10 (7 – 12) 0.86 16.5 (8 – 27) 0.33 
Prior Mtb infection  22 11 (7 – 12)   17 (10 – 41)  
      
All clustered cases with unknown 
HIV statusa  
231 10 (7 – 12) 0.12 16 (7 – 27) 0,06 
Prior Mtb infection  5 8 (7 – 9)  7 (5 – 13)  
Note: clustering defined as in main analysis; excluding the first patient and all other patients from the 
first six months to reduce misclassification. 
a Excluding cases with a confirmed prior Mtb infection  
b p-value for two-sample Wilcoxon rank-sum test 
 
5.4.4 Sensitivity analyses 
Table 5.3 shows the results from the sensitivity analyses. Changing the minimum and 
maximum values for large and small TST to more or less extreme values, or changing the 
definitions for clustering did not change the observed trends.  
Table 5.3. Association between prior Mtb infection status and clustering in sensitivity analyses 
No Sensitivity analysis All   
OR (95% CI) 
HIV-negative  
OR (95% CI) 
HIV-positive  
OR (95% CI) 
Unknown HIV 
status 
OR (95% CI) 
1 Higher minimum value for large 
TST (=>17mm induration)  
0.46      
(0.19 – 1.10) 
0.09         
(0.01 – 0.56) 
1.81          
(0.31 – 10.6) 
0.09          
(0.04 – 2.35) 
2 Lower maximum value for small 
TST (0 mm induration). 
0.49      
(0.22 – 1.11) 
0.10          
(0.02 – 0.48) 
2.15          
(0.46 – 10.1) 
0.30          
(0.02 – 3.87) 
1 + 2 More extreme values for large 
and small TST  
0.43      
(0.17 – 1.08) 
0.07          
(0.01 – 0.46) 
2.05          
(0.33 – 12.6) 
0.12          
(0.05 – 3.13) 
3 TST cut-off at 15mm: =>15mm 
for large, <15mm for small  
0.56      
(0.26 – 1.18) 
0.11          
(0.03 – 0.48) 
2.55          
(0.48 – 13.49) 
0.56          
(0.10 – 3.15) 
4 All excluded cases classified as 
clustered 
0.68      
(0.33 – 1.41) 
0.28          
(0.09 – 0.89) 
1.57          
(0.36 – 6.86) 
0.83          
(0.13 – 5.21) 
5 All excluded cases classified as 
unique 
0.63      
(0.40 – 0.97) 
0.24          
(0.09 – 0.66) 
1.15          
(0.63 – 2.13) 
0.43          
(0.15 – 1.17) 
6 Exclude all cases from first 2 
years of cluster 
0.51      
(0.22 – 1.17) 
0.17          
(0.04 – 0.75) 
1.75          
(0.37 – 8.36) 
0.29          
(0.02 – 3.44) 
Note: Table examines the impact of different criteria for Mtb infection status based on the TST 
induration and different definitions for cluster status. Analyses were conducted including all cases and 
by HIV infection status at time of first TB episode. All OR’s were adjusted for sex, BCG status at time of 
TST, time between TST and first TB episode and age at first TB episode  
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5.5 Discussion 
5.5.1 Overall interpretation 
This chapter describes the association between the long term Mtb infection history of an 
individual in relation to pathogenesis of their first TB episode. The results showed that HIV-
negative TB cases with evidence of Mtb infection many years before their first TB episode 
were less likely to have currently circulating strains of Mtb than were cases with no evidence 
of long term prior infection. This was expected, reflecting an increased proportion of re-
activation disease. In contrast, in the HIV-positive population the proportion of cases with 
currently circulating strains was not influenced by prior Mtb infection status.  
These results suggest that HIV-associated TB is mainly due to TB following a recent infection 
or reinfection and give supportive empirical evidence for recent re-infection being important 
in disease burden for both HIV-negative and HIV-positive groups in a setting with a 
generalised HIV epidemic and moderate to high levels of ongoing Mtb transmission. 
5.5.2 Potential limitations 
5.5.2.1 Internal and external validity 
These conclusions are based on the combined interpretation of two measurement tools, TST 
and DNA fingerprinting, and are therefore vulnerable to the assumptions that underlie their 
interpretation. However, the tools gave expected findings given established understanding of 
TB pathogenesis in the immunocompetent, i.e. HIV-negative population. [8, 15, 17] As HIV 
status at time of first TB episode will not affect the result of a TST done 10 or more years 
before or change the result for a DNA fingerprint, the same credibility should extend to the 
results in the HIV-positive group, which in itself fit with other results. [72, 73, 139, 142-146, 
162] The analyses in the HIV-negatives thus acted as an internal control for the HIV-positive 
results. The consistency of the results in the sensitivity analyses suggests that they are robust 
despite the relatively small numbers available for analysis.  
The TST can be false positive, due to BCG or infection with environmental non-tuberculous 
mycobacteria, or false negative due to anergy following HIV infection. [4] We chose 
conservative values when interpreting TST indurations to reduce the possibility of 
misclassification and showed that the associations held if more extreme and less extreme 
values were chosen. The low HIV prevalence and all negative HIV tests at the time of TST make 
it unlikely that our TST results were influenced by anergy, further strengthening the 
distinction between those with and those without a prior Mtb infection.  
5.5.2.2 Interpretation of TST and DNA fingerprinting results 
An important limitation lies in the interpretation of DNA fingerprint results, specifically in 
interpreting TB disease with a shared Mtb strain as indicating recent infection [59]. The 
observed proportion clustered using the current definition is ~80%, which is high compared to 
other settings [128, 132, 133] but consistent with expectations considering study setting, 
completeness of the sample and the duration of follow up as described in Chapter 2. [74] It is 
possible that the strains occurring in apparent recent re-infection cases were circulating at the 
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time when these individuals became infected initially, i.e. before 1980 – 1989. Reactivation of 
these old infections while the strain continued to circulate in the population would lead to 
them being seen as clustered and hence misclassified as re-infections. [101]  While this makes 
it difficult to draw conclusions about the likelihood of re-infection disease in individual cases, 
it does not explain the very clear difference seen between the HIV-positive and HIV-negative 
patients.  
Exposure to and (re-) infection with Mtb are relatively rare events. Despite the case-control 
rather than cohort study approach, these results seem to suggest that in the HIV-positive 
population the risk of progression following a recent infection is greater than the risk of 
progression from a prior infection, even in individuals already known to be infected.  
5.5.3 Implications and conclusions 
These results give further support for WHO’s “three I’s” policy for TB control in the presence 
of a generalised HIV epidemic [165]; Intensified case finding in the community to reduce the 
number and duration of undiagnosed infectious TB disease [183], infection control in hospitals 
[184] and Isoniazid prophylaxis for all HIV-positive individuals at risk of Mtb infection, not just 
those with latent infections. [185]  
These analyses confirm and extend results from previous studies on recurrent TB and TB in 
populations and the work described in chapter 3 and 4. Together they point towards an 
apparent dominance of recent Mtb infection, regardless of previous Mtb infection status, as 
the cause of TB disease in HIV-positive individuals in settings with moderate to high rates of 
ongoing Mtb transmission. [72, 73, 139, 162]  
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6 Estimation of total population size, HIV prevalence and ART 
uptake in Karonga District  
6.1 Summary 
This chapter describes the data collection and processing of estimates for the total population 
size, HIV prevalence and ART uptake in Karonga District, which are needed in order to 
estimate TB incidence by HIV and ART status in Chapter 7. 
6.2 Introduction 
6.2.1 Background 
The work so far has applied a case control approach to the question of TB molecular 
epidemiology in settings with generalised HIV epidemics and moderate to high rates of Mtb 
transmission. Also, thus far I have also not explored the effect of ART on the epidemiology of 
TB in these settings.  
In the coming chapters I will focus on the incidence of TB in different HIV/ART subpopulations 
(Chapter 7). 
This chapter describes the data collection and processing of estimates for the denominators 
used in the coming incidence chapters; the sizes of the general population, the population HIV 
positive and HIV negative and finally, the population receiving ART in the district. For this 
purpose I collected the following pieces of information while working at KPS headquarters in 
Chilumba between February 2009 and February 2010: 
1. An up to date estimate of the population by age and sex as well as their distribution 
within Karonga district 
2. An estimate of the proportion of this population that was HIV positive at certain 
periods and comparing those to existing estimates. 
3. The number of people receiving ART and the distribution of time they spent on ART.  
These will allow me to estimate the person years at risk in the different age, sex, HIV and ART 
categories for different periods.  
6.3 Population size 
I required estimates of the Karonga population for two purposes. Firstly, to generate a 
standard population for age, sex and area standardisation of the HIV prevalence estimations 
found in studies that recorded HIV status from a random sample of the population (see table 
6.4 for details of the studies) and secondly, to estimate the person years denominator for the 
incidence analyses.  
6.3.1 Standard population 
The purpose of the standard population is to adjust a crude HIV prevalence from study that 
collected HIV results but potentially oversampled high risk populations, e.g. randomly selected 
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controls from the general population that were age, sex and area matched to TB cases (see 
table 6.4). Using one standard population for each study I adjusted for potential imbalances 
from three factors: age group, sex and area of district. That the risk of being HIV positive is 
different by age and sex is well known and has been shown in the Karonga population. [186, 
187]  The standardisation by area aims to compensate for the differences in HIV risk and 
prevalence patterns between the more urban areas (e.g. Karonga Town) and the other areas 
in the district. [187] 
The National Statistics Office (NSO) of Malawi performs a full population census every ten 
years, most recently in 2008. KPS has used information from the 1988 (area distribution) and 
1998 (age and sex distribution) to standardise HIV prevalences. [186] To update these 
standardisation files I acquired the individual level record for Karonga from the 1998 census to 
get the area distribution by age and sex. Unfortunately the 2008 census results were not yet 
publicly available in required detail at the time of these analyses (March 2010).  
To convert the 1998 census data into proportions of the population by area I used the 
expertise available from local KPS field staff, who converted the census enumeration areas 
into KPS village codes. These were subsequently then divided into one of the six areas 
described in [187] and section 6.3.1.2 (below).  
6.3.1.1 Age structure 
Age groups were coded as 15-24, 25-34, 35-44, 45-54, 55+ to allow comparison with models 
of HIV prevalence and incidence from White et al [186]. 
6.3.1.2 Areas in the district 
The KPS village codes were grouped to represent the 6 areas within KPS district as defined 
previously by Crampin et al. [187] Briefly, the district was divided into the following areas (see 
figure 6—1 on next page) : 
1. rural with a trading and truck-stop area 
2. rural with farming and fishing 
3. peri-urban  
4. urban 
5. rural with a trading area 
6. rural with an international border. 
These areas capture part of the heterogeneity of HIV risk in the district and are thus useful to 
standardise if the population sample that was tested for HIV was likely to be biased to the 
areas with higher HIV prevalences.  
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Figure 6—1: KPS defined HIV areas and ART clinics in Karonga District  
 
Map shows Karonga District and the 6 areas defined as the  
6.3.1.3 Standard population 
Table 6.1 shows the area distribution by age group and sex of the standard population, 
expressed as the percentage of all individuals in that age and sex group, for males (left side) 
and females (right side). These were used to acquire area standardised HIV prevalences by age 
and sex group.  
Table 6.2 shows the area and age distribution by sex of the standard population, expressed as 
the percentage of all males (left) or females (right). These were used to acquire area and age 
standardised HIV prevalences by sex.  
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Table 6.1: Standard population distribution within age groups by area and sex (males on left and females on right) 
Males        Females       
 15 – 24 25 – 34 35 – 44  45 – 54  55+ All ages   15 – 24 25 – 34 35 – 44  45 – 54  55+ All ages 
Area 1 17.4 16.2 14.8 14.6 15.1 16.0  Area 1  16.5 16.5 15.3 15.3 19.2 16.5 
Area 2 20.9 18.9 20.6 21.8 21.5 20.6  Area 2 20.0 20.1 21.0 22.8 19.7 20.4 
Area 3 18.2 17.9 18.9 19.5 20.3 18.6  Area 3 178 17.8 19.4 20,3 19.3 18.5 
Area 4 12.4 13.6 12.6 10.8 10.5 12.3  Area 4 12.5 12.2 11.0 11.2 10.0 11.8 
Area 5 16.9 16.3 15.4 16.4 16.7 16.4  Area 5 17.0 17.1 16.7 16.5 16.1 16.8 
Area 6 14.6 17.1 17.8 16.9 15.9 16.1  Area 6 16.2 16.3 16.6 14.0 15.7 16.0 
Total % 
(N) 
100 
(19,206) 
100 
(13,226) 
100 
(7,162) 
100 
(4,813) 
100 
(6,734) 
100 
(49,229) 
 Total % 
(N) 
100 
(22,394) 
100 
(13,226) 
100 
(8,475) 
100 
(5,670) 
100 
(6,574) 
100 
(56,339) 
Totals represent the total number of males or females in each age group  
 
Table 6.2: Standard population distribution within age and sex groups by area (males on left and females on right) 
Males        Females       
 15 – 24 25 – 34 35 – 44  45 – 54  55+ All ages   15 – 24 25 – 34 35 – 44  45 – 54  55+ All ages 
Area 1 6.7 3.7 2.2 1.4 2.1 16.0  Area 1  6.6 3.9 2.3 1.5 2.2 16.5 
Area 2 8.2 4.4 3.0 2.1 3.0 20.6  Area 2 7.9 4.7 3.2 2.3 2.3 20.4 
Area 3 7.1 4.1 2.8 1.9 2.8 18.6  Area 3 7.1 4.2 2.9 2.0 2.3 18.5 
Area 4 4.8 3.1 1.8 1.1 1.4 12.3  Area 4 5.0 2.9 1.7 1.1 1.2 11.8 
Area 5 6.6 3.7 2.2 1.6 2.3 16.4  Area 5 6.8 4.0 2.5 1.7 1.9 16.8 
Area 6 5.7 3.9 2.6 1.7 2.2 16.1  Area 6 6.4 3.8 2.5 1.4 1.8 16.0 
Karonga  39.0 23.0 14.6 9.8 13.7 100   Karonga 39.8 23.5 15.0 10.1 11.7 100  
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6.3.2 Population size estimates 
6.3.2.1 Population size between 1986 - 1998 
To estimate the population sized for each year between the 1988 and 1998 census I assumed 
a standard exponential population growth within each age and sex category:  
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The annual growth between 1988 and 1998 was calculated for each age and sex group using 
the following formula: 
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For 1986 and 1987 the same growth rate was used for a retrospective estimation of the 
population decreased in those years.  
6.3.2.2 Population between 1999 - 2009 
For the period between 1999 and 2009 I used a similar approach. I obtained the official 2008 
census results by age and sex for Karonga District and assumed a standard exponential growth 
rate between the 1998 and 2008 census. The population size for 2009 was estimated by 
extending the 1998 – 2008 population growth 1 more year.  
6.3.2.3 Population size estimates  
Table 6.3 shows the Karonga population estimates by age, sex and time period. These 
numbers are used as the overall denominator, which for the later chapters will be further 
subdivided by HIV and ART status. In the next section I will describe the estimates for the HIV 
prevalence in the district by age and sex between 1986 and 2010.  
Table 6.3 Population sizes for Karonga District (1986 – 2009) 
  
Period 
    
  
1986 -  1990 -  1995 -  2000 -  2005 -  
Sex Age 1989 1994 1999 2004 2009 
Male 15-24 14,068 16,415 19,415 21,815 24,132 
 
25-34 8,003 9,490 11,479 14,189 17,655 
 
35-44 5,611 6,349 7,292 8,539 10,063 
 
45-54 4,898 4,908 4,945 5,373 5,984 
 
55+ 6,633 6,750 6,906 7,498 8,300 
Female 15-24 14,980 18,012 21,977 24,593 26,794 
 
25-34 10,301 11,674 13,585 16,119 19,206 
 
35-44 6,707 7,475 8,534 9,576 10,662 
 
45-54 6,654 6,265 5,916 6,180 6,671 
 
55+ 6,556 6,671 6,847 7,938 9,570 
Total 
 
84,412 94,010 106,898 121,820 139,037 
Note: population sizes are averages for the specified 4 or 5 year periods  
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6.4 HIV prevalence in Karonga District 
This section builds on previous work by Richard White et al. [186] In their paper they 
estimated the HIV prevalence in Karonga District using a mathematical model that 
incorporated the incidence of HIV and used the time since HIV seroconversion to estimate the 
need for ART in Karonga district. The data guiding the model was based on KPS studies 
(described below).  
One of the main shortcomings of the model is that it does not take into account the roll out of 
ART (which started in July 2005 (see section 6.5). The prolonged survival of HIV cases starting 
on ART (who otherwise would be expected to have a very short survival) would probably 
increase the proportion HIV positive. I explore the effect of this through sensitivity analyses in 
Chapter 7. 
6.4.1 Studies on HIV prevalence in general population 
Since its start in 1981 various KPS studies have collected HIV status from random populations 
which can yield a study HIV prevalence representative for the HIV prevalence in the general 
population. These include retrospective testing of blood spots collected on filter papers from 
the 2 surveys done in the 1980s [182] and the various TB case control studies done since. 
[188-190] 
6.4.1.1 Retrospective testing of filter papers 
During the 2 district wide house to house surveys filter papers with dried blood spots were 
collected from all individuals in area 1 and area 6 of Karonga District. With permission from 
the Malawi Health Sciences Research Committee, these were retrospectively tested for HIV 
[182].  
To estimate the data for the whole district, the area (only for area 1 and 6) and age 
standardised HIV prevalences were adjusted assuming that the ratio between the HIV 
prevalence in area 1 and area 6 compared to the whole district was identical to that found in 
the first study of community controls for TB cases (see next section) which were tested 
between 1988 and 1990.  
6.4.1.2 Random controls for the TB cases  
From 1988 onwards KPS has almost continuously conducted case control studies to explore 
risk factors for TB disease, with the exception of the period between 1993 and 1998. For these 
studies controls are randomly selected from the population which are matched for age, sex 
and area of residence in Karonga district.  
As HIV is a strong risk factor for TB [171] the population of controls is not directly comparable 
to the general population as age, sex and areas with a higher HIV prevalence will be 
oversampled. HIV prevalences for these studies were therefore standardised using the 
standard populations described in section 6.3  
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Table 6.4.Crude and standardised HIV prevalences in adults (15 years or older) in Karonga District (by sex) 
    Overall Males  Females  
Study Period Description Consent % (n/N) Crude   Crude Standa Crude Standa 
LEP 1c 81 – 84   Retrospectively tested filter paper collected from all individuals in 
area 1 and 6 of Karonga District 
100 (10183/10183) 0.1 0.1 0.1 0.1 0.1 
LEP 2c 86 – 89 Retrospectively tested filter paper collected from all individuals in 
area 1 and 6 of Karonga District 
100 (11308/11308) 1.7 1.4 1.4 1.9 3.3 
TB CC 1 88 – 90 Community controls, matched TB cases b on age, sex and area of 
residence in district 
99.6 (1710/1717) 2.8 2.7 2.9 2.9 3.8 
TB CC 2 91 – 93  Community controls, matched TB cases b on age, sex and area of 
residence in district 
99.4 (722/726) 7.3 6.8 8.5 7.9 11.4 
TB CC 2 97 – 01 Community controls, matched TB cases b on age, sex and area of 
residence in district 
87 (911/1046) 13.6 13.0 11.0 14.1 11.9 
TB CC 3 02 – 05  Community controls, matched TB cases b on age, sex and area of 
residence in district 
73 (591/811) 15.5 13.0 11.6 17.8 14.0 
TB CC 4 07 – 09  Community controls, matched TB cases b on age, sex and area of 
residence in district 
80 (379/475) 17.4 13.6 8.0 20.3 13.5 
Note This overall data was combined with the age specific HIV prevalences to inform the mathematical model [186] that estimated HIV prevalence (by age and sex)  
a standardisation was done for age and area of residence in Karonga district using standard populations described in table 6.2. 
b Controls selection based on TB cases year before. [144, 168]  
c Standardised HIV prevalence for LEP1 and LEP2 were adjusted using ratio HIV prevalence area 1+6 / HIV prevalence whole district in TB CC 1.  
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6.4.2 Mathematical model for HIV prevalence 
As said in the previous section, this thesis applies the estimates from the published 
mathematical model. [186] I will therefore describe the overall workings and main 
assumptions regarding HIV prevalence, but not go into too much detail.  
6.4.2.1 Main assumptions in model 
The model extended methods to estimate the incidence of HIV during the initial phase of the 
epidemic, assuming an exponential increase in HIV incidence at the start of the epidemic. 
Survival time after HIV infection was assumed to decrease with age of HIV infection, from 12.5 
years if infection occurred between the ages of 5-14 to 3.7 years for those infected after 65 
years of age.  
The combination of incidence and survival (i.e. the duration of infection) allowed the model to 
estimate the prevalence of HIV at a given time point using the formula  
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The model explored 2 scenarios of the HIV epidemic. HIV incidence was assumed to a stable 
phase after an initial peak, or HIV incidence was allowed to decrease (e.g. following a change 
in risk behaviour).  
As stated before, the model did not account for prolonged survival following ART initiation.  
6.4.2.2 Model input and output 
The model was fitted to the age and area standardised HIV prevalences from the LEP and TB 
CC studies including data up to 2004. Figures 6—2 and 6—3 show the data points used to 
calibrate the model and added the new data points to assess how well the previous output 
from a models allowing a decline allowed (figure 6—2) or not allowing a decline (figure 6—3) 
fit with the new data. 
6.4.2.3 Interpretation 
The model fits best when a decline in HIV incidence is allowed (figure 6—2). Considering the 
relative low numbers in the later data points (see table 6.4) the distance between the last 
data points in the males and the curve is relatively acceptable. We explored updating the HIV 
estimates with the newer data, but this proved impossible to do within the time span of this 
PhD. Considering the weight and location of the additionally available data it is unlikely the 
prevalence curves would make a substantial difference. 
If the model is rerun it would have to be extended to account for improved survival because 
of ART. 
6.4.3 Population estimates 
The model output included a year by year HIV prevalence, by sex (see figure 6—2) or by sex 
and age group. The age specific HIV prevalences were applied to the total population size 
estimates discussed in section 6.3 to separate the population into HIV negative and HIV 
positive.
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Figure  6—2 Age and area standardised HIV prevalences by sex (markers) and estimated HIV prevalence (line)  
 
 
 
 
 
Note: Lines 
show the 
model estimates of HIV prevalence (in % on Y-axis) over time (in years on X-axis) in the model that allows a decline in HIV incidence. Markers show the age and area 
standardised HIV prevalences found in KPS studies. The yellow marker shows the data point that was not yet used to fit the model  
The figures show that the overall trends fit reasonably well with the last data point as well. For the males the model may have overestimated the HIV prevalence in later 
years.  
 
Figure 6—3 Age and area standardised HIV prevalences by sex (markers) and estimated HIV prevalence (line) 
 
 
 
 
 
 
 
 
 
 
 
Note: Lines show the model estimates of HIV prevalence in the model that does not allow a decline in HIV incidence. The figures show that model fit is less good than 
above overall fit is less good than when a decline is allowed.  
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6.5 Patients receiving ART 
6.5.1 ART uptake in Karonga district.  
The first ART clinic, named Buyu (=baobob tree) in Karonga opened up in 2005 in Karonga 
Town, followed by Mwabi (= chance or luck) clinic in Chilumba which opened in 2006. In 
January 2008 two other clinics opened, Kaporo clinic in the North and Moonlight clinic in 
Nyungwe in the middle of the district (figure 6—1).  
6.5.1.1 Patient ART mastercards 
Patients who start on ART in Malawi are issued a patient mastercard by their ART clinic as part 
of the government system. On this mastercard several basic pieces of demographic 
information (age, sex, current village) are recorded, as well as their reason for starting ART, 
their ART regimen and a record of every time the patient has visited the clinic to receive 
medication. When a patient transfers between clinics they are supposed to take their 
mastercard with them so staff at the new ART clinic can copy the data onto a new mastercard. 
6.5.1.2 ART patient registers 
Each ART clinic also keeps a handwritten patient register. A line is filled for each patient when 
they register for ART. Apart from the name of the patient and their guardian the register holds 
the following information: 
1. Demographic: age, sex and current village 
2. ART history: date registered at this clinic (which is a close proxy for the date first 
received ART at this clinic) and date first started on ART at any clinic 
3. Outcome: alive and receiving ART at this clinic, Transferred to a different clinic, Died, 
Defaulted or Stopped and the date of outcome if the outcome was not ‘Alive’.  
6.5.2 ART patient register study 
For the purpose of the analyses in this thesis I required the number of patients receiving ART 
in Karonga District by age and sex. I also required the time spent on ART to distinguish 
between patients whose immune system was still recovering and patients for whom ART 
could have been expected to have had a substantial effect on their immune system. In this 
chapter I set that cut-off on 6 months. In the coming chapters I will explore the effect of 
applying different cut-offs on the results of the analyses. 
This information was available in the patient registers, which I aimed to record.  
Note: this work was in part funded through the Gordon Smith Travelling Scholarship. 
6.5.2.1 Objective and data collection  
In the ART patient register study I aimed to collect the demographic, ART history and outcome 
information for each patient record in the patient registers. After obtaining ethical approval 
from the National Health and Sciences Research Committee in Malawi (reference number 
424) and the LSHTM Ethics Committee (reference number 5067) anonymised digital pictures 
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were taken during August 2009 from each page of all patient registers at the 4 clinics (see 
figure 6—4 for an example of an anonymised picture).  
Data were double entered and discrepancies checked and decided on by a third reviewer 
based on the original picture.  
A total of 5575 records were double entered in the KPS database. Village names as recorded 
by the ART staff were recoded into KPS village codes and further into the 6 HIV areas 
mentioned described in section 6.2.  
6.5.2.2 Transferred patients  
Of these records, 917 indicated that the patient in question had either transferred into a 
Karonga District ART clinic from outside of the district or transferred between ART clinics 
within the district, probably because an ART clinic opened closer to their home.  
Although this migration of patients is understandable, it poses a complication for the 
interpretation of the data as the same person could potentially be counted twice if one 
wanted to record the total number of people started on ART in Karonga district.  
Ideally, I would be able to follow the course of each individual who started receiving ART as 
they moved between clinics within Karonga District. I tried an approach to solve this by 
accessing the individual patient mastercards for those patients that transferred into a clinic. In 
theory, these mastercards would hold information on a patient’s previous clinic and patient 
number. This would allow us to link records of the same patient as they moved between 
different clinics. In practice, this system turned out to be unworkable; missing mastercards as 
well as missing or incorrect numbers caused the required workload per individual record to be 
very high, and even with the extra effort a high proportion of transferred patients could not 
be linked.  
The exercise turned out to be useful however, as the inspection of mastercards from patients 
that had transferred into a clinic showed that the date this patient first started ART as 
recorded in the register was often incorrect. In those cases the date this person was first 
tested HIV positive was copied into the register as the date first started ART. For all the 
transferred patients the mastercards were re-checked and if the date first started ART was 
recorded wrongly in the register the data was amended in the KPS database. 
As for the problem of time on ART, the main purpose of these data was to provide a 
denominator for the incidence of TB in patients receiving ART, by sex, age group and time 
spent on ART. For that purpose the number of person years in each category is more 
important than the absolute number of patients starting on ART.  
This number of person years at risk of TB in a set period, by age, sex and time spent on ART 
can be constructed using the available data, as I describe in the next section.  
  
6.5.3 Data processing
6.5.3.1 Survival analysis approach
What was required was a was the number of people receiving ART in a set period (e.g.2005
2006) and the average time these patients had been on ART before they entered that time 
period. In more technical terms, for set periods I needed to know the total per
on ART (and thus at risk of TB) in Karonga district, by age, sex and time on ART. 
In essence this is a straightforward survival analysis question in which the total observation 
time, rather than the number of individuals in the cohort, is 
analysis groups.  
To extract and split the observation time 3 pieces of information are required, known in Stata 
as ‘origin’ (start of clock), ‘enter’ (start of follow up/observation time) and ‘exit’(end of follow 
up/observation time). See figure 6
Figure 6—4: Calculating observation time from ART patient registers records
Table 6.5: Variables in observation time calculation
Variable Description 
Origin Time when the clock starts
Enter Start of follow up
Exit Exit from study, censor event
 
This method builds on the idea that patients transferring between clinics may have multiple 
records, but their observation times are unlikely to overlap, which solves the problem of 
double counting individuals.
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split between the required 
—5 and table 6.5 for an illustration of the calculation. 
 
 
In this study 
 Date first started ART 
 time  Date started ART in this clinic 
 If alive: end of study period. If different outcome
 
 
90 
-
son years alive 
 
 
 
: date of outcome 
  
Figure 6—5: Example picture of ART patient register study
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: first column gives the clinic registration number. 
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6.5.3.2 Person years on ART in Karonga District 
To calculate the person years of observation I used the stsplit command in Stata. Table 6.6 
shows the total number of person years recorded for each calendar year, the age and sex 
distribution and the proportion of person years where the patient had been on ART more than 
6months  
Table 6.6: Adult person years receiving ART in Karonga District  
 Person years <=6m on 
ART 
>6m on 
ART 
Age 
(med+IQR) 
Sex 
(%male) 
Aug 05 – Dec 05 137 82 55 37 (32–45) 0.39 
Jan 06 – Dec 06 762 289 473 37 (31–45) 0.39 
Jan 07 – Dec 07 1517 424 1093 37 (31–44) 0.39 
Jan 08 – Dec 08 2225 530 1695 36 (30–45)  0.39 
Jan 09 – Aug 09 1615 309 1306 36 (30–45) 0.39 
This table shows the number of person years on ART 
6.5.4 ART in Karonga District 
The data in table show that the delivery of ART in Karonga District expanded quickly in the 
first years. The records suggest that is a combined effect of people first starting ART in a 
Karonga clinic because they can now access their clinic, and people who were previously 
receiving their ART from clinics outside of the district who now have transferred into a 
Karonga clinic. The pattern of patients repeatedly moving between clinics suggests that ease 
of access is an important factor for these patients. The ART programme in Karonga District is 
scheduled to start serving patients at 2 additional ART clinics in the rural South West area and 
far North area of the District, thus proceeding with the drive to reduce the barrier for patients 
in need of ART.  
6.6 From denominator to incidence 
This chapter describes the data collection and processing for the denominators of TB 
incidence in Chapters 7. In the following chapters I will describe the data collection for the 
numerator of the incidence equation and analyse the resulting trends.  
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7 TB incidence in Karonga District after the roll out of ART 
7.1 Summary 
The roll out of ART is hoped to reduce TB related morbidity and mortality in HIV positive 
patients. [21] However, mathematical modelling and cohort studies have suggested that this 
effect may be limited, especially if HIV positive patients are severely immunocompromised 
when they start on ART. [34, 36]  
In this chapter I estimate TB incidence over time by HIV and ART status in Karonga District. I 
specifically focus on how the introduction of ART in July 2005 has affected incidence trends.  
7.2 Introduction 
The roll out of ART has further diversified the population of HIV positive patients in sub 
Saharan settings. Patients with severe immunosuppression and a short life expectancy before 
ARTs were available are now eligible for, and often have access to ART.  
As a part of this highly vulnerable patient group is started on ART a new sub population is 
created of previously severely immunocompromised patients now supposedly en route to 
immunological recovery. Although the first months after ART initiation are marked by a highly 
elevated risk of opportunistic illnesses, including TB [191], after a certain period taking ARTs a 
patient’s immune system is expected to have started recovering, usually measured by the CD4 
counts returning to normal levels. [36] 
7.2.1 ART and the relative incidence of TB in HIV positive individuals 
There are several studies describing TB incidence in patients receiving ART, [35-46, 192] which 
mostly show that TB incidence is high in the first 3-6 months after ART initiation and then 
decreases with time spent on ART. Also, when CD4 data were available, studies showed that 
patients with lower CD4 counts have a higher risk of developing TB. [35, 36, 38, 44, 45, 192] 
Several of these studies were able to compare the relative incidence of TB between HIV 
positive/ART naive patients with patients on ART. [43-46] Overall, they suggested that TB 
incidence in patients was lower in patients on ART, especially after correction for CD4 count.  
However, patients in these studies are often closely monitored and have access to high level 
laboratory services, which is not representative of the regular setting of ART clinics in Sub 
Saharan Africa. Also 3 out of 4 of these studies based their results on less than 10 TB episodes 
in patients on ART. [43, 45, 46] Finally, most did not exclude TB cases with recurrent TB or 
patients without a laboratory diagnosis.  
These studies leave the question of the relative incidence of TB in HIV positive patients started 
late on ART (WHO stage 3/4 or <200 CD4 count) in complete population settings where the 
available clinical and laboratory support is minimal. As the majority of HIV positive patients 
live and will access ART in such settings it is important to get an estimate of what to expect 
after ART arrives in these populations.  
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Also, none of the studies directly compared the relative incidence in patients receiving ART 
with that of a HIV negative cohort from the same population. 
7.2.2 ART and TB incidence in the population 
Only one study from a European cohort explored the impact of more widespread uptake of 
ART (between 1995-1997) on the TB incidence in a cohort of HIV positive cases. [44]  It 
showed that TB incidence decreased with the uptake of ART and associated increase in 
median CD4 count of the population.  
No study has been able to look at the effect of ART on the TB incidence rates in a whole 
population, including HIV negatives, or in a rural Sub Saharan population. It was hoped that 
the introduction of ART would not only improve survival for HIV positive patients but that ART 
would have a knock on effect on TB incidence in populations through the improved immune 
status of HIV positive patients. [21] However, in a mathematical model Williams and Dye 
warned that because of the prolonged survival in patients receiving ART the effect on TB 
incidence would be limited unless patients were started early (e.g. from a CD4 = 500 cells/µL) 
and coverage and compliance were both over 90% [34]. In a study from South Africa Lawn et 
al. confirmed that patients that started ART with severe immunosuppression (CD4 count <100 
cells/µL) remained at higher risk of TB compared to patients starting ART with CD4 count ≥100 
cells/µL throughout 5 years of follow up. [36]   
7.2.3 TB incidence in Karonga District 
In this chapter I explore the effect of ART on the incidence of TB in the context of a well 
functioning TB control programme and a health centre based ART programme which is 
unsupported by CD4 or viral load count facilities.  
KPS has a complete overview of all diagnosed TB cases in Karonga District since 1986, 
including reliable data on smear and/or culture confirmed TB. The database also holds 
information on the HIV status and ART history for most TB cases. The level and quality of 
health care other than TB in Karonga District is probably representative for other Sub Saharan 
settings. As described in Chapter 6, ART arrived in mid 2005, and is distributed through local 
health clinics, with little clinical or laboratory support for the monitoring of patients. This is 
typical for Malawi and similar to other rural SSA settings. This provides a good opportunity to 
study the impact of ART roll out on TB rates in a rural population. 
The first line ART regimen has been the same since the roll out started in Malawi. The 
standard first line therapy includes the 2 nucleoside reverse transcriptase inhibitors (NRTI) 
Stavudine and Lamivudine and 1 non-nucleoside reverse transcriptase inhibitor (NNRTI) 
Nevirapine. [193] For second line therapy an NRTI backbone of Zidovudine, Lamivudine and 
Tenofovir is combined with a protease inhibitor combination of Lopinavir/Ritonavir. [193]  
Previous KPS studies have shown that the incidence of TB at KPS peaked in the mid 90s and 
seemed to be decreasing up to 2001[171]. This chapter adds information on TB trends since 
then and explores the impact of ART in 2005. Based on the assumption that most HIV positive 
patients starting ART in Karonga will be highly immunosuppressed, the hypothesis is that they 
will have a high risk of TB. Whether this will lead to a change in TB incidence trends in other 
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groups e.g. the HIV negative population, i.e. whether there is an indirect effect of ART, will be 
explored as well.  
7.3 Methods  
7.3.1 Population denominators 
These data are described in detail in chapter 6; I will briefly summarise them here. 
7.3.1.1 General population 
In short, I used the results from 3 full censuses of the population in Karonga District in 1988, 
1998 and 2008 as data points. I then assumed an exponential growth between these data 
points and directly before (1986-1987)  and directly after (2009) to get estimates by age and 
sex group in each year.  
7.3.1.2 HIV prevalence 
I applied the results from a mathematical model run by Richard White et al, which was 
published in 2007. [186] This model incorporated an estimate of the incidence of HIV and 
used the time since HIV seroconversion to estimate the need for ART in Karonga district. The 
data guiding the model were based on KPS studies that tested randomly selected controls for 
TB cases or complete populations during whole population surveys (LEP1 and LEP2). [182, 
188-190] The model that fitted the data best allowed the incidence of HIV to decline in 
Karonga after a peak in the early 1990s.[186] 
One of the main shortcomings of the model is that it does not take into account the roll out of 
ART (which started in July 2005 (see section 6.5)). The prolonged survival of HIV cases starting 
on ART (who otherwise would be expected to have a very short survival) would probably 
increase the proportion HIV positive. I explore the effect of this through sensitivity analyses. 
The original model also did not incorporate data beyond 2005, although the new data points 
fit reasonably well with the estimated curve as is shown in figure 6—2. 
7.3.1.3 Person years spent on ART 
This was recorded through the ART patient register study, as described in Chapter 6. We 
recorded demographic, ART history and outcome information for each patient starting ART in 
Karonga district. This information was converted into person years on ART in Karonga district 
by age and sex and by time spent on ART. To calculate the incidence of TB in the HIV positive 
population not receiving ART the total HIV positive person years were reduced by the 
observed person years on ART.  
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7.3.2 TB case population 
7.3.2.1 Inclusion and exclusion criteria 
I included adult (15 years or older) TB cases with a TB diagnosis between Jan 1986 and the 
start of Aug 2009. The end time was determined by the data from the ART patient register 
study (see Chapter 6). 
Only new TB cases were included. Patients who reported a previous TB episode in the 
interview or recorded in the KPS database were excluded.  
For the main analysis I included patients diagnosed with pulmonary TB who had at least 1 
clear positive sputum smear (SS+) result from a sample examined at the KPS laboratory, thus 
excluding cases with 1 marginally positive smear (fewer than 10 acid-fast bacilli per 100 
fields). This case algorithm is reproducible and has been applied with similar rigour 
throughout the history of KPS. [144, 171]  Also, SS+ pulmonary TB cases represent the main 
source of new Mtb infections in a population, thus drive TB epidemic and thus are a highly 
relevant group for the study of the TB epidemic in a population. 
7.3.3 Variable definitions 
7.3.3.1 HIV status of TB cases 
HIV status of TB cases at the time of the TB episode was extracted from the KPS database, 
which holds the results of all confirmed HIV test results for an individual. Tests on urine or 
saliva were excluded.  
A TB case was considered HIV negative at time of their episode if their negative HIV test was 
recorded after or within 1 year before their TB was diagnosed. Conversely, a TB case was 
considered to be HIV positive at time of their TB episode if their first recorded positive HIV 
test was done before or within one year after the end of their TB episode. 
7.3.3.2 ART status of TB cases 
The first months after an immunocompromised HIV patient is started on ART are usually 
marked by a high risk of a variety of diseases, including TB. [194] The complex of these disease 
episodes is sometimes referred to as immune reconstitution syndrome (IRS), although it is 
unclear which diseases can be referred to as IRS and which are considered as expressions of 
the regular burden of opportunistic infections in severely immunocompromised patients. 
[195] 
This period marked by increased rates of opportunistic infections precedes the time period 
where a patient is expected to enter a phase of presumed immune recovery and subsequent 
lower risk of TB disease. Some studies quote 1 month, others 3. [191]  
For the purpose of this analysis I will use a 6 months cut-off for distinguishing between 
patients recently started on ART and those receiving ART for longer. In patients receiving ART 
for over 6 months we can expect ART to have had an effect on the risk of TB. This gives 4 
groups in the analysis of TB by HIV and ART status: 
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1. HIV negative 
2. HIV positive not receiving ART 
3. HIV positive and recently started on ART (i.e. within 6 months)  
4. HIV positive and receiving ART for a longer period.  
7.3.3.3 Period analysis  
Overall and HIV specific TB incidences were calculated by year. TB incidence by ART status was 
calculated for the complete August 2005-July 2009 period.  
In the main analyses I explored TB incidence by HIV and ART status by the following periods: 
Period Start End Mid point 
1 1997 1999 June 1998 
2 1000 2002 June 2001 
3 2003 2005 June 2004 
4 2006 Aug 2009 October 2007 
7.3.3.4 Age 
Age was grouped into 5 categories, 15-24, 25-34, 35-44, 45-54, 55 and older. 
7.3.4 Incidence estimates 
7.3.4.1 Overall Incidence: January 1986 – Aug 2009 
The overall TB incidence of new pulmonary SS+ TB cases was estimated by dividing the total 
number of cases (by age and sex category) by the total number of observed person years, 
taken as the population size that year. All incidence estimates are expressed as the number of 
cases per 100,000 person years:  
7.3.4.2 Incidence by HIV: January 1996 – August 2009 
HIV test results are available for a large proportion of TB patients, and have been routinely 
offered to TB cases since 1988. From 1997 onwards TB incidence is stratified by HIV status. I 
report the observed incidence by HIV status, in which TB cases with unknown HIV status at 
time of their TB episode are excluded. I used Multiple Imputation using Chained Equations 
(MICE) to fill in and explore the potential bias that followed from excluding them through an 
analysis of the imputed dataset (see section 7.3.5) 
7.3.4.3 Incidence by HIV and ART status: August 2005 – August 2009  
As said in Chapter 6 ART became available from a clinic in Karonga District in July 2005 and 
more widely from 2006. TB incidence was estimated as the total number of TB cases on ART 
for different lengths of time, between August 2005 and July 2009 divided by the total number 
of observed person years of patients receiving ART in that age, sex and ART category during 
that period. TB cases with missing values for ART status were excluded from this analysis. 
MICE was used to explore the potential bias from those exclusions. 
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7.3.5 Imputation of missing values 
7.3.5.1 Background 
As in any study some observations will have missing values. One variable often missing is the 
HIV status, in this case the HIV status at time of an individual’s TB episode. This may be due to 
refusal to undergo testing, or because the patient died (or defaulted) soon after diagnosis, 
before a HIV test could be done.  
These missing values pose a problem in the analysis. Often patients with missing values for 
core variables such as HIV are excluded from the analyses. These ‘completer’ analyses only 
include cases for which information on all variables in the analysis are available.  
Such analyses are inefficient as cases can be lost because of 1 missing value and likely to 
introduce some bias in the results if the missing data do not satisfy the missing completely at 
random assumption (MCAR, see below for explanation). One can try to assess the extent of 
this bias by analysing patients with missing HIV status as a separate group [72], or run 
sensitivity analyses as well in which all patients with unknown HIV status are assumed to be 
HIV positive or HIV negative.  
However, most of these techniques have the potential to introduce new bias of their own or 
underestimate the inherent uncertainty of filling in missing data (see 
http://missingdata.lshtm.ac.uk/start.html, accessed 10-2-2010). In incidence analyses the 
effect is even more severe, as missing data will result in absolute underestimation of the 
incidence in each group, e.g. HIV negative and HIV positive group, as well as potentially 
biasing the relative incidence rates between groups. 
In recent years imputation of missing values has become increasingly accessible to medical 
researchers following the development of computing power and statistical software packages. 
In modern imputation the value of the missing data is filled in, i.e. imputed, based on the 
observed values for that and other variables.  
7.3.5.2 Missing at random assumption 
Imputation of missing values relies on the core assumption that data are either missing 
completely at random (MCAR) or that any systematic differences in the observed and missing 
data can be explained by differences in the observed data, which is referred to as data Missing 
At Random (MAR). [196] If this is not possible the data are considered to be Missing Not At 
Random (MNAR), and imputation is not possible. In other words, if the reason for missingness 
is a direct consequence of an unmeasured factor e.g. a prior test result, the MAR assumption 
is violated. Imputation will only compound the bias introduced by the missing value and its 
results will not be useful or interpretable. 
Unfortunately there is no hard and fast way to determine whether data are MAR or NMAR. In 
practice part of the data will always be NMAR, i.e. some of the systematic differences will not 
be explained by covariates. This is similar to residual variation in regression models, with the 
difference that it cannot be quantified. One has to look carefully at the patterns of missing 
data and the imputed values across other variables, consider the theoretical framework of 
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why the variable may be missing and then make an informed judgement call on whether the 
MAR assumption is sufficiently valid and the imputed data can be presented.  
7.3.5.2.1 MCAR, MAR and NMAR in the context of HIV 
HIV is a good example of how data can be MCAR, MAR and NMAR at the same time. Part of 
the missing values for HIV status will be MCAR, e.g. a HIV test that was not done because the 
tube of venous blood was accidently dropped in the lab. These values can be imputed based 
on information on the person’s age, sex and perhaps area of the district (e.g. urban or rural) 
they were living in. In the KPS data each of these are shown to be strongly associated with an 
individual’s HIV status. [182, 186, 187]  
Another part of the missing values for HIV will be MAR, for example because a missing HIV 
test result is more likely if the patient died before he/she could be tested. As death during 
treatment is also more likely if the patient is HIV positive, the recorded outcome can help 
explain some of the systematic differences between missing and observed data. In this case, 
patients with missing HIV values are more likely to be HIV positive than patients with an 
observed HIV status. 
However, for another group of patients with missing HIV status the systematic difference 
cannot be captured by other observed variables. For example, it is known that patients who 
have tested positive for HIV are less likely to consent to a future test. [197, 198] In the context 
of KPS data this issue comes up if the patient was tested positive outside of KPS. Their 
previous test result will not be recorded in the KPS database and this information cannot be 
used to correct for the missing data. In Karonga District the number of HIV testing facilities has 
increased following the roll-out of ART. This has been shown to be a problem in an annual 
sero-survey. [197] 
7.3.5.3 Multiple Imputation using Chained Equations (MICE)  
There are various approaches to multiple imputation, most of which lead to similar results. In 
this chapter I will use the MICE command, which is available in the Stata statistical software 
package.  
7.3.5.3.1 MICE 
MICE stands for Multiple imputation using Chained Equations. Multiple imputation refers to 
the fact that missing values for all specified (i.e. multiple) variables are imputed in the same 
process. Chained equations refers to the system of regression equations that works 
cumulatively; after missing values in the first variable are imputed these values are in turn 
used in the imputation of missing values in the next variable. The imputation of each variable 
thus builds on previous imputations, in which each imputation is linked through a ‘chain’ of 
regression equations.  
7.3.5.3.2 Basic principle 
I will not describe MICE in great technical detail, but give an overview of its basic workings. For 
a detailed discussion please see [199]  
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7.3.5.3.2.1 Variables in the imputation 
In the MICE command one has to specify the variables to be imputed and the regression 
model that MICE should apply for each of them.  
MICE will always start the imputation cycle with the variable that has the least missing values 
and build from there. Once the imputation for that variable is complete, it will move to the 
next variable with the least missing data and thus progress through the variables in order of 
missingness. As a result the variable with the most values missing will be imputed last, using 
all observed and imputed values of the other variables.  
7.3.5.3.2.2 Imputation variables  
First the missing values for the variable are randomly filled in with values that lie within the 
range of the observed values. Then an appropriate regression model is run in which the 
imputed variable is the outcome (e.g. a logistic regression to impute values for the binomial 
variable HIV status) and the variables specified in the MICE command as covariates.  
This regression model results in a probability distribution of values for the missing value, given 
the values, observed and randomly chosen, for the other variables of that observation. The 
imputed value is drawn at random from that distribution.  
Please note that observations for which all covariates are missing are ignored in the MICE 
command. No imputed value is generated for the simple reason that there are no data to 
inform the model. 
This process is repeated for every variable with missing values in order of the proportion of 
missing observations. One such sequence of regression models in which all the variables with 
missing data are imputed once is called a cycle. 
7.3.5.3.2.3 Cycles within an imputation 
Please note that in the first cycle all missing values were randomly filled in, and then replaced 
by imputed values. Therefore, in the first cycle the regression models that generate the 
distributions for these imputed values will be guided to an undesirable extent by the 
randomly entered values. To get away from those randomly filled in values, the cycles 
described in the previous section are repeated a specified number of times.  
The second cycle will use the imputed values from the first cycle as substitutes for the 
originally missing values, rather than the random values used in the first cycle, and the third 
cycle will use the imputed values from the second cycle. Through this mechanism of 
repeatedly cycling through the chained regression equations the imputed values will move 
increasingly away from the randomly chosen starting values in the first cycle and have a 
stronger base in the observed data.  
The required number of cycles is not clear. A minimum of 10 cycles is usually recommended. 
[200] In this thesis each imputation is run with 20 cycles.  
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7.3.5.3.2.4 Number of imputation runs 
The complete imputation process is repeated a number of times, to assess the uncertainty of 
the imputed values. The recommended number of repeats is under discussion, but a minimum 
of 10 imputations is usually advised. In this thesis I repeat each imputation 20 times.  
7.3.5.4 Covariates in the imputation 
For multiple imputation it is generally recommended to use as many and diverse variables as 
possible, provided that they do not have too many observations missing, i.e. introduce too 
much additional uncertainty in the imputation model.[196] There is no general rule for what 
constitutes a high level of missing, one has to make a judgement call. In the imputations for 
chapter 7 all the covariates I use in MICE have less than 5 percent of observations missing.  
7.3.5.4.1 Sex 
Imputations were done stratified by sex as various associations between HIV and other 
variables, for example HIV patterns by age, differ between the sexes. Rather than introduce 
interaction terms in the MICE command I chose to run separate imputation models for males 
and females.  
7.3.5.4.2 Age 
Age is strongly associated with HIV status. Age was not missing for any of the observations, so 
no regression model needed to be specified.  
7.3.5.4.3 Outcome 
Outcome of the TB episode was included in the imputation, coded as ‘Completed’, ‘Died 
before treatment completion’, ‘Left before end of treatment’, ‘Transferred out’. Multinomial 
logistic regression was used in the imputation model to impute missing values.  
7.3.5.4.4 Area in district 
The HIV prevalence is higher in some areas of the district, as described in Chapter 6. We 
included which area the TB case was from in the imputation as a categorical variable with 6 
values. Multinomial logistic regression was used to impute missing values for this variable. 
7.3.5.4.5 Year of episode 
The HIV prevalence among TB cases may well vary over time. Year of diagnosis of the TB 
episode was included in the imputation. This variable had no missing values.   
7.3.5.4.6 Type of TB  
TB type was coded as PTB only, or PTB and either lymph node or other EPTB. This variable had 
no missing values.  
7.3.5.5 Imputation of HIV status 
7.3.5.5.1 Time span 
HIV status for TB cases was imputed for the years 1997 – 2009. This cut off is based on a too 
high percentage of HIV status missing in the earlier period (HIV status was unknown for over 
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85% of cases between 1994 and 1996 following concerns of the reliability of HIV tests done 
during that period).  
7.3.5.5.2 MAR assumption -outcome 
As illustrated in section 7.3.5.2.1, one of the main variables that could account for HIV status 
MAR is outcome. Table 7.1 (first 3 columns) shows the distribution of outcome for HIV 
negative, HIV positive and cases with unknown HIV status.  
Table 7.1: HIV status by outcome – missing and imputed 
Outcome HIV Neg 
% (n/N) 
HIV Pos % 
(n/N) 
HIV unknown 
% (n/N) 
 Observed 
HIV 
prevalence 
% of missing 
imputed as 
HIV positivea 
Cured 81.8 
(356/435) 
68.1 
(425/624) 
30.2   
(90/298) 
 54.4 
(425/781) 
54.2      
Died 4.6 
(20/435) 
19.6 
(122/624) 
44.6 
(133/298) 
 85.9 
(122/142) 
80.5  
Lost 2.3 
(10/435)  
3.5 
(22/624) 
13.4   
(40/298) 
 68.8     
(22/32) 
65.9      
Transferred 3.0 
(13/435) 
3.7 
(23/624) 
8.7     
(26/298) 
 63.9     
(23/36) 
60.0      
Unknown or missingb 8.3 
(36/435) 
5.1 
(32/624) 
3.0       
(9/298) 
 47.1     
(32/68) 
58.3          
Note: table includes new SS+ pulmonary TB cases with start of episode before August 2009. Results 
show that the proportion of outcome = death in the HIV unknown is high compared to those with 
known HIV status. This fits with a MAR assumption. Imputed values mostly follow the observed 
proportions in each group, as can be expected with MICE.   
a percentage calculated as average across 20 imputations.  
b includes 3 failure cases that were merged with unknown category to prevent overfitting in the 
imputation. 
 
As with any regression analysis, categories with too few data cause problems. For the purpose 
of the imputation I therefore merged category Failure with the Unknown category. This 
conservative approach exchanges a bit of additional missingness in the imputation for the 
benefit of increased stability in the regression models. 
The last 2 columns of table 7.1 show that the imputed values for HIV follow the observed HIV 
prevalence in each outcome category, e.g. a high HIV prevalence in the cases who die before 
completing treatment.  
Table 7.2 summarises the results of the HIV imputation based on all variables described in 
section 7.3.5.4. Figure 7—1 gives a graphical illustration of the imputation. As the majority of 
TB cases with missing HIV status were imputed as HIV positive the imputed HIV prevalence in 
TB cases was higher than the observed in most years. 
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Table 7.2: Observed and imputed HIV prevalence among TB cases by year 
Year missing % (n/N) Observed 
prevalence %(n/N) 
Imputed 
prevalence %
a
  
1997 17.4 (21/121) 54.0 (54/111) 55.5  
1998 31.3 (42/134) 55.4 (51/97) 58.2  
1999 33.0 (36/109) 58.9 (43/74) 61.9  
2000 20.3 (24/118) 67.0 (63/99) 69.5  
2001 45.3 (53/117) 53.1 (34/67) 60.6  
2002 47.5 (49/103) 61.1 (33/55) 61.7  
2003 16.7 (17/102) 69.4 (59/88) 69.9  
2004 18.7 (17/91) 51.4 (38/81) 56.5  
2005 14.4 (14/97) 57.8 (48/81) 58.9  
2006 4.0  (4/97) 69.9 (65/97) 70.1  
2007 5.9  (6/102) 60.4 (58/97) 60.3  
2008 11.6 (11/95) 52.4 (44/87) 54.2  
2009 5.6    (4/71) 50.8 (34/67) 52.4  
Total 22.0 (298/1357) 59.2 (624/1059) 61.0  
Note: 2009 cases only included cases with diagnosis before 1
st
 of August 2009  
a percentage calculated as average across 20 imputations.  
 
Figure 7—1: Observed and imputed HIV prevalence (1997 – 2009) 
 
This graph shows that the main effect of the imputation was to even out some of the artificial drop in 
2001 and 2002. It suggests a decrease in the proportion of TB cases that is HIV positive since 2006.  
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7.3.5.6 Imputation of ART status 
ART status was missing for 17% (70/415) of SS+ pulmonary TB cases with diagnosis between 
31
st
 of July 2005 and 1
st
 Aug 2009 (table 7.3)  
Broadly the same imputation model was used as in section 7.3.5.5, with the same explanatory 
variables. The main difference was that the HIV variable was replaced with a 4-category 
variable that described an individual’s HIV and ART status. These 4 categories followed those 
described in section 7.3.3.2:  
1. HIV negative (and therefore not receiving ART) 
2. HIV positive not receiving ART 
3. HIV positive and recently started on ART (i.e. 6 months or less)  
4. HIV positive and receiving ART for a longer period (i.e. more than 6 months).  
This joint variable has the advantage that it automatically informs the imputation model of 
the restriction that HIV negative patients should not be receiving ART. Also, there is a 
statistical advantage in that HIV and ART status now share a joint probability distribution, 
which is advantageous in the MICE statistical framework.  
Table 7.3 shows the proportion of new SS+ pulmonary TB cases between August 2005 and July 
2009 that had a missing value for ART status. Table 7.4 shows the missing, observed and 
imputed values for ART. The missing values were for the most part imputed as not on ART, 
although the proportion of cases imputed as being on ART is slightly higher than in the groups.  
Table 7.3:  Proportion of cases with missing ART status (August 2005 – July 2009) 
Year missing % (n/N 
2005 20.0 (10/50) 
2006 13.4  (13/97) 
2007 15.7  (16/102) 
2008 17.7 (17/95) 
2009 19.7   (14/71) 
Total 16.9 (70/415) 
 
Table 7.4:  Observed and imputed values for ART status (August 2005 – July 2009) 
ART category Observed % (n/N) Imputed %
b
  Total % 
 
Not on ART
a 
82.3 (284/345) 77.1 81.4 
Recently started ART (<=6 months 
before start TB episode) 
8.4 (29/345) 9.4 8.6  
On ART  > 6 months 9.3 (32/345) 13.6 10.0   
Total cases 345 1400
a 
8300
a 
a combined HIV negative and HIV positive patients not on ART 
a percentage calculated as average across 20 imputations.  
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7.3.6 Statistical analyses 
7.3.6.1 Analyses with imputed datasets 
All analyses with imputed datasets were done using the ‘mim’ prefix in Stata v10. This prefix 
informs Stata that the dataset is the result of multiple imputations and ensures that the 
uncertainty from the imputed values (i.e. variation between imputations in imputed value for 
each observation) is reflected in the estimated accuracy of the effect estimates. The main 
effect is that the confidence intervals are wider than in a regular analysis.  
7.3.6.2 Relative incidence by HIV and ART status 
The relative incidence of TB by HIV and ART status was expressed as the incidence rate ratio 
(IRR). IRR’s were calculated using Poisson regression in Stata.  
7.3.6.3 Trends in TB incidence in the general, HIV negative and HIV positive 
population 
Trends in the incidence of new SS+ pulmonary TB were inspected visually and through 
regression analysis. Poisson regression and the lincom command were used to estimate TB 
incidence by period.  
Piecewise Poisson regression was used to explore a change (or the absence thereof) in trends 
in the annual TB incidence between the period up to the introduction of ART in 2005 (1997 – 
2005) and the period from the inclusion of ART (2005 – 2009). Piecewise regression fits 2 
variables to describe the annual trend in TB incidence. The first variable described the trend in 
annual TB incidence for the period 1997 up to and including 2005. The second described the 
same trend but starting in 2005 running up to Aug 2009. These 2 variables describe 2 linear 
curves with a shared point in 2005 and thus allow for a ‘dent’ in the curve.  
The exponentiated coefficient (i.e. IRR) for these piecewise regression variables represent the 
annual increase or decrease in TB incidence for that period, in which the first year is taken as 
the baseline. The contribution of a second variable to describe the annual trend was assessed 
using the Wald test.  
7.3.6.4 Direct effect of ART on TB incidence trend in the overall and HIV positive 
population 
The additional ART related cases are expected to affect the TB incidence in the population 
both directly as well as indirectly.  There are the additional cases in the ART receiving 
population who are directly attributable to their treatment with anti-retroviral drugs. For 
example, without ART these patients would not have survived to develop their first TB 
episode. However, there will also be an indirect effect as these additional cases will increase 
Mtb transmission in the overall population, which in turn can lead to additional cases.  
As a rough exploration of the direct effect of ART on TB trends I excluded all TB cases that had 
been on ART for more than 6 months. The reasoning is that these cases were severely 
immunocompromised at the time of starting ART, otherwise they would not have been 
eligible under the government ART eligibility criteria [193] which have followed WHO 
recommendations. It is likely that a proportion of these cases would have died soon 
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afterwards if they had been started on ART, and so would not have developed active TB more 
than 6 months later.  
Please note that some of these cases will actually be due to Mtb transmission from fellow ART 
receiving TB cases. The line between a direct and indirect becomes blurry in these cases.  
7.3.7 Sensitivity analyses 
7.3.7.1 SS+ versus All TB 
I compared incidence trends in new pulmonary SS+ cases with trends in the incidence of all 
new TB. Imputations were run identically for the all new TB cases population, apart from the 
addition of a variable to indicate whether the patient was smear positive or not.  
7.3.7.2 No decline in population HIV prevalence  
The current model for population HIV prevalence allows for a decline in HIV incidence. 
Compared to a model that does not allow a decline the relative size of the HIV positive 
population will be higher in the later years compared to the HIV negative population. The 
relative reduction in population size also reduces the denominator of the incidence, thus 
increasing the incidence estimate. 
I will explore the impact of not allowing a decrease in HIV incidence to the observed trends in 
TB incidence. 
7.3.7.3 Effect of new studies  
From 2007 onwards KPS started intensive screening for TB in admitted patients in the district 
hospital. This added a level of active case finding, and some of the cases found through this 
study might otherwise not have been diagnosed with TB and recorded in the KPS database. I 
explored the impact of cases identified this way on the proportion of TB that was SS+ and the 
effect on overall trends if I excluded these cases from the analysis.  
7.3.7.4 Different methods of imputation 
There is no hard and fast rule for setting up imputation models. I therefore explored the effect 
of imputing HIV alone for the period 1997-2004 and imputing HIV and ART separately for the 
2005 – 2009 period.  
7.4 Results 
7.4.1 TB incidence by ART status (Aug 05 – July 09) 
Table 7.5 shows the relative incidence of TB by HIV status (top half) in Karonga District for the 
2005-2009 period. TB was much more likely in the HIV positive population compared to the 
HIV negative population (adjusted IRR (95% CI) = 10.89 (8.87 – 13.36)).  
Patients recently started on ART experienced a high incidence of TB (observed and imputed 
incidence >1600/100,000/year) which was about 6 times the risk experienced by the HIV 
positive population not receiving ART (observed adjusted IRR (95% CI) = 6.41 (4.25 – 9.67)).  
Chapter 7 – TB incidence in Karonga District 
 
107 
 
The incidence is lower in patients receiving ART for >6m, but still about 2.5 times higher than 
in the ART naive population (adjusted IRR (95% CI) = 2.46 (1.66 – 3.67)).  
After imputation of HIV and ART status the estimated incidences for this period were 
increased, most notably in the HIV positive population (observed incidence = 377, versus 
imputed incidence = 416 cases/100,000/year) although not dramatically different. However, 
observed and imputed data gave similar results when assessing relative incidences between 
groups.  
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Table 7.5: Incidence of SS+ pulmonary TB in Karonga District by HIV/ART status (2005-2009) 
 Observed      Imputed     
Period and group    IRR (95% CI)      IRR (95% CI)  
 n py inc Crude Adjusteda  nc  pyc Inc Crude Adjusteda 
Jan 05- Aug 09            
Overall 462 633686 73 n.a. n.a.  - - - - - 
            
HIV negative 174 567555 31 1   186.7 567555 33 1  
HIV positive 249 66130 377 12.28              
(10.12 – 14.91) 
10.89                
(8.87 – 13.36) 
 275.3 66130 416 12.66        
(10.45–15.33) 
11.44         
(9.33 – 14.03) 
            
Jul 05 - Aug 09b            
HIV+ no ART 124 51602 240 1 1  149.4 51602 323 1 1 
HIV+<=6m ART 29 1635 1774 7.38                
(4.93 – 11.06) 
6.41               
(4.25 – 9.67) 
 35.6 1635 1810 7.48            
(4.73 – 11.81) 
6.51           
(4.08 – 10.39) 
HIV+ >6m ART 32 4624 692 2.88                
(1.95 – 4.25) 
2.46            
(1.66 – 3.67) 
 41.5 4624 940 3.10            
(2.12 – 4.53) 
2.66           
(1.79 – 3.94) 
n = number of cases; py = person years at risk; inc = Incidence expressed as cases/100,000/year; IRR = Incidence Rate Ratio; n.a. not applicable as no comparison is 
made  
Note: no imputations were done for the overall category. so no separate imputation results are given 
a IRR’s adjusted for age group (15-24, 25-34, 35-44, 45-54, >=55) and sex 
b Period adjusted to opening of first ART clinic in Karonga District 
c Numbers represent the average across all 20 imputations  
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7.4.2 Trends in TB incidence  
7.4.2.1 TB incidence in general population 
In figure 7—2 the top line shows the incidence of all new SS+ cases of pulmonary TB in 
Karonga district since 1986. It clearly shows the previously reported steep increase through 
the late 80s and early 90s following the spread of HIV in the district. [171] Incidence peaked 
around 1995 at 115 cases /100,000 /year. Since then the incidence decreased strongly until 
the 2003  – 2005 period, after which the incidence appeared to reach a plateau with an 
average annual incidence between 75 /100,000 in the 2003 – 2005 period and 72/100,000 in 
the 2006 – 2009 period.  
7.4.2.2 TB incidence in HIV negative population (1997 – 2009)  
The bottom two curves in figure 7—2 show the incidence in the HIV negative population from 
1997 onwards. The dotted line shows the incidence in patients with a known negative HIV 
status. The solid line shows the incidence after imputation of missing values for HIV status. 
The observed curve suggests that TB incidence in the HIV negative reached a low on 23 cases / 
100,000 around 2002 and has slowly increased since then to 31/100,000 in the 2006 – 2009 
period. However, the imputed data suggest that the incidence decreased until the 2003-2005 
period, where incidence reached the lowest point 32 /100,000 and suggests stayed low at 33 / 
100,000 in the 2006 – 2009 period.  
Figure 7—2 Incidence of new SS+ pulmonary TB cases in Karonga District (all and HIV negative only) 
 
Graph shows observed values and after imputation of missing HIV status. Period markers show mid-
point of time periods. Note: ART was introduced in Karonga district in mid 2005.  
7.4.2.3 TB incidence in HIV positive population 
In figure 7—3 I show the observed (dotted line) and imputed (solid line) incidence of new SS+ 
pulmonary TB in the HIV positive populaton. It shows how the variation of missing values for 
HIV status over the years (see table 7.2) skew the observed incidence trends. 
Chapter 7 – TB incidence in Karonga District 
 
110 
 
The imputed trend suggests that the annual incidence in the HIV positive decreased strongly 
between the 2000 – 2002 and 2003 – 2005 periods from 509 to 421 cases /100,000. This 
decline appeared to become plateaued in the period after the introduction of ART. 
Figure 7—3 Incidence of new SS+ pulmonary TB in HIV positive patients 
 
Graph shows observed values and after imputation of missing HIV status. Period markers show mid-
point of time periods. Note: ART was introduced in Karonga district in mid 2005.   
 
Table 7.6 shows the incidence for the periods used in figures 7—2 and 7—3 for reference.  
Table 7.6: TB incidence by period and HIV status 
 
Incidence expressed as n/100,000/year. 
  Overall HIV negative  HIV positive  
period   Observed Imputed Observed Imputed 
1986 1987 
47             
(37 – 58)     
1988 1990 
79             
(70 – 91)     
1991 1993 
85              
(75 – 96)     
1994 1996 
115      
(103 – 127)     
1997 1999 
111      
(100 – 123) 
41                  
(34 – 49) 
53        
(44 – 63) 
354       
(301 – 416) 
508       
(441 – 586) 
2000 2002 
95          
(85 – 106) 
26                  
(21 – 33) 
39         
(32 – 47) 
306       
(257 – 363) 
509       
(440 – 589) 
2003 2005 
75          
(67 – 85) 
28                  
(23 – 35) 
32          
(27 – 39) 
340          
(289 – 400) 
421          
(364 – 490) 
2006 2009 
73          
(66 – 81) 
31                  
(26 – 36) 
33          
(28 – 39) 
387          
(337 – 445) 
421          
(367 – 481) 
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7.4.3 Regression analyses 
Table 7.7 shows an analysis of the linear trend in annual TB incidence allowing for a break in 
trend in 2005, the year that ART was introduced in Karonga District.  
These analyses confirm the trends seen in figure 7—2 and 7—3. In the overall population TB 
incidence appeared to decrease roughly 7% annually in the 1997 – 2005 period (IRR (95% CI) = 
0.93 (0.91 – 0.96)), after which the trend changed (p value Wald test = 0.03) and incidence 
plateaued. In the HIV negative population TB incidence declined between 1997 and 2005 
(adjusted IRR (95% CI) = 0.91 (0.88 – 0.95)). In the period afterwards the data suggest that 
incidence was increasing  (IRR (95% CI) = 1.09 (1.00 – 1.19)).For the HIV positive population 
the decline in the pre ART phase is shallower, around 3-4% annually, but in the post ART 
phase TB incidence plateaued (IRR (95% CI) = 1.00 (0.92 – 1.10)). Adjusting the estimates for 
age and sex had little effect the results.  
The p values for a change in trend suggest that in both the Overall and HIV negative 
population the change in trend was statistically significant (p-value Wald test < 0.05).  
Table 7.7 Trends in annual incidence of TB pre and post the introduction of ART 
 Jan 1997 – Dec 2005 Jan 2005 -  Aug 2009 P valuesa 
 IRR (95% CI) IRR (95% CI)  
Overall     
Crude 0.94 (0.92 – 0.96) 1.01 (0.96 – 1.07) 0.03 
Adjustedb 0.93 (0.91 – 0.95) 1.01 (0.96 – 1.07) 0.03 
    
HIV negative    
Crude 0.91 (0.88 – 0.95) 1.09 (1.00 – 1.19) 0.004 
Adjustedb 0.91 (0.88 – 0.95) 1.09 (0.99 – 1.19) 0.005 
    
HIV positive    
Crude 0.97 (0.94 – 1.00) 0.98 (0.91 – 1.06) 0.77 
Adjustedb 0.96 (0.93 – 0.99) 0.99 (0.92 – 1.07) 0.58 
Note: Coefficients express linear annual increase or decrease in TB incidence in that period, with the 
first year of the period (1997 or 2005) taken as baseline. Imputed datasets were used. 
IRR = ‘Incidence Rate Ratio’ 
a p-value for change in trend in 2005.  
b IRR’s adjusted for age group (15-24, 25-34, 35-44, 45-54, >=55) and sex 
  
7.4.3.1 Direct effect of ART 
Figure 7—4 shows the TB incidence trends if cases on ART for >6 months (32 in observed data, 
on average 41 in the 20 imputed datasets) were excluded from the trends analysis.  
The curves show that without the TB cases in patients receiving ART for over 6 months the 
incidence in the HIV positive population would have continued to decrease strongly. As a 
consequence the overall incidence of TB also seems to continue to decrease. 
  
Chapter 7 – TB incidence in Karonga District 
 
112 
 
Table 7.8 shows the incidence for the periods used in figure 7—4.  
Table 7.8: TB incidence by period and HIV status after excluding TB cases on ART > 6 months 
 
Incidence expressed as n/100,000/year. 
Note: HIV negative and HIV positive rates are post imputation for HIV and ART status  
 
7.4.4 Sensitivity analyses 
7.4.4.1 SS+ versus All TB 
Table 7.9 shows the incidence of all new TB episodes diagnosed in Karonga District, regardless 
of foci of disease or laboratory confirmation. It shows that trends were similar to those in new 
SS+ pulmonary cases; a decrease up to 2005, after the decrease becomes more shallow 
(overall and HIV positive population) or TB incidence appears to increase after 2005 (HIV 
negative population).  
Table 7.9: Incidence of all TB cases by period and HIV status 
 
Incidence expressed as n/100,000/year.  
 
period  Overall HIV negative HIV positive 
1997 1999 111      (100 – 123) 48      (41 – 56) 526      (466 – 594) 
2000 2002 95          (85 – 106) 36      (29 – 44) 483      (416 – 561) 
2003 2005 75          (67 – 85) 31          (25 – 37) 413          (356 – 480) 
2006 2009 65          (58 – 72) 33          (27 – 41) 326          (280 – 379) 
   HIV negative  HIV positive  
period  Overall Observed Imputed Observed Imputed 
1986 1987 
78             
(66 – 93)     
1988 1990 
191             
(176 –209)     
1991 1993 
197              
(181 – 214)     
1994 1996 
198      
(183 – 215)     
1997 1999 
267      
(250 – 285) 
66               
(34 – 49) 
101      
(44 – 63) 
804          
(722 – 894) 
1409               
(1292 – 1537) 
2000 2002 
217          
(202 – 233) 
42                     
(21 – 33) 
73         
(32 – 47) 
607         
(537 – 685) 
1275               
(1163 – 1399) 
2003 2005 
157         
(145 – 170) 
44               
(23 – 35) 
53          
(27 – 39) 
734          
(657 – 820) 
986               
(894 – 1089) 
2006 2009 
149          
(139 – 160) 
56               
(26 – 36) 
59          
(28 – 39) 
829          
(754 – 911) 
925               
(846 – 1013) 
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7.4.4.2 Model assumptions for HIV prevalence in general population  
7.4.4.2.1 No decline in incidence of HIV 
Figure 7—5 shows the poor fit of the modelled HIV prevalence to known data points if no 
decline in HIV incidence was assumed. This suggests that the model with decline was more 
appropriate. 
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Figure 7—4: Trends in TB incidence after excluding TB cases with onset over 6 months after starting ART 
 
Incidence expressed as n/100,000/year on y-axis 
 
Figure 7—5: HIV prevalence in Karonga District (by sex) if no decline in HIV incidence is assumed 
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Figure 7—6 shows the incidence of TB by HIV if the prevalence of HIV in the general 
population is assumed to remain stable. This affects the denominators in the incidence 
analysis by HIV. For the HIV positive the denominator is increased, which results in lower 
incidence estimates. Under this assumption, the incidence actually continues to decline 
lightly, rather than plateau in the last period. For the HIV negative population the 
denominator is decreased, resulting in a more pronounced increase post ART. In short, 
changing the model assumption on HIV incidence would only make the change in incidence 
after 2005 more pronounced in the HIV negative, but less pronounced in the HIV positive.  
Table 7.10 shows the results from the annual trend analyses. When these numbers are 
compared with those in table 7.7 the differences are small, and the trend in TB incidence that 
was observed in the main analysis with a break in the decline after 2005 is sustained.  
Table 7.10 Trends in annual incidence of TB under the no decline in HIV incidence assumption 
 Jan 1997 – Dec 2005 Jan 2005 -  Aug 2009 P valuesa 
 IRR (95% CI) IRR (95% CI)  
Overall     
Adjustedb 0.94 (0.92 – 0.96) 0.97 (0.92 – 1.03) 0.24 
    
HIV negative    
Adjustedb 0.92 (0.88 – 0.96) 1.06 (0.97 – 1.17) 0.02 
    
HIV positive    
Adjustedb 0.97 (0.94 – 1.00) 0.95 (0.88 – 1.02) 0.71 
Note: Coefficients express linear annual increase or decrease in TB incidence, with the first year of the 
period (1997 or 2005) taken as baseline. Imputed datasets were used. 
IRR = ‘Incidence Rate Ratio’ 
a p-value for 2
nd
 variable describing linear trends in annual TB incidence 
b IRR’s adjusted for age group (15-24, 25-34, 35-44, 45-54, >=55) and sex 
7.4.4.2.2 Prolonged survival in HIV positive patients receiving ART 
The model used to estimate the HIV prevalence in the general population does not take into 
account the prolonged survival of patients starting on ART.  
Without rerunning the model one can make some inference about the likely direction and 
magnitude of including these cases.  
The HIV prevalence in the post 2005 period would increase compared to the original estimate. 
This would have been similar to the scenario explored in the previous section, as HIV 
prevalence is higher in the last years before increasing the HIV prevalence. 
The magnitude of the effect depends on the number of patients receiving ART and their 
survival. In the extreme case, assuming complete survival, all patients starting ART in Karonga 
would be added cumulatively to the HIV positive population.  
I simulated this scenario which results in a stable HIV prevalence between 2006 and 2009, and 
the results were similar to the models shown in figures 7—5 and 7—6 and table 7.10.  
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It is important to note that this assumption of complete survival on ART does not hold in real 
life. From the patient register data (described in Chapter 6) I recorded that one third of HIV 
patients starting ART died (or defaulted) in the first 3 years after starting ART (unpublished 
data). So in reality the effect of including ART is probably less strong.  
7.4.4.3 Effect of new studies  
Tables 7.11 and 7.12 and figure 7—7 look at the trends in new SS+ pulmonary TB incidence 
after  the exclusion of TB patients who were first picked up from the general wards in Karonga 
District Hospital after active screening. During 2008 and 2009 a total of 34 cases were 
excluded for this sensitivity analysis. It shows that the trends were affected slightly and that 
the change in the annual trend of TB incidence post ART was less strong, but that the overall 
picture, as seen in the imputed data, was sustained.  
Table 7.11: Incidence of new SS+ pulmonary TB cases by period and HIV status after exclusion of potential ICF 
cases 
period  Overall HIV negativea HIV positivea 
1997 1999 111 (100 – 123) 53 (44 – 63) 508 (441 – 586) 
2000 2002 95 (85 – 106) 39 (32 – 47) 509 (440 – 587) 
2003 2005 75 (67 – 85) 32 (27 – 39) 422 (364 – 490) 
2006 2009 69 (62 – 77) 31 (27 – 37) 398 (347 – 458) 
a all results based on imputed datasets   
 
Table 7.12: Trends in annual incidence of new SS+ pulmonary TB pre and post the introduction of ART (excluding 
potential ICF cases) 
 Jan 1997 – Dec 2005 Jan 2005 -  Aug 2009 P valuesa 
 IRR (95% CI) IRR (95% CI)  
Overall     
Adjustedb 0.94 (0.92 – 0.96) 0.97 (0.92 – 1.03) 0.24 
    
HIV negative    
Adjustedb 0.92 (0.88 – 0.96) 1.06 (0.97 – 1.16) 0.005 
    
HIV positive    
Adjustedb 0.97 (0.94 – 1.00) 0.95 (0.88 – 1.03) 0.42 
Note: Coefficients express linear annual increase or decrease in TB incidence, with the first year of the 
period (1997 or 2005) taken as baseline. Imputed datasets were used. 
IRR = ‘Incidence Rate Ratio’ 
a p-value for 2
nd
 variable describing linear trends in annual TB incidence 
b IRR’s adjusted for age group (15-24, 25-34, 35-44, 45-54, >=55) and sex 
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Figure 7—6: TB incidence in HIV negative (left) and HIV positive (right) under ‘no decline in HIV incidence’ assumption 
 
Note: Incidence of new SS+ pulmonary cases on y-axis expressed as n/100,000/year.  
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Figure 7—7: Incidence of smear positive pulmonary TB in HIV negative (left) and HIV positive (right) patients after excluding cases from ICF  
 
Note: Incidence on y-axis expressed as n/100,000/year.  
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Table 7.13 shows the incidence of all new TB cases over the 1997 – August 2009 period. Again, 
a similar trend is seen as in the main analysis.  
Table 7.13: Incidence of all new TB cases by period and HIV status after exclusion of potential ICF cases 
 
incidence expressed as n / 100,000 / year 
 
7.4.4.4 Different methods of imputation 
Applying different methods of imputation did not affect the results or trends in a relevant 
way. 
7.5 Discussion  
7.5.1 Summary of results 
This is the first analysis of the effect of ART on the relative incidence of TB using high quality 
data collected from an uncontrolled ART programme setting. The analyses include data from 
~3500 new SS+ TB cases with onset since 1986 of which >60 cases were receiving ART before 
their TB episode started. The results show that patients starting ART experience a very high 
risk of TB in the first 6 months. After 6 months the incidence comes down, but remains 
elevated compared to HIV positive/ART naive patients. 
In the first analysis to couple TB surveillance data with population data stratified by HIV and 
ART status I also show that the incidence in Karonga District appears to have levelled off in the 
period after ART was rolled out after declining in the previous decade. 
On a methodological note, this chapter shows that multiple imputation is useful to highlight 
and correct for biases due to missing values and is essential for incidence analyses where 
absolute values, rather than relative rates are the outcome of interest. 
7.5.2 TB incidence in patients with ART 
TB incidence in Karonga District appears to be about 7 times higher in patients on ART for 6 
months or less compared to HIV positive/ART naive patients. This is probably a consequence 
of the severely compromised immune status of these patients when they are started on ART. 
Already at a high risk of developing TB disease, their high risk is compounded by the additional 
‘TB unmasking’ effect of initiating ART.[45, 191, 195]  
Patients that have been on ART for >6 months still suffer from an elevated risk of TB, about 3 
times higher than HIV positive patients not receiving ART.  
period  Overall HIV negative HIV positive 
1997 1999 267 (250 – 285) 101 (88 – 115) 1409 (1292 – 1537) 
2000 2002 217 (202 – 232) 73 (62 – 85) 1275 (1163 – 1399) 
2003 2005 157 (145 – 170) 53 (46 – 62) 986 (894 – 1089) 
2006 2009 142 (132 – 153) 58 (51 – 65) 876 (799 – 961) 
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7.5.3 TB incidence in population after the introduction of ART 
Between the mid 90s and 2005 the incidence of new SS+ pulmonary TB in Karonga District 
declined at an average rate of about 7% annually. This decline was seen and statistically 
significant overall and in both the HIV negative (strongest decline with 9% annually) and HIV 
positive (3% annual decline) population. 
After the introduction of ART the overall incidence appears to have plateaued, which follows 
from an apparently flat or slightly increasing incidence trend in the HIV negative population 
and a shallower decrease in the HIV positive population.  
The apparent plateau in the HIV positive population seems to be a direct effect of ART, as 
shown in figure 7—4. The plateau in the HIV negative population could be due to TB following 
recent transmission from the additional SS+, i.e. infectious, TB cases in the ART receiving 
group.  
7.5.4 Interpretation 
7.5.4.1 TB incidence  
The data suggest that in the absence of ART a TB control programme following the basic WHO 
DOTS guidelines can successfully reduce TB incidence in settings with generalised HIV 
epidemics and moderate rates of TB and ongoing Mtb transmission. For example, HIV 
negative incidence has fallen below the overall level of 1986, when the effect of HIV was still 
moderate.  
However, the steady decrease of TB was halted after the arrival of ART. A new group of 
patients at high to very high risk of TB is kept alive longer and will directly (see figure 7—4) 
and indirectly increase TB incidence in the population. The onward transmission of ART 
receiving TB cases will be within their own patient group during days that they collect their 
medication as well as within the general population in which they are again functioning.  
It is difficult to quantify the exact size of this indirect effect from ART receiving TB cases. 
Currently used molecular epidemiological techniques are not sufficiently sensitive and flexible 
to plot complete transmission chains, i.e. answer the question of ‘who transmitted to whom?’. 
Whole genome sequencing which is developing fast may be better suited to answer this 
question, and has been tested in a cluster from the Netherlands. [201] 
Also, one needs to consider that not all of the change in incidence trend is due to ART and 
that some can be due to the new studies (although the trends persisted after excluding those 
cases) and due to a natural levelling off of the decrease as a standard DOTS programme 
reaches the limit of its capabilities to control TB in a population like Karonga with moderate 
Mtb transmission and HIV prevalence.  
It is important to note that during the study period there was no active Isoniazid Prophylactic 
Therapy (IPT) programme running in Karonga District. Several hundred TST positive HIV 
positive individuals with positive TST have been given IPT in the context of KPS studies, but 
this is unlikely to have had a relevant impact on the TB incidence trends. 
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7.5.4.2 Imputation as a tool to reduce bias 
These analyses explore the effect of imputations. The datasets with imputed values appeared 
to give more valid values in the incidence trend analyses, and similar IRR’s.  
7.5.5 Limitations 
As any population based study, there are limitations to the level and detail of the available 
data. 
Firstly, KPS did not have the resources to record CD4 count for the complete TB case 
population (i.e. numerators), let alone from a representative sample of the HIV positive or 
ART receiving populations (i.e. the denominators). It is likely that the high incidence in the ART 
receiving population is similar to that seen in a population with the same CD4 cell count 
distribution. However, from a public health perspective these analyses identify potential high 
risk populations that can be targeted with intensified TB screening without involving CD4 
count machines, which are often not available at the rural clinic level. 
The annual population estimates are an approximation and not as precise as one would like. 
However, the data are anchored in 3 data points (1988, 1998 and 2008) which gives them 
reasonable strength.  
The HIV prevalence follows from a model that fits a likely curve of HIV prevalence to data 
points. [186] Although the model’s approach was based on current best practices, it is still 
applying assumptions which in turn add uncertainty. The sensitivity analyses showed however 
that the results were robust.  
The data on the ART uptake from clinics in Karonga will be reasonably complete. One risk is 
that HIV positive patients from Karonga District were receiving ART from an ART clinic outside 
Karonga. These patients would not add to the denominator for ART, but would add to the 
numerator of ART associated TB incidence if they were diagnosed with or treated for TB in 
Karonga District which would lead to an overestimation of the incidence of TB in those 
categories.  
The analyses of imputed datasets were corrected for the uncertainty from imputing missing 
data.  
7.5.6 Setting specificity  
These findings will be setting specific to an extent. The direct effect of ART will depend on the 
immune status of HIV positive patient when they are eligible for and started on ART. [36]  
Higher ongoing rates of Mtb transmission in the population will also affect the rates of TB in 
the ART receiving population and subsequently their contribution to overall Mtb transmission. 
[202] This depends in part on the relative sensitivity to TB following recent Mtb transmission 
in the different populations. The ART receiving population is a special subgroup of the HIV 
positive population. As shown in Chapters 3, 4 and 5, HIV positive patients are more likely to 
develop TB disease from recent Mtb infection, and it is likely that ART receiving patients have 
a similar, if not more pronounced if they are started on ART with advanced 
immunocompromisation, sensitivity to recent Mtb infection.  
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Karonga District has moderate rates of ongoing Mtb transmission, like the majority of areas in 
Sub Saharan Africa. The HIV prevalence in the district is estimated to be around 11%, which is 
also moderate and representative of rural populations in Sub Saharan Africa. Finally, the ART 
roll out in Malawi and Karonga District is an example of a low tech programme delivering 
services to a large proportion of the eligible population and thus reflects the likely future 
situation in most areas in Sub Saharan Africa.  
7.5.7 Public health implications and future research 
7.5.7.1 Potential Interventions: 
This work shows that patients receiving ART are at a high risk of developing TB. Integration of 
the TB and ART programmes to facilitate intensified case finding in this highly vulnerable 
population could help reduce the incidence of TB and additional ongoing Mtb transmission in 
the population.[203] One step forward is that the ventilation considerations recommended 
for TB clinics should be extended to ART clinics, to reduce the risk of nosomical Mtb 
infections.[184]  
7.5.7.2 Future research 
Future studies in Karonga should include measuring CD4 levels in all TB cases and estimate the 
CD4 count distribution in the population to allow for comparisons between groups in CD4 
strata  
The main question that remains however is the size and characteristics of the indirect effect of 
ART (and HIV infection) on TB incidence; to what extent do these extra cases contribute to 
ongoing Mtb transmission and to whom do they mainly transmit? This can be assessed 
through modelling studies that incorporate estimates of the relative infectiousness of both 
cases, or through the application of more flexible molecular epidemiological techniques such 
as whole genome sequencing, which will hopefully provide detailed transmission chains and 
provide an estimate of the indirect effect of ART and HIV on the TB rates in the HIV negative 
population.  
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8 Conclusion and Discussion 
8.1 Overview 
In this final chapter I will recap the results from each chapter and integrate them into the 
main conclusions that result from this thesis. For each conclusion I will summarise the existing 
knowledge, what this thesis had added and what the implications are. Finally I will describe 
future research that can build upon the results from this thesis.  
8.2 Main results 
8.2.1 Chapter 2 -TB clustering in populations  
8.2.1.1 What was known 
Previous studies had shown that the observed proportion clustered in a population is affected 
by or dependent on various factors related to study design, setting and population. [59, 77, 
78]. 
8.2.1.2 What does this thesis add 
In Chapter 2 I systematically reviewed the literature of population based studies on TB 
clustering. The results showed that although the observed proportion clustered varies widely 
between studies, a comparison between the observed and expected proportion clustered 
(based on factors describing study design and setting) can highlight true outliers.  
8.2.1.3 What are the implications 
Researchers that explore the proportion of cases in a cluster should make sure they interpret 
their results in the context of study design and setting, especially when informing policy 
makers.  
8.2.2 Chapter 3-5: HIV and the risk of TB following recent infection 
8.2.2.1 What was known? 
From early observations it was assumed that TB in HIV positive patients mostly followed 
reactivation of latent Mtb infections. [141] However, evidence from study on recurrent TB [72, 
73] and age patterns [142-146] suggested that TB in HIV positive patients was more likely to 
follow recent infection with Mtb.  
8.2.2.2 What does this thesis add? 
Chapters 3 and 4 and 5 focussed on the question of what is the dominant pathway to TB 
disease in HIV positive individuals. The pooled analysis of all suitable individual patient data in 
Chapter 3 suggested that TB following recent Mtb infection was the main mechanism, which 
was further strengthened by the time period analysis of KPS data in Chapter 4. Chapter 5 
showed that even in those with a known prior infection a first TB episode in an HIV positive 
individual may often be due to re-infection. [175] 
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8.2.2.3 What are the implications? 
The policy recommendations following from the results described in chapters 3 through 5 are 
described in their respective chapters. In short, if the majority of TB disease is the 
consequence of ongoing Mtb transmission new interventions should focus on interrupting 
that transmission. The WHO’s “three I’s” policy emphasize exactly that and should be taken 
forward, especially in the presence of a generalised HIV epidemic [165]; Intensified case 
finding in the community and high risk groups (e.g. patients receiving ART) to reduce the 
number and duration of undiagnosed infectious TB disease [183], infection control in hospitals 
[184] and Isoniazid prophylaxis for all HIV-positive individuals at risk of Mtb infection, not just 
those with latent infections. [185]  
Each of these efforts should help reduce Mtb transmission, thus reducing TB incidence in the 
general and HIV positive population.  
The results also have implication for vaccine development. If a previous Mtb infection does 
not confer protection from re-infection before their first episode (as Chapter 5 suggests), 
vaccines attempting to mimic or boost the body’s immune response to an Mtb infection may 
not be as effective as hoped.  
8.2.3 Chapter 7: TB incidence after the introduction of ART 
8.2.3.1 What was known? 
There are several studies describing TB incidence in patients receiving ART, [35-46, 192] which 
mostly show that TB incidence is high in the first 3-6 months after ART initiation and then 
decreases with time spent on ART. Also, when CD4 data were available, studies showed that 
patients with lower CD4 counts have a higher risk of developing TB. [35, 36, 38, 44, 45, 192] 
However, most of these studies described ART programmes with reasonable laboratory and 
clinical support, and none described the overall effect of the introduction of ART on the TB 
incidence in the overall population, i.e. including the HIV negative population.  
8.2.3.2 What does this thesis add? 
Chapter 7 described an analysis of the effect of ART on the incidence of TB, by HIV and ART 
status in the context of an ART programme in rural Africa with limited laboratory and clinical 
support. The results show that patients starting ART experience a very high risk of TB in the 
first 6 months, after which the risk decreases but remains elevated compared to HIV 
positive/ART naive patients. This is in line with observations from other studies. 
In the second part of Chapter 7 I described the first analysis of how TB incidence trends in the 
general population were affected by the introduction of ART. The results suggested that a well 
supported DOTS programme can control TB incidence in a setting with generalised HIV 
epidemic and moderate Mtb transmission. However, the burden of additional cases and, 
probably, additional Mtb transmission, associated with the roll-out of ART has apparently 
halted this decline in TB incidence in Karonga District. 
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8.2.3.3 What are the implications? 
It seems that starting ART at a severely immunosuppressed state, e.g. at a CD4 level of 200 
cells/µL or less, leaves many patients at a prolonged high risk of TB disease. 
However, the obvious theoretical solution of starting patients earlier on ART is not necessarily 
practical. Even though the most recent WHO ART policy recommends that patients are put on 
ART earlier, at CD4 count of <350 cells/µL [204], some immediate complications arise. Firstly, 
many of the rural clinics (or some of the more central clinics) do not have CD4 count facilities 
available, which complicates staging based on this qualification. Also, many ART programmes 
are already struggling to find the financial or human resources required to meet ART demand 
for the previously eligible population, and it is unclear where the additional support required 
to adequately serve an expanded population will come from. Furthermore, if these services 
become available it requires HIV positive patients to actually come for staging regularly so 
they are captured before their CD4 count drops (far) below 350. As this level of 
immunosuppression is less easily characterised by other symptoms such as opportunistic 
infections, it will probably require that patients come repeatedly for ART staging, which is not 
easy to achieve.  
One approach that warrants discussion in my opinion is putting all patients that test positive 
on ART immediately, and thus avoid adding further barriers in the pathway from repeated HIV 
testing to treatment access. Obviously this would compound some of the practical issues 
above, but from a TB control perspective, the earlier HIV positive patients start on ART the 
lower the incidence of TB (and subsequently their indirect contribution to Mtb transmission in 
the general population) will be. 
Another clear message from these results is the need for better integration of ART and TB 
services. [203] The work in this thesis confirms that patients receiving ART are a high risk 
population for TB, which is relatively easy to reach. Measures could include adding a TB 
specific checklist or regular sputum collections at every contact, especially during the first 
months after ART initiation.  
One obvious integration (as suggested in section 8.2.2.3) is applying the recommendations on 
building ventilation for TB clinic buildings [184] to ART clinics. This would reduce the risk of 
infectious TB cases transmitting their Mtb strain to a vulnerable population of fellow patients 
receiving ART while both are attending the clinic.  
8.3 Future work 
8.3.1 Who transmits to whom in an IS6110 RFLP defined cluster?  
One of the main assumptions in this thesis is that HIV positive patients are less likely to be the 
source of onward Mtb transmission when part of a cluster. Although this assumption is 
supported by sufficient indirect [11, 12, 22, 29, 147-150] and some direct [71] evidence, it 
would be useful and interesting to have a more complete overview of who transmitted to 
whom within a cluster of TB cases defined by IS6110 RFLP.  
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Ideally we would be able to directly map transmission chains. In some settings this has been 
attempted based on timing of the source and secondary case [10], but such data are difficult 
to interpret considering the highly variable period between Mtb infection and TB disease 
(estimated between 3-6 months and lifelong), especially in settings with high to moderate 
rates of ongoing Mtb transmission in the general population where the time of transmission is 
usually not known. 
Whole genome sequencing, a newly developed tool for TB molecular epidemiology detects 
differences in the Mtb DNA to a much higher extent. It has been successfully used to construct 
a phylogenetic tree of a single cluster in the Netherlands. [201] When applied to the 
epidemiologically well described TB clusters in Karonga District, one could construct 
phylogenetic trees (and therefore likely transmission chains) for all cases and thus obtain a 
direct estimate of the relative risk of being a source of a secondary TB case by HIV and ART 
status, and whether/how this changed since 1997.   
Genetic studies could also potentially lead to the identification of genetic markers in the Mtb 
genome that are associated with successful Mtb transmission (i.e. a new Mtb infection that 
leads to active TB disease), which could be translated into targets for vaccine or drug 
development.  
8.3.2 Incidence by CD4 count strata 
As discussed in Chapter 7, it would be interesting to stratify TB incidence estimates in the HIV 
positive and ART receiving populations by CD4 count. In future KPS studies it would be useful 
to record CD4 status for all TB cases. For comparison it would be good to have baseline CD4 
counts for patients starting ART and an impression of the CD4 count for the general HIV 
positive population, e.g. by including CD4 count  in the HIV test offered to the random TB 
controls described in chapter 6. 
8.3.3 Intervention studies on Mtb transmission in patients with ART 
Although it seems obvious that TB and ART services should be integrated better, how this can 
best be done in the context of small rural ART clinics is not clear. Multiple approaches can be 
tried, for example improve ventilation in ART clinics as discussed or introduce a more 
intensive form of TB case finding in this highly vulnerable population, especially during the 
first six months.  
One would like to be able to quantify the effect of such interventions, which would require 
some thought; mostly of whether there is a comparison group. The problem is that the annual 
number of TB cases on ART in Karonga District each year is probably too low (less than 10, see 
chapter 7) to allow a standard trial design with a control group (i.e. control ART clinic). Also 
analyses in Chapter 7 suggested that TB incidence Karonga is changing, which complicates 
using it as a historical baseline group. Whole genome sequencing could potentially provide an 
indirect measure by estimating changes in the proportion of cases in each HIV/ART group that 
were the source of transmission for another case.  
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8.4 Conclusion 
The work in this thesis has hopefully provided sufficient support for the hypothesis that HIV 
positive individuals are mainly at risk of TB following recent Mtb infection in settings with 
generalised HIV and TB epidemics. 
The roll out of ART, although an essential lifeline to people living with HIV, has further 
complicated TB control in settings where the National TB programmes were already struggling 
to reduce TB incidence. Renewed efforts are required, including a better integration of ART 
delivery and regular TB services to make sure that the resources spent in one programme are 
not simply adding work on the other.  
Under those conditions I believe that TB can be controlled by a well supported DOTS 
programme in most settings, as long as TB programmes are sufficiently resourced to 
consistently diagnose and successfully treat the majority of TB cases in the population. The 
work in this thesis suggests that DOTS can control TB incidence from exorbitant high to 
apparently pre-HIV levels (in the HIV negative) and will, with some modifications, probably be 
able to cope with the roll out of ART as well. 
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10 Appendices 
This section holds a copy of publications that are based on the work described in this thesis. Three 
items have appeared in peer reviewed journals do far: 
1. From Chapter 2: ‘A System A systematic review and meta-analysis of molecular 
epidemiological studies of tuberculosis: development of a new tool to aid interpretation’. 
Paper published In: Tropical Medicine & International Health 2009;volume 14, pages: 892-
909 
2. From Chapter 2: ‘Systematic review and analysis of population-based molecular 
epidemiological studies.’ Letter to the editor and author reply published in:  International 
Journal of Tuberculosis and Lung Disease. 2009; volume 13, pages 275-6 
3. From Chapter 4: ‘HIV and the risk of tuberculosis due to recent transmission over 12 years in 
Karonga District, Malawi’. Invited paper in Transactions of the Royal Society of Tropical 
Medicine & Hygiene. 2009;volume 103, pages 1187-1189 
Other papers are currently in press (describing work from Chapters 3 and 5, in IJTLD), submitted 
(describing work from Chapter 7) and in preparation (work from Chapter 6). 
Note: To reduce the size of the document (i.e. make it ready for circulation) I removed the copies. I 
have attached these publications as .pdf where they were available to me. Others should become 
available through pubmed in due time.  
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